Abnormal O
degree O
centrality O
in O
chronic B-SubstanceDisorder
users I-SubstanceDisorder
of I-SubstanceDisorder
codeine-containing I-SubstanceDisorder
cough I-SubstanceDisorder
syrups I-SubstanceDisorder
: O
A O
resting-state O
functional O
magnetic O
resonance O
imaging O
study O
Codeine-containing O
cough O
syrups O
( O
CCS O
) O
have O
become O
one O
of O
the O
most O
popular O
drugs O
of O
abuse O
in O
young O
population O
worldwide O
. O

However O
, O
the O
neurobiological O
mechanisms O
underlying O
CCS-dependence O
are O
yet O
ill-defined O
. O

Therefore O
, O
understanding O
the O
brain O
abnormalities O
in O
chronic O
users O
of O
CCS O
is O
crucial O
for O
developing O
effective O
interventions O
. O

The O
present O
study O
depicted O
the O
intrinsic O
dysconnectivity O
pattern O
of O
whole-brain O
functional O
networks O
at O
the O
voxel O
level O
in O
chronic O
users O
of O
CCS O
. O

In O
addition O
, O
the O
degree O
centrality O
( O
DC O
) O
changes O
were O
correlated O
to O
the O
Barratt B-BarrattImpulsivenessQuestionnaire
Impulsiveness I-BarrattImpulsivenessQuestionnaire
Scale I-BarrattImpulsivenessQuestionnaire
( I-BarrattImpulsivenessQuestionnaire
BIS I-BarrattImpulsivenessQuestionnaire
- I-BarrattImpulsivenessQuestionnaire
11 I-BarrattImpulsivenessQuestionnaire
) I-BarrattImpulsivenessQuestionnaire
total O
score O
, O
dose O
, O
duration O
of O
CCS O
use O
, O
and O
the O
age O
at O
first O
use O
of O
cough O
syrups O
. O

The O
current O
study O
included O
38 O
chronic B-SubstanceDisorder
CCS I-SubstanceDisorder
users I-SubstanceDisorder
and O
34 O
matched O
control B-NoKnownDisorder
subjects I-NoKnownDisorder
. O

All O
patients O
were O
evaluated O
using O
the O
BIS B-BarrattImpulsivenessQuestionnaire
- I-BarrattImpulsivenessQuestionnaire
11 I-BarrattImpulsivenessQuestionnaire
. O

Next O
, O
resting-state B-RestingStateImaging
functional I-RestingStateImaging
magnetic I-RestingStateImaging
resonance I-RestingStateImaging
imaging I-RestingStateImaging
( I-RestingStateImaging
rs-fMRI I-RestingStateImaging
) I-RestingStateImaging
datasets O
were O
acquired O
from O
these O
CCS B-SubstanceDisorder
users I-SubstanceDisorder
and O
controls B-NoKnownDisorder
. O

Whole-brain O
connectivity O
was O
analyzed O
using O
a O
graph O
theory O
approach O
: O
degree O
centrality O
( O
DC O
) O
. O

CCS-dependent B-SubstanceDisorder
individuals I-SubstanceDisorder
exhibited O
low O
DC O
values O
in O
the O
left O
inferior O
parietal O
lobule O
and O
the O
left O
middle O
temporal O
gyrus O
, O
while O
high O
DC O
values O
were O
noted O
in O
the O
right O
pallidum O
and O
the O
right O
hippocampus O
( O
P O
  O
< O
  O
0.01 O
, O
AlphaSim O
corrected O
) O
. O

Also O
, O
significant O
correlations O
were O
established O
between O
average O
DC O
value O
in O
the O
left O
inferior O
parietal O
lobule O
and O
attentional O
impulsivity O
scores O
and O
the O
age O
at O
first O
CCS O
use O
. O

The O
rs-fMRI B-RestingStateImaging
study O
suggested O
that O
the O
abnormal O
intrinsic O
dysconnectivity O
pattern O
of O
whole-brain O
functional O
networks O
may O
provide O
an O
insight O
into O
the O
neural O
substrates O
of O
abnormalities O
in O
the O
cognitive O
control O
circuit O
, O
the O
reward O
circuit O
, O
and O
the O
learning O
and O
memory O
circuit O
in O
CCS-dependent O
individuals O
. O

Highlights O
The O
abuse B-SubstanceDisorder
of I-SubstanceDisorder
CCS I-SubstanceDisorder
has O
gained O
a O
severe O
foothold O
among O
young O
individuals O
worldwide O
. O

DC O
is O
one O
of O
the O
more O
reliable O
and O
compelling O
measures O
among O
several O
nodal O
network O
metrics O
. O

The O
present O
study O
depicted O
intrinsic O
dysconnectivity O
pattern O
of O
whole-brain O
functional O
networks O
in O
CCS-dependent B-SubstanceDisorder
individuals I-SubstanceDisorder
. O

CCS-dependent B-SubstanceDisorder
individuals I-SubstanceDisorder
showed O
altered O
DC O
in O
the O
right O
pallidum O
, O
right O
hippocampus O
, O
left O
IPL O
and O
left O
middle O
temporal O
gyrus O
. O

Significant O
correlations O
were O
established O
between O
average O
DC O
value O
in O
the O
left O
IPL O
and O
attentional O
impulsivity O
scores O
and O
the O
age O
at O
first O
CCS O
use O
. O

Materials B-StudyMethod
and I-StudyMethod
methods I-StudyMethod
Participants O
This O
prospective O
study O
was O
approved O
by O
the O
Ethics O
Committee O
of O
Guangdong O
Second O
Provincial O
General O
Hospital O
. O

Written O
informed O
consent O
was O
obtained O
from O
all O
subjects O
. O

A O
total O
of O
72 O
right-handed O
participants O
, O
including O
34 O
control B-NoKnownDisorder
subjects I-NoKnownDisorder
and O
38 O
CCS-dependent B-SubstanceDisorder
individuals I-SubstanceDisorder
, O
were O
enrolled O
in O
this O
study O
. O

The O
CCS-dependent B-SubstanceDisorder
individuals I-SubstanceDisorder
were O
recruited O
from O
the O
patients O
seeking O
treatment O
at O
the O
Addiction O
Medicine O
Division O
of O
the O
Guangdong O
Second O
Provincial O
General O
Hospital O
. O

All O
the O
patients O
were O
screened O
based O
on O
the O
DSM-IV O
criteria O
from O
medical O
history O
and O
underwent O
a O
urine O
test O
and O
an O
interview O
on O
the O
same O
day O
. O

All O
participants O
regularly O
smoked O
cigarettes O
but O
did O
not O
use O
any O
type O
of O
psychotropic O
agents O
prior O
to O
the O
rs-fMRI B-RestingStateImaging
scan I-RestingStateImaging
. O

The O
exclusion O
criteria O
for O
all O
participants O
included O
central O
nervous O
system O
diseases O
, O
schizophrenia O
, O
bipolar O
disorder O
, O
prior O
significant O
head O
trauma O
, O
positive O
human O
immunodeficiency O
virus O
( O
HIV O
) O
status O
, O
diabetes O
, O
hepatitis O
C O
, O
other O
major O
medical O
illness O
, O
and O
left-handedness O
. O

The O
inclusion O
criteria O
for O
the O
control B-NoKnownDisorder
subjects I-NoKnownDisorder
was O
the O
absence O
of O
diagnosis O
of O
any O
type O
of O
substance O
abuse O
or O
dependence O
. O

Impulsivity B-BarrattImpulsivenessQuestionnaire
assessment I-BarrattImpulsivenessQuestionnaire
BIS I-BarrattImpulsivenessQuestionnaire
- I-BarrattImpulsivenessQuestionnaire
11 I-BarrattImpulsivenessQuestionnaire
was O
used O
for O
assessing O
the O
impulsivity O
. O

This O
30 O
- O
item O
self-rated O
scale O
has O
three O
oblique O
factors O
: O
attentional O
/ O
cognitive O
that O
measures O
the O
toleration O
for O
cognitive O
complexity O
and O
persistence O
; O
motor O
that O
estimates O
the O
tendency O
to O
act O
on O
the O
spur O
of O
the O
moment O
; O
and O
non-planning O
impulsivity O
, O
which O
evaluates O
the O
lack O
of O
sense O
of O
the O
future O
. O

Items O
are O
rated O
from O
1 O
( O
rarely O
/ O
never O
) O
to O
4 O
( O
almost O
always O
/ O
always O
) O
. O

To O
determine O
the O
overall O
impulsiveness O
scores O
, O
all O
items O
are O
summed O
; O
high O
scores O
indicate O
remarkable O
impulsivity O
. O

BIS B-BarrattImpulsivenessQuestionnaire
- I-BarrattImpulsivenessQuestionnaire
11 I-BarrattImpulsivenessQuestionnaire
is O
a O
valid O
and O
reliable O
instrument O
for O
healthy O
Chinese O
and O
psychiatric O
populations O
. O

Data O
acquisition O
All B-MagneticResonanceImaging
MRI I-MagneticResonanceImaging
datasets I-MagneticResonanceImaging
were O
obtained O
using O
a O
Philips O
Achieva O
1.5 O
  O
T O
Nova O
dual O
MR O
scanner O
at O
the O
Department O
of O
Medical O
Imaging O
, O
Guangdong O
Second O
Provincial O
General O
Hospital O
. O

These O
datasets O
included O
rs-fMRI B-RestingStateImaging
dataset O
and O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
structural I-T1WeightedImaging
images I-T1WeightedImaging
. O

The O
rs-fMRI B-RestingStateImaging
dataset I-RestingStateImaging
[ O
22 O
axial O
slices O
, O
repetition O
time O
( O
TR O
) O
/ O
echo O
time O
( O
TE O
) O
  O
= O
  O
2000 O
  O
ms O
/ O
50 O
  O
ms O
, O
matrix O
  O
= O
  O
64 O
  O
× O
  O
64 O
, O
field O
of O
view O
( O
FOV O
) O
  O
= O
  O
230 O
  O
× O
  O
230 O
  O
mm2 O
, O
slice O
thickness O
  O
= O
  O
4.5 O
  O
mm O
without O
gap O
, O
flip O
angle O
  O
= O
  O
90 O
° O
] O
was O
acquired O
using O
an O
echo O
planar O
imaging O
( O
EPI O
) O
sequence O
. O

Each O
functional B-FunctionalMagneticResonanceImaging
run I-FunctionalMagneticResonanceImaging
contained O
240 O
volumes O
( O
8 O
  O
min O
) O
[ O
the O
slices O
were O
approximately O
along O
the O
anterior O
commissure-posterior O
commissure O
( O
AC-PC O
) O
line O
and O
covered O
approximately O
230 O
to O
60 O
in O
the O
inferosuperior O
direction O
] O
, O
and O
the O
subjects O
were O
asked O
to O
lie O
quietly O
with O
their O
eyes O
closed O
and O
avoid O
eye O
movement O
or O
thinking O
of O
anything O
specific O
or O
falling O
asleep O
while O
in O
the O
scanner O
, O
during O
the O
rs-fMRI O
data O
acquisition O
. O

Sagittal O
structural B-StructuralImaging
images I-StructuralImaging
( O
160 O
sagittal O
slices O
, O
TR O
/ O
TE O
  O
= O
  O
25 O
  O
ms O
/ O
4.1 O
  O
ms O
, O
thickness O
  O
= O
  O
1.0 O
  O
mm O
, O
no O
gap O
, O
in-plane O
resolution O
  O
= O
  O
231 O
  O
× O
  O
232 O
, O
FOV O
  O
= O
  O
230 O
  O
× O
  O
230 O
  O
mm O
, O
flip O
angle O
  O
= O
  O
30 O
° O
) O
were O
acquired O
using O
a O
fast O
field O
echo O
( O
FFE O
) O
three-dimensional O
( O
3D O
) O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
sequence I-T1WeightedImaging
. O

Data O
pre-processing O
and O
DC O
calculation O
Data O
Processing O
Assistant O
for O
Resting-State O
Functional O
MR O
Imaging O
toolbox O
( O
http O
: O
/ O
/ O
www.restfmri.net.sci-hub.cc O
/ O
forum O
/ O
DPARSF O
, O
) O
was O
used O
for O
the O
post-processing O
of O
the O
imaging O
data O
. O

Before O
pre-processing O
, O
the O
first O
10 O
volumes O
were O
discarded O
for O
each O
subject O
so O
that O
magnetization O
reached O
a O
steady O
state O
and O
subjects O
adapted O
to O
the O
MRI O
scanning O
noise O
. O

Then O
, O
the O
remaining O
230 O
fMRI B-FunctionalImagingProtocol
images I-FunctionalImagingProtocol
were O
obtained O
with O
slice O
time O
correction O
for O
the O
acquisition O
time O
delay O
and O
realignment O
of O
the O
head O
motion O
correction O
. O

One O
patient O
and O
two O
control B-NoKnownDisorder
subjects I-NoKnownDisorder
, O
who O
showed O
head O
motion O
> O
1.5 O
  O
mm O
or O
1.5 O
° O
during O
image O
acquisition O
, O
were O
excluded O
in O
subsequent O
analysis O
. O

All O
realigned O
images O
were O
normalized O
to O
the O
standard O
Montreal O
Neurological O
Institute O
( O
MNI O
) O
template O
by O
applying O
the O
echo O
planar O
imaging O
( O
EPI O
) O
template O
at O
a O
3 O
  O
× O
  O
3 O
  O
× O
  O
3 O
  O
mm3 O
resolution O
. O

The O
normalized O
functional O
image O
was O
subjected O
to O
spatial O
smoothing O
[ O
6 O
  O
mm O
half O
high O
full-width O
( O
FWHM O
) O
Gaussian O
kernel O
] O
. O

Finally O
, O
the O
imaging O
data O
were O
processed O
to O
remove O
the O
linear O
trends O
and O
filtered O
using O
typical O
temporal O
bandpass O
( O
0.01 O
– O
0.08 O
  O
Hz O
) O
to O
reduce O
the O
low-frequency O
drift O
and O
high-frequency O
noise O
. O

For O
calculating O
the O
DC O
, O
we O
performed O
voxel-wise O
voxel-based O
whole-brain O
correlation O
analysis O
on O
the O
pre-processed O
fMRI O
data O
, O
as O
described O
previously O
. O

The O
time O
course O
of O
each O
voxel O
in O
each O
brain O
was O
correlated O
to O
every O
other O
voxel O
time O
course O
in O
the O
GM O
mask O
. O

Thus O
, O
we O
could O
acquire O
a O
n O
  O
× O
  O
n O
matrix O
of O
Pearson's O
correlation O
coefficients O
between O
any O
pair O
of O
voxels O
, O
where O
n O
is O
the O
voxel O
number O
of O
the O
GM O
mask O
. O

Next O
, O
we O
transformed O
the O
Pearson's O
correlation O
data O
into O
normally O
distributed O
Fisher O
Z-scores O
and O
constructed O
the O
whole-brain O
functional O
network O
by O
thresholding O
each O
correlation O
at O
r O
  O
> O
  O
0.25 O
. O

The O
threshold O
was O
the O
default O
setting O
while O
constructing O
the O
DC O
map O
. O

Only O
positive O
Pearson's O
correlation O
coefficients O
were O
considered O
in O
the O
present O
study O
. O

For O
a O
given O
voxel O
, O
the O
DC O
was O
calculated O
as O
the O
sum O
of O
the O
significant O
connections O
at O
the O
individual O
level O
. O

As O
described O
by O
previous O
studies O
, O
DC O
represents O
the O
number O
of O
direct O
connections O
for O
a O
given O
voxel O
in O
the O
voxel-based O
graphs O
. O

It O
has O
been O
widely O
used O
to O
represent O
the O
node O
characteristics O
of O
large-scale O
brain O
intrinsic O
connectivity O
networks O
. O

Statistical O
analysis O
The O
differences O
in O
age O
, O
education O
, O
and O
nicotine O
use O
between O
the O
CCS-dependent O
and O
control O
groups O
were O
assessed O
by O
two-sample O
two-tailed O
t-tests O
using O
SPSS O
statistical O
software O
. O

A O
two-tailed O
Pearson's O
chi-square O
test O
was O
performed O
to O
determine O
the O
differences O
in O
the O
gender O
between O
the O
two O
groups O
. O

To O
examine O
the O
between-group O
differences O
in O
the O
DC O
using O
zDC O
maps O
, O
a O
two-sample O
t-test O
was O
performed O
between O
the O
two O
groups O
using O
REST O
. O

A O
correction O
for O
multiple O
comparisons O
was O
performed O
by O
Monte O
Carlo O
simulation O
using O
the O
AlphaSim O
program O
, O
( O
http O
: O
/ O
/ O
afni.nimh.nih.gov O
) O
. O

The O
AlphaSim O
program O
was O
implemented O
in O
the O
REST O
software O
by O
combining O
the O
height O
threshold O
of O
P O
  O
< O
  O
0.001 O
and O
an O
extent O
threshold O
of O
P O
  O
< O
  O
0.01 O
, O
which O
corresponded O
to O
a O
corrected O
P O
  O
< O
  O
0.01 O
. O

The O
average O
DC O
values O
of O
all O
voxels O
in O
the O
significantly O
different O
regions O
demonstrated O
by O
voxel-based O
analysis O
were O
extracted O
independently O
using O
the O
extract O
time O
series O
in O
REST O
and O
entered O
into O
SPSS O
. O

Then O
, O
a O
Pearson's O
correlation O
analysis O
was O
performed O
to O
clarify O
the O
relationships O
between O
abnormal O
DC O
values O
of O
significantly O
different O
regions O
and O
clinical O
characteristics O
in O
CCS-dependent O
patients O
, O
including O
the O
duration O
of O
CCS O
usage O
, O
age O
at O
first O
CCS O
use O
, O
and O
BIS O
- O
11 O
scores O
; O
the O
significance O
levels O
were O
set O
at O
P O
  O
< O
  O
0.05 O
( O
two-tailed O
) O
. O

The O
major O
depressive O
disorder O
GWAS-supported O
variant O
rs10514299 O
in O
TMEM161B-MEF2C O
predicts O
putamen O
activation O
during O
reward O
processing O
in O
alcohol B-AlcoholAbuse
dependence I-AlcoholAbuse
Alcohol I-AlcoholAbuse
dependence I-AlcoholAbuse
( I-AlcoholAbuse
AD I-AlcoholAbuse
) I-AlcoholAbuse
frequently O
co-occurs O
with O
major O
depressive O
disorder O
( O
MDD O
) O
. O

While O
this O
comorbidity O
is O
associated O
with O
an O
increase O
in O
disease O
burden O
, O
worse O
treatment O
outcomes O
, O
and O
greater O
economic O
costs O
, O
the O
underlying O
neurobiology O
remains O
poorly O
understood O
. O

A O
recent O
large-scale O
GWAS O
of O
MDD O
has O
identified O
a O
locus O
in O
the O
TMEM161B-MEF2C O
region O
( O
rs10514299 O
) O
as O
a O
novel O
risk O
variant O
; O
however O
, O
the O
biological O
relevance O
of O
this O
variant O
has O
not O
yet O
been O
studied O
. O

Given O
previous O
reports O
of O
disrupted O
reward O
processing O
in O
both O
AD B-AlcoholAbuse
and O
MDD O
, O
we O
hypothesized O
that O
rs10514299 O
would O
be O
associated O
with O
differences O
in O
striatal O
BOLD O
responses O
during O
reward O
/ O
loss O
anticipation O
in O
AD B-AlcoholAbuse
. O

DNA O
samples O
from O
45 O
recently O
detoxified O
patients O
with O
AD B-AlcoholAbuse
and O
45 O
healthy B-NoKnownDisorder
controls I-NoKnownDisorder
( I-NoKnownDisorder
HC I-NoKnownDisorder
) I-NoKnownDisorder
were O
genotyped O
for O
rs10514299 O
. O

Participants O
performed O
the O
Monetary B-TaskParadigmImaging
Incentive I-TaskParadigmImaging
Delay I-TaskParadigmImaging
task I-TaskParadigmImaging
in I-TaskParadigmImaging
a I-TaskParadigmImaging
3 I-TaskParadigmImaging
- I-TaskParadigmImaging
Tesla I-TaskParadigmImaging
MRI I-TaskParadigmImaging
scanner I-TaskParadigmImaging
. I-TaskParadigmImaging

Effects O
of O
rs10514299 O
on O
striatal O
activation O
during O
anticipation O
of O
high O
/ O
low O
reward O
/ O
loss O
were O
investigated O
. O

Furthermore O
, O
we O
examined O
associations O
between O
rs10514299 O
and O
lifetime O
AD B-AlcoholAbuse
diagnosis O
in O
two O
independent O
clinical O
samples O
[ O
NIAAA O
: O
n O
= O
1858 O
( O
1123 O
cases O
, O
735 O
controls O
) O
; O
SAGE O
: O
n O
= O
3838 O
( O
1848 O
cases O
, O
1990 O
controls O
) O
] O
, O
as O
well O
as O
its O
association O
with O
depression O
severity O
in O
a O
subsample O
of O
individuals O
with O
a O
lifetime O
AD B-AlcoholAbuse
diagnosis O
( O
n O
= O
953 O
) O
. O

Patients O
carrying O
the O
T O
allele O
showed O
significantly O
greater O
putamen O
activation O
during O
anticipation O
of O
high O
reward O
( O
p O
= O
0.014 O
) O
, O
low O
reward O
( O
at O
trend-level O
; O
p O
= O
0.081 O
) O
, O
high O
loss O
( O
p O
= O
0.024 O
) O
, O
and O
low O
loss O
( O
p O
= O
0.046 O
) O
compared O
to O
HCs B-NoKnownDisorder
. O

Association O
analyses O
in O
the O
NIAAA O
sample O
showed O
a O
trend-level O
relationship O
between O
rs10514299 O
and O
a O
lifetime O
AD B-AlcoholAbuse
diagnosis O
in O
the O
European O
American O
subgroup O
( O
odds O
ratio O
= O
0.82 O
, O
p O
= O
0.09 O
) O
. O

This O
finding O
was O
not O
replicated O
in O
the O
SAGE O
sample O
. O

In O
the O
NIAAA O
sample O
, O
the O
T O
allele O
was O
significantly O
associated O
with O
greater O
depression O
symptom O
severity O
in O
individuals O
with O
a O
lifetime O
AD B-AlcoholAbuse
diagnosis O
( O
β O
= O
1.25 O
, O
p O
= O
0.02 O
) O
; O
this O
association O
was O
driven O
by O
the O
African O
American O
ancestry O
subgroup O
( O
β O
= O
2.11 O
, O
p O
= O
0.008 O
) O
. O

We O
show O
for O
the O
first O
time O
that O
the O
previously O
identified O
MDD O
risk O
variant O
rs10514299 O
in O
TMEM161B-MEF2C O
predicts O
neuronal O
correlates O
of O
reward O
processing O
in O
an O
AD B-AlcoholAbuse
phenotype O
, O
possibly O
explaining O
part O
of O
the O
shared O
pathophysiology O
and O
comorbidity O
between O
the O
disorders O
. O

Boldface O
indicates O
a O
significant O
between-group O
difference O
. O

Numbers O
reported O
are O
N O
( O
% O
) O
, O
unless O
stated O
otherwise O
. O

Ethnicity O
reported O
in O
this O
table O
was O
based O
on O
self-report O
. O

Diagnoses O
are O
based O
on O
DSM-IV-TR O
and O
were O
assessed O
with O
the O
SCID-IV B-StructuredClinicalInterviewforDSMDisorders
MADRS B-Montgomery–AsbergDepressionRatingScale
Montgomery-Asberg I-Montgomery–AsbergDepressionRatingScale
Depression I-Montgomery–AsbergDepressionRatingScale
Rating I-Montgomery–AsbergDepressionRatingScale
Scale I-Montgomery–AsbergDepressionRatingScale
The O
Neuroimaging O
Sample O
included O
90 O
participants O
( O
45 O
AD B-AlcoholAbuse
and O
45 O
HC B-NoKnownDisorder
) O
with O
a O
mean O
age O
of O
39.78 O
( O
SD O
= O
11.33 O
; O
see O
Table O
1 O
) O
. O

Prior O
to O
study O
participation O
, O
participants O
in O
the O
Neuroimaging O
and O
NIAAA O
Sample O
provided O
informed O
written O
consent O
in O
accordance O
with O
the O
Declaration O
of O
Helsinki O
and O
as O
approved O
by O
the O
National O
Institute O
on O
Alcohol O
Abuse O
and O
Alcoholism O
Review O
Board O
. O

All O
participants O
completed O
the O
Structured B-StructuredClinicalInterviewforDSMDisorders
Clinical I-StructuredClinicalInterviewforDSMDisorders
Interview I-StructuredClinicalInterviewforDSMDisorders
for I-StructuredClinicalInterviewforDSMDisorders
DSM-IV-TR I-StructuredClinicalInterviewforDSMDisorders
Axis I-StructuredClinicalInterviewforDSMDisorders
I I-StructuredClinicalInterviewforDSMDisorders
Disorders I-StructuredClinicalInterviewforDSMDisorders
( I-StructuredClinicalInterviewforDSMDisorders
SCID-IV I-StructuredClinicalInterviewforDSMDisorders
) I-StructuredClinicalInterviewforDSMDisorders
. O

Given O
that O
DSM O
- O
5 O
criteria O
for O
alcohol O
use O
disorder O
are O
less O
stringent O
compared O
to O
DSM-IV O
criteria O
for O
AD B-AlcoholAbuse
, O
all O
individuals O
likely O
fall O
into O
the O
moderate O
/ O
severe O
alcohol O
use O
disorder O
categories O
in O
DSM O
- O
5 O
. O

Exclusion O
criteria O
included O
left-handedness O
, O
contraindications O
for O
MRI O
( O
e.g O
. O
, O
claustrophobia O
or O
pregnancy O
) O
, O
and O
the O
presence O
of O
any O
significant O
medical O
or O
neurological O
diagnoses O
as O
assessed O
by O
a O
history O
and O
physical O
exam O
. O

Additional O
exclusion O
criteria O
for O
the O
HC B-NoKnownDisorder
group O
included O
DSM-IV-TR O
diagnoses O
of O
current O
/ O
past O
AD B-NoKnownDisorder
, O
positive O
urine O
drug O
screens O
, O
and O
alcohol O
breathalyzer O
readings O
above O
zero O
. O

FMRI B-FunctionalMagneticResonanceImaging
scans O
were O
obtained O
while O
participants O
completed O
a O
modified O
version O
of O
the O
MID B-TaskParadigmImaging
task I-TaskParadigmImaging
where O
approximately O
70% O
of O
trials O
were O
successful O
. O

Participants O
were O
not O
on O
any O
psychotropic O
medications O
on O
the O
day O
of O
the O
scan O
and O
there O
were O
no O
alcohol O
abstainers O
among O
the O
HC B-NoKnownDisorder
group O
. O

DNA O
samples O
were O
obtained O
from O
all O
participants O
for O
genotyping O
. O

Demographics O
and O
characteristics O
of O
the O
NIAAA O
Sample O
and O
the O
Lifetime O
Alcohol O
Dependence O
Sample O
NIAAA O
Sample O
N O
= O
1858 O
NIAAA O
subsample O
with O
lifetime O
AD O
Cases O
N O
= O
1123 O
Controls O
N O
= O
735 O
N O
= O
955 O
Gender O
, O
N O
, O
( O
% O
) O
Male O
323 O
( O
28.8 O
) O
325 O
( O
44.2 O
) O
669 O
( O
70.0 O
) O
Female O
800 O
( O
71.2 O
) O
410 O
( O
55.8 O
) O
286 O
( O
30.0 O
) O
Age O
, O
mean O
years O
( O
SD O
) O
42.6 O
( O
10.9 O
) O
32.8 O
( O
11.6 O
) O
42.8 O
( O
10.8 O
) O
Ethnicity O
, O
N O
, O
( O
% O
) O
Black O
/ O
African O
American O
507 O
( O
45.2 O
) O
232 O
( O
31.6 O
) O
439 O
( O
46.0 O
) O
European O
American O
531 O
( O
47.3 O
) O
411 O
( O
55.9 O
) O
441 O
( O
46.1 O
) O
Asian O
16 O
( O
1.4 O
) O
47 O
( O
6.4 O
) O
12 O
( O
1.3 O
) O
Multiracial O
21 O
( O
1.9 O
) O
20 O
( O
2.7 O
) O
18 O
( O
1.9 O
) O
Native O
American O
or O
Alaska O
Native O
5 O
( O
0.5 O
) O
2 O
( O
0.3 O
) O
5 O
( O
0.5 O
) O
Native O
Hawaiian O
or O
other O
Pacific O
Islander O
1 O
( O
0.1 O
) O
1 O
( O
0.1 O
) O
1 O
( O
0.1 O
) O
Unknown O
42 O
( O
3.7 O
) O
22 O
( O
3.0 O
) O
39 O
( O
4.1 O
) O
Smokers O
, O
N O
, O
( O
% O
) O
662 O
( O
59.0 O
) O
44 O
( O
6.1 O
) O
595 O
( O
62.3 O
) O
MADRS O
score O
, O
mean O
( O
SD O
) O
13.2 O
( O
9.8 O
) O
1.3 O
( O
3.2 O
) O
13.2 O
( O
9.8 O
) O
Major O
depressive O
disorder—current O
, O
N O
, O
( O
% O
) O
108 O
( O
5.8 O
) O
8 O
( O
0.4 O
) O
103 O
( O
10.8 O
) O
Major O
depressive O
disorder—lifetime O
, O
N O
, O
( O
% O
) O
216 O
( O
11.6 O
) O
49 O
( O
2.6 O
) O
196 O
( O
20.5 O
) O
Note O
. O

Ethnicity O
reported O
in O
this O
table O
was O
based O
on O
self-report O
MADRS O
Montgomery-Asberg O
Depression O
Rating O
Scale O
The O
NIAAA O
Sample O
consisted O
of O
1123 O
individuals O
with O
a O
DSM-IV-TR O
diagnosis O
of O
AD B-AlcoholAbuse
and O
735 O
HCs B-NoKnownDisorder
who O
enrolled O
in O
research O
studies O
at O
the O
National O
Institute O
on O
Alcohol O
Abuse O
and O
Alcoholism O
at O
the O
National O
Institutes O
of O
Health O
Clinical O
Center O
in O
Bethesda O
, O
MD O
( O
see O
Table O
2 O
) O
. O
531 O
individuals O
with O
AD O
and O
411 O
controls O
were O
of O
European O
American O
( O
EA O
) O
descent O
. O

A O
total O
of O
507 O
individuals O
with O
AD B-AlcoholAbuse
and O
232 O
controls B-NoKnownDisorder
were O
of O
African O
American O
( O
AA O
) O
descent O
. O

All O
participants O
provided O
blood O
samples O
for O
genotyping O
. O

The O
SAGE O
was O
funded O
by O
the O
National O
Human O
Genome O
Research O
Institute O
as O
part O
of O
the O
Gene O
Environment O
Association O
Studies O
( O
GENEVA O
) O
that O
consisted O
of O
three O
major O
studies O
of O
addictive O
disorders O
: O
The O
Collaborative O
Study O
on O
the O
Genetics O
of O
Alcoholism O
( O
COGA O
) O
, O
the O
Family O
Study O
of O
Cocaine O
Dependence O
( O
FSCD O
) O
, O
and O
the O
Collaborative O
Genetic O
Study O
of O
Nicotine O
Dependence O
( O
COGEND O
) O
. O

The O
accession O
number O
of O
dbGaP O
is O
phs000092 O
. O
v1 O
. O
p1 O
. O

The O
EA O
subgroup O
of O
the O
SAGE O
Sample O
consisted O
of O
1162 O
cases O
( O
mean O
age O
= O
38.2 O
( O
9.94 O
) O
; O
62% O
male O
) O
and O
1346 O
controls B-NoKnownDisorder
( O
mean O
age O
38.6 O
( O
9.44 O
) O
; O
30.3% O
male O
) O
. O

The O
AA O
subgroup O
consisted O
of O
686 O
cases O
( O
mean O
age O
= O
40.3 O
( O
7.7 O
) O
; O
61% O
male O
) O
and O
644 O
controls O
( O
mean O
age O
= O
39.6 O
( O
7.2 O
) O
; O
36% O
male O
) O
. O

All O
cases O
met O
lifetime O
DSM-IV O
criteria O
for O
AD B-AlcoholAbuse
, O
and O
were O
excluded O
if O
they O
had O
schizophrenia O
or O
any O
other O
psychotic O
illness O
. O

Controls B-NoKnownDisorder
were O
defined O
as O
individuals O
who O
had O
been O
exposed O
to O
alcohol O
, O
but O
had O
not O
met O
lifetime O
criteria O
for O
AD B-AlcoholAbuse
or O
other O
illicit O
substances O
. O

Experimental O
paradigm O
Participants O
completed O
a O
modified O
version O
of O
the O
MID B-TaskParadigmImaging
task I-TaskParadigmImaging
, O
which O
required O
a O
fast O
button O
response O
to O
a O
target O
to O
win O
or O
avoid O
losing O
money O
. O

A O
trial O
started O
with O
a O
crosshair O
for O
fixation O
, O
then O
a O
2 O
- O
second O
presentation O
of O
a O
cue O
( O
a O
shape O
indicating O
the O
type O
of O
trial O
: O
reward O
, O
loss O
, O
or O
neutral O
) O
. O

After O
a O
delay O
screen O
of O
variable O
duration O
( O
between O
0.75 O
and O
1.75 O
s O
) O
the O
target O
was O
presented O
( O
a O
white-filled O
square O
to O
which O
the O
participants O
were O
trained O
to O
respond O
to O
) O
. O

Next O
, O
another O
delay O
screen O
of O
variable O
duration O
( O
between O
0.75 O
and O
3 O
s O
) O
was O
presented O
before O
the O
feedback O
screen O
appeared O
. O

The O
feedback O
screen O
showed O
the O
amount O
that O
was O
won O
or O
lost O
in O
the O
previous O
trial O
, O
which O
represented O
if O
the O
participant O
had O
successfully O
pressed O
the O
button O
in O
time O
to O
win O
or O
avoid O
losing O
the O
target O
amount O
. O

The O
total O
amount O
of O
money O
accumulated O
up O
to O
that O
point O
was O
also O
presented O
on O
the O
feedback O
screen O
. O

After O
practicing O
outside O
of O
the O
scanner O
and O
being O
informed O
that O
gains O
/ O
losses O
during O
the O
task O
would O
be O
reflected O
in O
their O
final O
payment O
, O
each O
subject O
completed O
a O
12 B-TaskParadigmImaging
- I-TaskParadigmImaging
minute I-TaskParadigmImaging
fMRI I-TaskParadigmImaging
session I-TaskParadigmImaging
of I-TaskParadigmImaging
the I-TaskParadigmImaging
MID I-TaskParadigmImaging
task I-TaskParadigmImaging
. I-TaskParadigmImaging

Five O
different O
cues O
were O
presented O
thirty O
times O
, O
each O
representing O
a O
different O
trial O
condition O
; O
neutral O
( O
no O
reward O
/ O
no O
loss O
) O
, O
low O
loss O
, O
high O
loss O
, O
low O
reward O
, O
and O
high O
reward O
. O

MRI O
data O
acquisition O
and O
preprocessing O
A B-MagneticResonanceImagingInstrument
Siemens I-MagneticResonanceImagingInstrument
3 I-MagneticResonanceImagingInstrument
T I-MagneticResonanceImagingInstrument
Skyra I-MagneticResonanceImagingInstrument
scanner I-MagneticResonanceImagingInstrument
was O
used O
to O
collect O
whole-brain O
echo-planar O
imaging O
functional O
( O
36 O
axial O
slices O
, O
4 O
mm O
slice O
thickness O
, O
64 O
× O
64 O
matrix O
and O
repetition O
time O
of O
2000 O
ms O
) O
and O
MPRGE B-StructuralImaging
structural I-StructuralImaging
data I-StructuralImaging
. O

Preprocessing O
and O
analysis O
was O
performed O
using O
AFNI O
software O
package O
. O

Large O
transients O
removal O
was O
performed O
before O
slice-time O
correction O
, O
then O
nuisance O
variables O
were O
de-trended O
, O
including O
the O
six O
parameter O
estimates O
for O
head O
motion O
. O

No O
participants O
had O
any O
condition O
censored O
more O
than O
20% O
( O
motion O
higher O
than O
0.3 O
mm O
was O
censored O
out O
) O
, O
a O
criterion O
to O
be O
excluded O
from O
the O
analysis O
. O

Images O
were O
then O
coregistered O
to O
the O
individual O
structural O
image O
, O
resampled O
( O
2 O
- O
mm O
isotropic O
) O
, O
smoothed O
( O
4 O
- O
mm O
full-width-half-maximum O
Gaussian O
kernel O
) O
, O
normalized O
by O
the O
mean O
signal O
intensity O
in O
each O
voxel O
to O
reflect O
percent O
signal O
change O
, O
and O
finally O
transformed O
into O
the O
standardized O
. O

BOLD O
fMRI B-FunctionalMagneticResonanceImaging
data O
and O
ROI O
analysis O
Single-subject O
level O
analysis O
was O
performed O
using O
AFNI O
. O

Then O
, O
using O
ROI O
masks O
of O
the O
bilateral O
caudate O
, O
putamen O
, O
and O
nucleus O
accumbens O
, O
generated O
with O
AFNI O
DrawDataset O
plugins O
and O
following O
previously O
published O
literature O
and O
subtracting O
all O
nuances O
effects O
( O
such O
as O
pre-motor O
activations O
) O
, O
except O
reward O
/ O
loss O
response O
, O
we O
computed O
average O
percent O
signal O
change O
( O
beta O
weights O
) O
of O
the O
following O
comparisons O
: O
high O
reward O
> O
neutral O
, O
low O
reward O
> O
neutral O
, O
high O
loss O
> O
neutral O
, O
low O
loss O
> O
neutral O
. O

For O
simplification O
purposes O
, O
we O
refer O
to O
these O
as O
high O
reward O
, O
low O
reward O
, O
high O
loss O
, O
and O
low O
loss O
, O
respectively O
. O

Genotyping O
NIAAA O
Sample O
Large-scale O
genotyping O
was O
performed O
at O
the O
NIAAA O
Laboratory O
of O
Neurogenetics O
using O
the O
Illumina O
OmniExpress O
BeadChip O
( O
Illumina O
, O
San O
Diego O
, O
CA O
) O
. O

Data O
for O
the O
SNP O
rs10514299 O
located O
within O
the O
TMEM161B-AS1 O
gene O
cluster O
was O
extracted O
from O
the O
larger O
array O
. O

Ancestry O
informative O
markers O
( O
AIMs O
; O
n O
= O
2500 O
) O
were O
extracted O
from O
the O
Illumina O
array O
to O
calculate O
ancestral O
proportions O
for O
all O
study O
participants O
. O

Using O
methods O
described O
previously O
for O
an O
AIM O
panel O
including O
186 O
markers O
, O
which O
were O
not O
available O
for O
the O
current O
data O
set O
, O
the O
ancestry O
assessment O
identified O
6 O
ethnic O
factors O
( O
Africa O
, O
Europe O
, O
Asia O
, O
Far O
East O
Asia O
, O
Oceania O
, O
and O
Americas O
) O
. O

SAGE O
Sample O
Whole-genome O
genotyping O
was O
completed O
using O
the O
Illumina O
Human O
- O
1M O
platform O
( O
Illumina O
Inc O
. O
, O
San O
Diego O
, O
CA O
) O
. O

The O
190 O
HapMap O
samples O
( O
48 O
HapMap O
control O
samples O
, O
55 O
CEU O
, O
55 O
YUR O
, O
13 O
CHB O
, O
and O
17 O
JPT O
) O
were O
genotyped O
in O
the O
same O
platform O
and O
population O
stratification O
analyses O
were O
performed O
using O
principal O
component O
analysis O
. O

After O
a O
series O
of O
quality O
control O
procedures O
( O
p O
value O
of O
Hardy-Weinberg O
equilibrium O
( O
HWE O
) O
< O
10e O
- O
5 O
, O
missing O
rate O
by O
SNP O
> O
2% O
, O
missing O
rate O
by O
individual O
> O
2% O
, O
minor O
allele O
frequency O
< O
1% O
, O
sex O
inconsistency O
) O
, O
there O
were O
1162 O
case O
and O
1346 O
control O
samples O
in O
the O
EA O
subgroup O
and O
686 O
case O
and O
644 O
control O
samples O
in O
AA O
subgroup O
. O

Two O
population O
stratification O
scores O
( O
PSS O
) O
calculated O
based O
on O
principal O
component O
analysis O
were O
used O
for O
statistical O
analyses O
. O

Statistical O
analysis O
Main O
analyses O
of O
the O
Neuroimaging O
Sample O
were O
run O
using O
SPSS O
statistical O
software O
package O
( O
IBM O
SPSS O
Statistics O
® O
20 O
, O
IBM O
Corp O
. O
© O
, O
Armonk O
, O
NY O
) O
. O

Baseline O
differences O
in O
demographic O
variables O
between O
cases O
and O
controls O
were O
determined O
using O
t-tests O
for O
continuous O
and O
chi-square O
tests O
for O
categorical O
variables O
. O

Chi-square O
tests O
were O
performed O
to O
test O
the O
genotypic O
distribution O
of O
the O
SNP O
in O
both O
cases O
and O
controls O
. O

The O
primary O
outcome O
measure O
was O
activation O
in O
the O
caudate O
, O
putamen O
, O
and O
nucleus O
accumbens O
during O
reward O
/ O
loss O
anticipation O
as O
measured O
by O
BOLD O
fMRI O
. O

Shapiro-Wilk O
tests O
confirmed O
that O
all O
four O
imaging O
outcomes O
( O
high O
reward O
, O
low O
reward O
, O
high O
loss O
, O
low O
loss O
) O
were O
normally O
distributed O
( O
all O
p O
≥ O
0.407 O
) O
. O

For O
the O
main O
analysis O
of O
effects O
of O
diagnosis O
, O
genotype O
, O
and O
their O
interaction O
on O
BOLD O
responses O
in O
the O
caudate O
, O
putamen O
, O
and O
nucleus O
accumbens O
, O
we O
conducted O
2 O
× O
2 O
analyses O
of O
covariance O
( O
ANCOVAs O
) O
with O
group O
( O
AD O
vs O
. O

HC O
) O
T O
allele O
carrier O
status O
( O
CC O
vs O
. O

TT O
/ O
CT–assuming O
a O
dominant O
model O
) O
as O
factors O
and O
age O
, O
gender O
, O
AIM O
score O
Europe O
, O
and O
AIM O
score O
Africa O
as O
covariates O
. O

All O
tests O
were O
two-tailed O
and O
considered O
to O
be O
statistically O
significant O
at O
p O
< O
0.05 O
. O

For O
the O
NIAAA O
Sample O
, O
minor O
allele O
frequency O
, O
HWE O
, O
and O
association O
analyses O
were O
conducted O
using O
PLINK O
version O
1.07 O
. O

Analyses O
were O
conducted O
first O
in O
the O
entire O
sample O
, O
and O
then O
separately O
for O
EA O
and O
AA O
subgroups O
, O
based O
on O
self-report O
. O

Case-control O
association O
with O
lifetime O
AD O
was O
determined O
using O
logistic O
regression O
, O
while O
association O
with O
the O
MADRS O
scale O
was O
determined O
using O
linear O
regression O
. O

Both O
analyses O
used O
an O
additive O
model O
and O
adjusted O
for O
age O
, O
gender O
, O
and O
AIM O
scores O
for O
European O
and O
African O
ancestry O
. O

Similarly O
, O
for O
the O
SAGE O
Sample O
, O
a O
logistic O
regression O
model O
controlling O
for O
age O
, O
gender O
, O
and O
2 O
PSS O
for O
African O
and O
European O
ancestry O
was O
performed O
with O
the O
assumption O
of O
an O
additive O
model O
. O

Analyses O
were O
performed O
separately O
in O
individuals O
of O
European O
and O
African O
ancestry O
. O

Modeling O
subjective O
relevance O
in O
schizophrenia B-Schizophrenia
and O
its O
relation O
to O
aberrant O
salience O
In O
schizophrenia B-Schizophrenia
, O
increased O
aberrant O
salience O
to O
irrelevant O
events O
and O
reduced O
learning O
of O
relevant O
information O
may O
relate O
to O
an O
underlying O
deficit O
in O
relevance O
detection O
. O

So O
far O
, O
subjective O
estimates O
of O
relevance O
have O
not O
been O
probed O
in O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
. I-Schizophrenia

The O
mechanisms O
underlying O
belief O
formation O
about O
relevance O
and O
their O
translation O
into O
decisions O
are O
unclear O
. O

Using O
novel O
computational O
methods O
, O
we O
investigated O
relevance O
detection O
during O
implicit O
learning O
in O
42 O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
and O
42 O
healthy B-NoKnownDisorder
individuals I-NoKnownDisorder
. O

Participants B-TaskParadigmImaging
underwent I-TaskParadigmImaging
functional B-FunctionalMagneticResonanceImaging
magnetic I-FunctionalMagneticResonanceImaging
resonance I-FunctionalMagneticResonanceImaging
imaging I-FunctionalMagneticResonanceImaging
while B-TaskParadigmImaging
detecting I-TaskParadigmImaging
the I-TaskParadigmImaging
outcomes I-TaskParadigmImaging
in I-TaskParadigmImaging
a I-TaskParadigmImaging
learning I-TaskParadigmImaging
task I-TaskParadigmImaging
. O

These O
were O
preceded O
by O
cues O
differing O
in O
color O
and O
shape O
, O
which O
were O
either O
relevant O
or O
irrelevant O
for O
outcome O
prediction O
. O

We O
provided O
a O
novel O
definition O
of O
relevance O
based O
on O
Bayesian O
precision O
and O
modeled O
reaction O
times O
as O
a O
function O
of O
relevance O
weighted O
unsigned O
prediction O
errors O
( O
UPE O
) O
. O

For O
aberrant O
salience O
, O
we O
assessed O
responses O
to O
subjectively O
irrelevant O
cue O
manifestations O
. O

Participants O
learned O
the O
contingencies O
and O
slowed O
down O
their O
responses O
following O
unexpected O
events O
. O

Model O
selection O
revealed O
that O
individuals O
inferred O
the O
relevance O
of O
cue O
features O
and O
used O
it O
for O
behavioral O
adaption O
to O
the O
relevant O
cue O
feature O
. O

Relevance O
weighted O
UPEs O
correlated O
with O
dorsal O
anterior O
cingulate O
cortex O
activation O
and O
hippocampus O
deactivation O
. O

In O
patients O
, O
the O
aberrant O
salience O
bias O
to O
subjectively O
task-irrelevant O
information O
was O
increased O
and O
correlated O
with O
decreased O
striatal O
UPE O
activation O
and O
increased O
negative O
symptoms O
. O

This O
study O
shows O
that O
relevance O
estimates O
based O
on O
Bayesian O
precision O
can O
be O
inferred O
from O
observed O
behavior O
. O

This O
underscores O
the O
importance O
of O
relevance O
detection O
as O
an O
underlying O
mechanism O
for O
behavioral O
adaptation O
in O
complex O
environments O
and O
enhances O
the O
understanding O
of O
aberrant O
salience O
in O
schizophrenia O
. O

Author O
summary O
Schizophrenia B-Schizophrenia
patients I-Schizophrenia
display O
deficits O
in O
the O
appropriate O
attribution O
of O
meaningfulness O
to O
stimuli O
; O
such O
as O
aberrantly O
increased O
processing O
of O
irrelevant O
and O
insufficient O
processing O
of O
relevant O
information O
. O

We O
aimed O
to O
investigate O
the O
subjective O
nature O
of O
relevance O
detection O
and O
its O
deficit O
in O
schizophrenia B-Schizophrenia
and O
developed O
an O
implicit B-TaskParadigmImaging
learning I-TaskParadigmImaging
paradigm I-TaskParadigmImaging
that O
allowed O
for O
parallel O
learning O
from O
relevant O
and O
irrelevant O
information O
. O

Based O
on O
the O
idea O
that O
subjective O
relevance O
might O
be O
captured O
by O
Bayesian O
precision O
we O
set O
up O
different O
computational O
models O
of O
how O
subjective O
relevance O
guides O
learning O
and O
behavioral O
adaptation O
. O

We O
found O
that O
subjects O
use O
Bayesian O
precision O
to O
estimate O
stimulus O
relevance O
in O
order O
to O
integrate O
multidimensional O
information O
and O
adapt O
more O
to O
the O
subjectively O
relevant O
stimuli O
. O

This O
relevance O
weighted O
adaptation O
correlated O
with O
brain O
activation O
within O
the O
salience O
network O
. O

Further O
, O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
displayed O
an O
increased O
aberrant O
tendency O
to O
irrelevant O
events O
which O
related O
to O
decreased O
striatal O
coding O
of O
the O
relevant O
learning O
signal O
. O

To O
conclude O
, O
our O
findings O
demonstrate O
how O
individual O
beliefs O
about O
relevance O
can O
be O
inferred O
from O
computational O
models O
. O

Furthermore O
, O
we O
suggest O
that O
aberrant O
salience O
observed O
in O
patients B-Schizophrenia
with I-Schizophrenia
schizophrenia I-Schizophrenia
reflects O
an O
idiosyncratic O
bias O
in O
states O
of O
high O
subjective O
uncertainty O
. O

Materials B-StudyMethod
and I-StudyMethod
methods I-StudyMethod
Ethics O
statement O
All O
participants O
gave O
written O
informed O
consent O
and O
received O
monetary O
compensation O
as O
well O
as O
the O
total O
wins O
of O
the O
task O
battery O
. O

The O
study O
was O
performed O
in O
accordance O
with O
the O
Declaration O
of O
Helsinki O
and O
was O
approved O
by O
the O
local O
ethics O
committee O
of O
Charité O
Universitätsmedizin O
. O

Participants O
In O
total O
, O
42 O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
and O
a O
matched O
healthy B-NoKnownDisorder
control I-NoKnownDisorder
group I-NoKnownDisorder
of O
42 O
individuals O
participated O
in O
this O
study O
. O

Healthy B-NoKnownDisorder
individuals I-NoKnownDisorder
reported O
no O
past O
or O
present O
psychiatric O
disorder O
according O
to O
the O
SKID-I O
. O

Patients O
were O
diagnosed O
with O
schizophrenia B-Schizophrenia
according O
to O
the O
DSM-IV O
and O
ICD O
- O
10 O
. O

Psychopathology O
was O
assessed O
using O
the O
Positive B-PositiveandNegativeSyndromeScale
and I-PositiveandNegativeSyndromeScale
Negative I-PositiveandNegativeSyndromeScale
Syndrome I-PositiveandNegativeSyndromeScale
Scale I-PositiveandNegativeSyndromeScale
( I-PositiveandNegativeSyndromeScale
PANSS I-PositiveandNegativeSyndromeScale
) I-PositiveandNegativeSyndromeScale
as O
well O
as O
the O
subscale O
for O
delusions O
and O
anhedonia O
of O
the O
Scale O
for O
the O
Assessment O
of O
Positive B-ScaleforAssessmentofPositiveSymptoms
( I-ScaleforAssessmentofPositiveSymptoms
SAPS I-ScaleforAssessmentofPositiveSymptoms
) I-ScaleforAssessmentofPositiveSymptoms
and O
Negative B-ScaleforAssessmentofNegativeSymptoms
Symptoms I-ScaleforAssessmentofNegativeSymptoms
( I-ScaleforAssessmentofNegativeSymptoms
SANS I-ScaleforAssessmentofNegativeSymptoms
) I-ScaleforAssessmentofNegativeSymptoms
, O
respectively O
( O
for O
information O
on O
demographics O
and O
psychopathology O
, O
see O
Table O
1 O
) O
. O

All O
patients O
were O
on O
antipsychotic B-MedicationStatus
medication I-MedicationStatus
( O
for O
more O
details O
, O
see O
Table O
A O
in O
the O
Supplement O
) O
. O

They O
were O
recruited O
from O
the O
inpatient O
and O
outpatient O
units O
of O
the O
Department O
of O
Psychiatry O
and O
Psychotherapy O
, O
Charité-Universitätsmedizin O
Berlin O
and O
the O
Psychiatric O
Department O
of O
the O
Schlossparkklinik O
Berlin O
. O

Aberrant O
salience O
raw O
data O
scores O
of O
a O
partially O
overlapping O
sample O
( O
37 O
healthy B-NoKnownDisorder
controls I-NoKnownDisorder
and O
34 O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
) O
were O
reported O
in O
a O
previous O
publication O
. O

Demographic O
and O
clinical O
characteristics O
. O

SCHIZOPHRENIA B-Schizophrenia
PATIENTS I-Schizophrenia
( O
N O
= O
42 O
) O
HEALTHY B-NoKnownDisorder
INDIVIDUALS I-NoKnownDisorder
( O
N O
= O
42 O
) O
STATISTICS O
Gender O
12 O
females O
, O
30 O
males O
16 O
females O
, O
26 O
males O
χ2 O
( O
1 O
) O
= O
.355 O
, O
p O
= O
0.488 O
AGE O
( O
IN O
YEARS O
) O
35.1 O
( O
± O
7.4 O
) O
33.5 O
( O
± O
7.8 O
) O
t O
( O
82 O
) O
= O
1 O
, O
p O
= O
0.321 O
VERBAL O
IQ O
101 O
( O
± O
9.4 O
) O
104.9 O
( O
± O
9.4 O
) O
t O
( O
78 O
) O
= O
2.13 O
, O
p O
= O
0.036 O
EHI O
67.4 O
( O
± O
53 O
) O
69.72 O
( O
± O
48.09 O
) O
t O
( O
77 O
) O
= O
.21 O
, O
p O
= O
.837 O
DURATION O
OF O
ILLNESS O
( O
YEARS O
) O
9.4 O
( O
± O
6 O
) O
AGE O
OF O
ILLNESS O
ONSET O
( O
YEARS O
) O
25.9 O
( O
± O
7.1 O
) O
PANSS B-PositiveandNegativeSyndromeScale
POSITIVE I-PositiveandNegativeSyndromeScale
20.7 O
( O
± O
6.7 O
) O
PANSS B-PositiveandNegativeSyndromeScale
NEGATIVE I-PositiveandNegativeSyndromeScale
22.6 O
( O
± O
7.6 O
) O
PANSS B-PositiveandNegativeSyndromeScale
GENERAL I-PositiveandNegativeSyndromeScale
41 O
( O
± O
10.9 O
) O
PANSS B-PositiveandNegativeSyndromeScale
TOTAL I-PositiveandNegativeSyndromeScale
84.5 O
( O
± O
21.5 O
) O
SAPS B-ScaleforAssessmentofPositiveSymptoms
DELUSIONS I-ScaleforAssessmentofPositiveSymptoms
21.3 O
( O
± O
10.9 O
) O
SANS B-ScaleforAssessmentofNegativeSymptoms
ANHEDONIA I-ScaleforAssessmentofNegativeSymptoms
12.4 O
( O
± O
4.9 O
) O
Implicit B-TaskParadigmImaging
salience I-TaskParadigmImaging
paradigm I-TaskParadigmImaging
( I-TaskParadigmImaging
ISP I-TaskParadigmImaging
) I-TaskParadigmImaging
This I-TaskParadigmImaging
paradigm I-TaskParadigmImaging
was I-TaskParadigmImaging
explicitly I-TaskParadigmImaging
instructed I-TaskParadigmImaging
like I-TaskParadigmImaging
a I-TaskParadigmImaging
target-detection I-TaskParadigmImaging
task I-TaskParadigmImaging
though I-TaskParadigmImaging
implicitly I-TaskParadigmImaging
being I-TaskParadigmImaging
a I-TaskParadigmImaging
learning I-TaskParadigmImaging
paradigm I-TaskParadigmImaging
where I-TaskParadigmImaging
features I-TaskParadigmImaging
of I-TaskParadigmImaging
neutral I-TaskParadigmImaging
stimuli I-TaskParadigmImaging
predicted I-TaskParadigmImaging
certain I-TaskParadigmImaging
outcomes I-TaskParadigmImaging
. I-TaskParadigmImaging

It O
consisted O
of O
160 O
trials O
where O
subjects O
were O
told O
to O
discriminate O
the O
outcomes O
( O
10 O
Eurocent O
coin O
or O
blue O
circle O
) O
of O
each O
trial O
. O

Therefore O
, O
their O
only O
task O
was O
to O
press O
a O
respective O
button O
when O
they O
saw O
a O
coin O
, O
versus O
another O
button O
when O
they O
saw O
the O
blue O
circle O
. O

Subjects O
were O
told O
that O
they O
would O
receive O
the O
amount O
of O
money O
they O
had O
seen O
during O
the O
task O
irrespective O
of O
whether O
they O
had O
pressed O
a O
button O
or O
not O
, O
though O
they O
were O
encouraged O
by O
the O
experimenters O
not O
to O
miss O
too O
many O
trials O
because O
this O
would O
impede O
the O
analysis O
. O

The O
outcomes O
were O
preceded O
by O
conditioned O
stimuli O
that O
differed O
in O
color O
and O
shape O
: O
gray O
or O
colorful O
squares O
or O
triangles O
( O
see O
Fig O
1A O
and O
1B O
) O
. O

During O
the O
instructions O
, O
subjects O
were O
told O
not O
to O
pay O
attention O
to O
these O
stimuli O
preceding O
the O
outcomes O
. O

However O
, O
prior O
to O
scanning O
, O
participants O
were O
primed O
with O
the O
stimulus O
features O
while O
they O
were O
asked O
to O
name O
the O
color O
and O
the O
shape O
of O
each O
of O
the O
four O
conditioned O
stimuli O
. O

Then O
, O
they O
practiced O
the O
outcome O
detection O
for O
10 O
trials O
. O

In O
this O
practice O
session O
, O
all O
outcomes O
were O
preceded O
by O
a O
stimulus O
that O
was O
not O
presented O
during O
the O
main O
experiment O
in O
the O
scanner O
. O

In O
the O
main O
experiment O
, O
the O
conditioned O
stimuli O
predicted O
the O
outcome O
types O
in O
a O
probabilistic O
manner O
that O
reversed O
during O
the O
task O
. O

Importantly O
, O
only O
one O
stimulus O
feature O
reliably O
predicted O
the O
outcome O
( O
eg O
, O
shape O
) O
. O

For O
instance O
, O
80% O
of O
all O
triangles O
were O
followed O
by O
the O
coin O
( O
20% O
circle O
) O
, O
and O
80% O
of O
all O
squares O
were O
followed O
by O
the O
blue O
circle O
( O
20% O
coin O
) O
. O

Whether O
the O
square O
or O
the O
triangle O
predicted O
the O
coin O
reversed O
every O
20 O
trials O
. O

In O
the O
meantime O
, O
the O
color O
of O
the O
stimuli O
was O
irrelevant O
in O
predicting O
the O
outcome O
; O
colorful O
and O
gray O
stimuli O
were O
equally O
followed O
by O
coins O
and O
circles O
( O
50% O
each O
) O
. O

After O
the O
first O
half O
of O
the O
experiment O
this O
was O
reversed O
, O
and O
then O
the O
formerly O
irrelevant O
feature O
( O
here O
: O
shape O
) O
predicted O
the O
outcome O
, O
whereas O
the O
other O
feature O
turned O
irrelevant O
( O
see O
Fig O
2 O
) O
. O

The O
relevant O
dimensions O
were O
counterbalanced O
across O
participants O
and O
coins O
and O
neutral O
outcomes O
were O
each O
displayed O
in O
50% O
of O
all O
trials O
. O

In O
total O
, O
the O
experiment O
lasted O
15 O
minutes O
and O
took O
place O
during O
fMRI B-FunctionalMagneticResonanceImaging
scanning I-FunctionalMagneticResonanceImaging
. O

Participants O
received O
the O
amount O
of O
coins O
seen O
in O
the O
experiment O
( O
8 O
Euro O
) O
. O

( O
A O
) O
Depiction O
of O
one O
ISP O
trial O
. O

Participants O
see O
one O
of O
four O
cues O
( O
B O
) O
that O
is O
then O
followed O
by O
either O
a O
coin O
( O
representing O
reward O
) O
or O
a O
blue O
circle O
( O
neutral O
outcome O
) O
. O

They O
have O
to O
respond O
to O
each O
outcome O
via O
a O
respective O
button O
press O
. O

( O
B O
) O
Conditioned O
cues O
varying O
in O
color O
and O
shape O
. O

( O
C O
) O
Log O
reaction O
times O
( O
logRT O
) O
and O
simulated O
logRT O
( O
dashed O
lines O
, O
based O
on O
the O
best O
model O
) O
for O
coin O
( O
green O
) O
and O
circle O
( O
orange O
) O
trials O
. O

Subjects O
were O
faster O
in O
coin O
than O
in O
circle O
trials O
and O
speeded O
up O
their O
responses O
over O
the O
course O
of O
each O
block O
. O

These O
effects O
were O
also O
captured O
by O
the O
best O
fitting O
model O
. O

Upper O
plot O
: O
Underlying O
task O
contingencies O
between O
color O
and O
outcome O
( O
blue O
) O
and O
shape O
and O
outcome O
( O
red O
) O
. O

Note O
that O
the O
direction O
of O
the O
trajectories O
reflects O
a O
tendency O
towards O
an O
association O
( O
eg O
, O
1 O
for O
[ O
triangle O
→ O
reward O
; O
square O
→ O
circle O
] O
and O
0 O
for O
the O
opposite O
associations O
) O
and O
does O
not O
reflect O
a O
reward O
value O
. O

In O
this O
example O
, O
during O
the O
first O
half O
of O
the O
ISP O
, O
color O
is O
relevant O
for O
predicting O
the O
outcome O
, O
whereas O
the O
squares O
and O
triangles O
both O
predict O
coin O
and O
circle O
with O
a O
probability O
of O
0.5 O
and O
are O
therefore O
irrelevant O
. O

The O
extradimensional O
relevance O
reverses O
after O
80 O
trials O
, O
and O
shape O
becomes O
relevant O
. O

Inside O
the O
relevant O
features O
, O
the O
80% O
rewarded O
feature O
manifestation O
reverses O
every O
20 O
trial O
block O
. O

That O
is O
to O
say O
, O
if O
colorful O
cues O
are O
rewarded O
in O
80% O
of O
trials O
( O
gray O
cues O
in O
20% O
) O
in O
the O
beginning O
, O
gray O
cues O
are O
followed O
by O
coins O
( O
colorful O
cues O
by O
a O
circle O
) O
for O
the O
next O
20 O
trials O
. O

Middle O
plot O
: O
One O
subject O
’ O
s O
individual O
belief O
trajectories O
for O
color O
( O
blue O
) O
and O
shape O
( O
red O
) O
associations O
with O
outcome O
based O
on O
the O
best O
fitting O
model O
( O
2HGF O
RelPE O
+ O
IrrelBias O
) O
. O

Lower O
plot O
: O
Trajectories O
that O
were O
used O
to O
determine O
individual O
reaction O
times O
in O
the O
best O
response O
model O
: O
Inferred O
relevance O
weights O
( O
see O
Eq O
5 O
) O
for O
color O
( O
blue O
) O
and O
shape O
( O
red O
) O
predictions O
and O
the O
mean O
relevance O
weighted O
prediction O
error O
( O
magenta O
; O
see O
Eq O
4.1.2 O
) O
. O

Raw O
data O
analysis O
In O
our O
raw O
data O
analysis O
of O
reaction O
times O
, O
we O
focused O
on O
two O
aspects O
: O
( O
i O
) O
learning O
of O
the O
regularly O
reversing O
relevant O
feature O
and O
( O
ii O
) O
aberrant O
salience O
towards O
one O
manifestation O
of O
the O
irrelevant O
feature O
. O

Extreme O
reaction O
times O
( O
< O
150 O
ms O
and O
> O
1.5 O
s O
) O
were O
excluded O
. O

For O
analyses O
of O
potential O
learning O
, O
reaction O
times O
( O
in O
ms O
) O
were O
log O
transformed O
to O
achieve O
normal O
distribution O
required O
for O
variance O
analyses O
. O

First O
, O
we O
tested O
whether O
subjects O
learned O
the O
cue-outcome O
contingencies O
and O
slowed O
down O
their O
responses O
if O
the O
outcome O
could O
not O
be O
predicted O
based O
on O
the O
preceding O
cues O
and O
thus O
violated O
their O
expectation O
. O

For O
that O
, O
log O
reaction O
times O
were O
compared O
for O
expected O
( O
i.e O
. O
trials O
when O
the O
0.8 O
rewarded O
feature O
was O
followed O
by O
reward O
and O
trials O
when O
the O
0.8 O
non-rewarded O
feature O
was O
followed O
by O
a O
circle O
) O
versus O
unexpected O
events O
( O
i.e O
. O
trials O
when O
the O
0.8 O
rewarded O
feature O
was O
followed O
by O
the O
circle O
and O
trials O
when O
the O
0.8 O
non-rewarded O
feature O
was O
followed O
by O
a O
coin O
) O
of O
the O
relevant O
condition O
in O
a O
repeated-measures O
ANOVA O
with O
group O
as O
between-subject O
factor O
( O
HC O
versus O
patients O
) O
and O
event O
type O
as O
within O
factor O
( O
expected O
versus O
unexpected O
) O
. O

Second O
, O
a O
change O
in O
reaction O
times O
over O
time O
following O
contingency O
changes O
inside O
the O
relevant O
cue O
feature O
was O
tested O
using O
a O
repeated-measures O
ANOVA O
. O

For O
all O
eight O
blocks O
with O
20 O
trials O
each O
, O
log-reaction O
times O
of O
the O
16 O
expected O
events O
( O
ie O
, O
spanning O
those O
8 O
trials O
when O
the O
rewarded O
feature O
was O
followed O
by O
reward O
and O
the O
8 O
trials O
when O
the O
non-rewarded O
feature O
was O
followed O
by O
a O
circle O
) O
were O
grouped O
for O
rewarded O
versus O
neutral O
outcome O
trials O
( O
Condition O
factor O
) O
and O
combined O
into O
4 O
time O
bins O
each O
, O
consisting O
of O
2 O
consecutive O
trials O
( O
Time O
factor O
) O
. O

For O
analyses O
targeting O
responses O
with O
regard O
to O
different O
cue O
features O
, O
please O
see O
the O
Supplement O
. O

For O
aberrant O
salience O
attribution O
, O
aberrant O
salience O
scores O
were O
calculated O
as O
in O
the O
previous O
literature O
, O
and O
reflected O
an O
individual O
bias O
towards O
one O
of O
the O
two O
irrelevant O
cue O
manifestations O
based O
on O
the O
ground O
truth O
contingencies O
. O

For O
that O
, O
the O
mean O
reaction O
times O
( O
in O
ms O
) O
to O
each O
of O
the O
four O
cue O
features O
when O
they O
were O
irrelevant O
to O
the O
task O
were O
calculated O
. O

Then O
, O
aberrant O
salience O
was O
calculated O
as O
the O
absolute O
difference O
in O
reaction O
times O
between O
both O
manifestations O
of O
each O
condition O
( O
eg O
, O
square O
over O
triangle O
when O
shape O
is O
irrelevant O
) O
. O

Then O
, O
these O
two O
scores O
were O
collapsed O
across O
test O
halves O
. O

Computational O
modeling O
of O
relevant O
and O
irrelevant O
predictions O
We O
used O
detailed O
computational O
modeling O
combined O
with O
model O
selection O
in O
order O
to O
assess O
the O
learning O
mechanisms O
driving O
the O
observed O
individual O
behavior O
. O

By O
that O
we O
tested O
if O
subjects O
learned O
the O
underlying O
cue-outcome O
associations O
and O
inferred O
the O
relevant O
cue O
feature O
. O

In O
keeping O
with O
our O
initial O
definition O
of O
relevance O
, O
a O
cue O
feature O
should O
be O
perceived O
as O
more O
relevant O
the O
more O
precisely O
it O
is O
believed O
to O
predict O
the O
outcome O
. O

In O
contrast O
, O
if O
the O
association O
between O
cue O
feature O
and O
outcome O
is O
very O
noisy O
, O
because O
the O
occurrence O
of O
reward O
and O
circle O
are O
equally O
probable O
this O
feature O
should O
be O
perceived O
as O
irrelevant O
. O

We O
set O
up O
novel O
response O
models O
that O
postulated O
slowing O
down O
of O
responses O
when O
the O
expectations O
were O
violated O
. O

Computationally O
, O
a O
violation O
was O
captured O
by O
the O
unsigned O
PE O
of O
each O
feature O
. O

In O
different O
models O
, O
we O
compared O
if O
unsigned O
PEs O
of O
the O
different O
cue O
features O
differentially O
affected O
behavior O
based O
on O
their O
current O
relevance O
. O

By O
the O
relevance O
weighted O
PE O
, O
we O
implemented O
increased O
adaptation O
to O
surprising O
events O
( O
unsigned O
PE O
) O
predicted O
by O
the O
most O
relevant O
cue O
feature O
as O
well O
as O
decreased O
adaptation O
to O
the O
irrelevant O
cue O
feature O
. O

Thereby O
, O
we O
tested O
if O
individuals O
adapted O
their O
behavior O
less O
to O
events O
when O
these O
had O
proven O
to O
be O
noisy O
and O
uninformative O
in O
the O
past O
. O

Instead O
, O
they O
would O
adapt O
their O
behavior O
to O
those O
unexpected O
events O
that O
were O
held O
to O
be O
informative O
because O
these O
may O
actually O
signal O
a O
real O
change O
in O
the O
environment O
( O
as O
the O
contingency O
changes O
in O
our O
task O
) O
. O

Our O
modeling O
analysis O
was O
guided O
by O
two O
aims O
: O
Modeling O
two O
parallel O
learning O
processes O
of O
predicting O
the O
relevant O
and O
the O
irrelevant O
cue O
feature O
in O
order O
to O
compute O
distinct O
prediction O
error O
trajectories O
[ O
for O
a O
comparable O
learning O
model O
, O
please O
see O
] O
. O

Here O
, O
it O
is O
crucial O
to O
determine O
a O
formal O
definition O
of O
“ O
relevance O
” O
since O
the O
participants O
had O
to O
dynamically O
infer O
which O
cue O
feature O
was O
relevant O
for O
predicting O
the O
outcome O
( O
even O
though O
this O
was O
not O
necessary O
to O
solve O
the O
task O
, O
that O
is O
, O
discriminating O
between O
a O
coin O
and O
a O
circle O
) O
. O

Describing O
the O
aberrant O
salience O
effect O
to O
an O
irrelevant O
feature O
as O
seen O
in O
previous O
analyses O
on O
a O
computational O
level O
by O
finding O
interindividual O
differences O
in O
model O
parameters O
capturing O
this O
effect O
. O

We O
modeled O
predictions O
for O
each O
of O
the O
two O
cue O
features O
, O
shape O
and O
color O
, O
in O
separate O
HGF O
learning O
models O
so O
that O
a O
trial-by-trial O
expectation O
was O
computed O
for O
each O
feature O
( O
learning O
model O
) O
. O

We O
did O
not O
model O
relevant O
and O
irrelevant O
conditions O
separately O
because O
of O
two O
reasons O
. O

First O
, O
the O
generative O
model O
was O
supposed O
to O
capture O
the O
subjects O
’ O
learning O
experience O
and O
they O
were O
not O
instructed O
about O
the O
task O
structure O
having O
relevant O
and O
irrelevant O
conditions O
. O

Instead O
they O
were O
only O
primed O
with O
the O
distinction O
by O
feature O
, O
color O
and O
shape O
, O
in O
the O
practice O
session O
. O

Second O
, O
after O
the O
first O
half O
of O
the O
experiment O
we O
switched O
the O
relevant O
dimension O
( O
e.g O
. O
shape O
to O
color O
) O
. O

Hence O
, O
modeling O
separately O
for O
relevance O
versus O
irrelevance O
would O
have O
introduced O
external O
information O
on O
the O
task O
structure O
that O
was O
not O
accessible O
to O
subjects O
and O
thus O
not O
generative O
. O

The O
resulting O
learning O
trajectories O
for O
shape O
and O
color O
were O
transformed O
into O
trial-by-trial O
predictors O
of O
reaction O
times O
( O
response O
model O
) O
. O

Hierarchical O
Gaussian O
filter O
[ O
HGF O
; O
] O
According O
to O
the O
‘ O
Bayesian O
brain O
’ O
hypothesis O
, O
an O
agent O
forms O
a O
generative O
model O
of O
the O
world O
in O
part O
by O
increasing O
the O
precision O
of O
predictions O
( O
μ O
) O
to O
successfully O
adapt O
one O
’ O
s O
behavior O
. O

The O
HGF O
offers O
a O
generic O
framework O
for O
Bayesian O
learning O
on O
multiple O
hierarchical O
levels O
. O

Crucially O
, O
the O
belief O
update O
at O
each O
level O
is O
comprised O
of O
a O
lower-level O
prediction O
error O
that O
is O
weighted O
according O
to O
a O
cross-level O
precision O
ratio O
( O
Eqs O
1 O
and O
2 O
; O
i O
for O
learning O
level O
, O
and O
k O
for O
trial O
number O
) O
. O

The O
precision O
of O
each O
level O
’ O
s O
prediction O
is O
defined O
as O
the O
inverse O
variance O
of O
the O
prediction O
. O

We O
used O
a O
“ O
two O
branches O
” O
version O
of O
the O
HGF O
for O
parallel O
learning O
of O
the O
shape O
and O
color O
associations O
with O
the O
outcome O
. O

In O
our O
modelling O
, O
we O
focused O
on O
the O
reliability O
and O
thus O
undirected O
beliefs O
about O
associations O
. O

Thus O
, O
the O
direction O
of O
the O
learning O
trajectories O
( O
association O
beliefs O
and O
prediction O
errors O
δ O
) O
did O
not O
reflect O
the O
reward O
value O
but O
an O
arbitrarily O
determined O
relationship O
between O
cue O
feature O
manifestations O
and O
outcomes O
. O

A O
more O
detailed O
description O
of O
the O
HGF O
and O
its O
levels O
can O
be O
found O
in O
the O
Supplement O
. O

A O
novel O
definition O
of O
relevance O
: O
First-level O
precision O
Since O
the O
core O
aim O
of O
this O
study O
was O
the O
dissociation O
between O
learning O
about O
relevant O
versus O
irrelevant O
cue O
features O
, O
the O
term O
relevance O
needs O
to O
be O
defined O
formally O
. O

In O
terms O
of O
the O
ISP O
, O
a O
cue O
feature O
should O
be O
perceived O
as O
more O
relevant O
the O
more O
precisely O
it O
is O
believed O
to O
predict O
the O
outcome O
. O

In O
contrast O
, O
if O
the O
belief O
of O
an O
association O
is O
0.5 O
it O
should O
be O
perceived O
as O
irrelevant O
for O
outcome O
prediction O
( O
because O
in O
this O
case O
reward O
and O
circle O
will O
occur O
with O
the O
same O
probability O
and O
cannot O
be O
reliably O
predicted O
) O
. O

In O
the O
HGF O
framework O
, O
this O
interpretation O
of O
relevance O
is O
reflected O
in O
the O
estimated O
precision O
of O
prediction O
on O
the O
first O
level O
( O
see O
4 O
) O
. O

It O
is O
a O
function O
only O
of O
the O
first-level O
association O
prediction O
, O
which O
ranges O
between O
0 O
and O
1 O
. O

has O
a O
minimum O
of O
4 O
for O
and O
increases O
symmetrically O
to O
infinity O
as O
approaches O
0 O
or O
1 O
. O

This O
relevance O
could O
affect O
how O
beliefs O
are O
updated O
( O
for O
this O
implementation O
( O
‘ O
precision O
feedback O
’ O
) O
, O
see O
the O
Supplement O
) O
and O
/ O
or O
how O
learning O
signals O
affect O
behavior O
, O
which O
we O
implemented O
in O
four O
response O
models O
. O

Our O
learning O
model O
space O
contained O
2 O
- O
level O
and O
3 O
- O
level O
HGFs O
with O
and O
without O
precision O
feedback O
( O
see O
Supplement O
) O
, O
leading O
to O
four O
different O
hierarchical O
learning O
models O
: O
2HGF O
, O
2HGFprecfb O
, O
3HGF O
, O
and O
3HGFprecfb O
. O

Response O
models O
Prediction O
errors O
relating O
to O
the O
cue O
feature O
that O
is O
thought O
to O
be O
more O
relevant O
might O
translate O
more O
strongly O
into O
reaction O
times O
, O
and O
the O
aberrant O
salience O
effect O
found O
in O
the O
raw O
data O
may O
be O
explained O
as O
a O
bias O
towards O
one O
of O
the O
irrelevant O
features O
on O
a O
trial-by-trial O
basis O
. O

Both O
aspects O
were O
formalized O
in O
the O
following O
four O
response O
models O
. O

The O
baseline O
response O
model O
( O
see O
Eq O
4 O
) O
postulates O
that O
trial-by-trial O
reaction O
times O
are O
a O
linear O
function O
of O
the O
mean O
of O
the O
prediction O
errors O
of O
both O
features O
( O
4.1.1 O
) O
, O
a O
constant O
bias O
towards O
one O
feature O
manifestation O
( O
eg O
, O
triangles O
over O
squares O
) O
and O
the O
outcome O
( O
eg O
, O
slower O
for O
circles O
than O
for O
coin O
trials O
; O
4.2.1 O
) O
. O

The O
four O
cue O
manifestation O
vectors O
m O
reflect O
whether O
the O
respective O
manifestations O
were O
displayed O
for O
every O
trial O
( O
eg O
, O
1 O
for O
triangles O
and O
0 O
for O
squares O
in O
mtriangle O
) O
. O

This O
response O
model O
was O
modified O
in O
three O
ways O
. O

In O
a O
first O
modification O
( O
4.1.2 O
) O
, O
the O
absolute O
prediction O
errors O
of O
each O
feature O
were O
weighted O
according O
to O
their O
respective O
relevance O
weight O
( O
rel O
; O
5 O
) O
. O

The O
latter O
is O
formalized O
as O
the O
relative O
amount O
of O
each O
feature O
’ O
s O
precision O
given O
the O
overall O
precisions O
of O
both O
features O
. O

In O
a O
second O
modification O
and O
in O
line O
with O
the O
aberrant O
salience O
effect O
, O
the O
constant O
bias O
was O
weighted O
according O
to O
its O
feature O
’ O
s O
irrelevance O
( O
irrel O
; O
see O
Eq O
4.2.2 O
) O
. O

The O
irrelevance O
weight O
of O
one O
feature O
was O
defined O
as O
the O
relevance O
weight O
of O
the O
opposing O
feature O
( O
see O
Eq O
5 O
) O
. O

From O
the O
four O
cue O
feature O
parameters O
( O
β2 O
, O
… O
, O
β5 O
) O
one O
composite O
parameter O
was O
calculated O
in O
two O
steps O
. O

First O
, O
the O
individual O
absolute O
differences O
between O
the O
β2 O
and O
β3 O
for O
irrelevance O
weighted O
manifestations O
within O
color O
( O
and O
between O
the O
β4 O
and O
β5 O
for O
shape O
manifestations O
) O
were O
calculated O
. O

Then O
, O
they O
were O
collapsed O
across O
color O
and O
shape O
to O
achieve O
one O
parameter O
βirrelevance O
capturing O
the O
bias O
towards O
one O
cue O
feature O
manifestation O
that O
increased O
with O
subjective O
irrelevance O
. O

Thus O
, O
we O
compared O
four O
different O
response O
models O
: O
the O
baseline O
model O
( O
Eq O
4 O
) O
, O
the O
baseline O
model O
with O
relevance O
weighted O
absolute O
prediction O
errors O
( O
Eq O
4 O
with O
modification O
term O
4.1.2 O
; O
RelPE O
) O
, O
the O
baseline O
model O
with O
only O
the O
irrelevance O
bias O
( O
Eq O
4 O
with O
modification O
term O
4.2.2 O
; O
IrrelBias O
) O
, O
and O
a O
full O
model O
with O
both O
modifications O
( O
Eq O
4 O
with O
modification O
terms O
4.1.2 O
and O
4.2.2 O
; O
RelPE O
+ O
IrrelBias O
) O
. O

This O
led O
to O
a O
total O
model O
space O
of O
16 O
model O
combinations O
( O
see O
Figure O
S1 O
) O
. O

Model O
fitting O
and O
Bayesian O
model O
comparison O
All O
models O
were O
fitted O
using O
the O
HGF O
toolbox O
4.15 O
as O
part O
of O
TNU O
Algorithms O
for O
Psychiatry-Advancing O
Science O
( O
TAPAS O
, O
http O
: O
/ O
/ O
www.translationalneuromodeling.org O
/ O
tapas O
/ O
) O
. O

For O
optimization O
, O
a O
quasi-Newton O
optimization O
algorithm O
was O
applied O
. O

We O
used O
random-effects O
Bayesian O
Model O
Selection O
[ O
BMS O
, O
spm_BMS O
in O
SPM12 O
, O
www.fil.ion.ucl.uk O
/ O
spm O
; O
] O
for O
each O
subject O
’ O
s O
and O
each O
model O
’ O
s O
negative O
free O
energy O
( O
as O
an O
approximation O
to O
log-model O
evidence O
) O
in O
order O
to O
identify O
which O
of O
the O
competing O
models O
best O
explained O
the O
subjects O
’ O
response O
time O
data O
. O

BMS O
takes O
into O
account O
accuracy O
of O
each O
model O
and O
also O
penalizes O
for O
complexity O
. O

It O
accounts O
for O
heterogeneity O
across O
subjects O
and O
treats O
each O
model O
as O
a O
random O
variable O
in O
the O
population O
. O

We O
report O
protected O
exceedance O
probabilities O
for O
each O
model O
( O
PXP O
) O
and O
posterior O
probabilities O
( O
PP O
) O
as O
well O
as O
exceedance O
probabilities O
( O
XP O
) O
for O
model O
families O
( O
HGF O
vs O
. O

HGFprecfb O
; O
2HGF O
vs O
. O
3HGF O
; O
BL O
vs O
. O

RelPE O
vs O
. O

IrrelBias O
vs O
. O

RelPE O
+ O
IrrelBias O
) O
. O

The O
XP O
describes O
the O
relative O
probability O
that O
the O
model O
would O
better O
replicate O
the O
data O
in O
comparison O
with O
the O
other O
models O
. O

The O
PXP O
that O
governed O
our O
model O
selection O
protects O
against O
the O
‘ O
null O
’ O
possibility O
that O
there O
are O
no O
differences O
in O
the O
likelihood O
of O
models O
across O
the O
population O
. O

Simulation O
analyses O
Based O
on O
the O
estimated O
individual O
parameters O
from O
the O
best-fitting O
model O
, O
we O
simulated O
trial-by-trial O
reaction O
time O
data O
. O

In O
addition O
to O
the O
Bayesian O
model O
comparison O
, O
we O
tested O
the O
model O
’ O
s O
credibility O
by O
carrying O
out O
the O
same O
analyses O
as O
in O
the O
raw O
data O
section O
on O
the O
simulated O
data O
( O
( O
1 O
) O
Expectedness O
* O
Group O
ANOVA O
, O
( O
2 O
) O
Condition O
* O
Time O
* O
Group O
ANOVA O
, O
( O
3 O
) O
‘ O
ground O
truth O
’ O
aberrant O
salience O
group O
differences O
) O
. O

Using O
this O
approach O
, O
we O
checked O
whether O
the O
model O
was O
capable O
of O
reproducing O
the O
meaningful O
effects O
and O
group O
differences O
that O
were O
evident O
in O
the O
data O
. O

Functional B-FunctionalMagneticResonanceImaging
magnetic I-FunctionalMagneticResonanceImaging
resonance I-FunctionalMagneticResonanceImaging
imaging I-FunctionalMagneticResonanceImaging
For O
single O
and O
group O
statistics O
, O
an O
event-related O
analysis O
was O
applied O
using O
the O
general O
linear O
model O
( O
GLM O
) O
approach O
as O
implemented O
in O
SPM12 O
( O
http O
: O
/ O
/ O
www.fil.ion.ucl.ac.uk O
/ O
spm O
/ O
software O
/ O
spm12 O
/ O
) O
. O

On O
the O
single O
subject O
level O
, O
the O
outcome O
onsets O
were O
convolved O
with O
the O
hemodynamic O
response O
function O
and O
its O
temporal O
derivative O
. O

As O
parametric O
modulator O
, O
the O
mean O
of O
the O
relevance O
weighted O
absolute O
prediction O
errors O
of O
the O
best O
fitting O
model O
( O
2HGF-RelPe O
+ O
IrrelBias O
) O
was O
introduced O
, O
representing O
how O
unexpected O
and O
salient O
the O
observed O
outcome O
was O
based O
on O
the O
subjects O
’ O
learned O
expectations O
about O
the O
two O
cue O
features O
. O

Regressors O
of O
no O
interest O
were O
no O
response O
trials O
, O
trials O
with O
reaction O
times O
> O
1.5 O
seconds O
and O
< O
150 O
milliseconds O
, O
realignment O
parameters O
with O
their O
first O
temporal O
derivative O
of O
translational O
movement O
, O
and O
one O
regressor O
for O
scans O
with O
> O
1mm O
scan-to-scan O
movement O
. O

For O
random O
effects O
group-level O
analysis O
, O
the O
individual O
contrast O
images O
for O
mean O
relevance O
weighted O
PEs O
were O
used O
in O
a O
two-sample O
t-test O
for O
between-group O
comparisons O
( O
controls O
vs O
. O
patients O
) O
. O

Explorative O
analysis O
probed O
the O
association O
between O
model O
parameter O
βirrelevance O
and O
neural O
relevance O
weighted O
PE O
signals O
in O
schizophrenia O
patients O
. O

Hence O
, O
interindividual O
βirrelevance O
scores O
were O
introduced O
as O
a O
covariate O
in O
a O
one-sample O
t-test O
using O
the O
Mean O
relevance O
weighted O
PE O
contrast O
. O

Results O
are O
reported O
using O
FWE O
correction O
at O
the O
voxel O
level O
across O
the O
whole O
brain O
. O

Based O
on O
our O
hypothesis O
concerning O
activations O
in O
areas O
previously O
shown O
to O
code O
salience O
such O
as O
the O
ACC O
and O
insula O
, O
namely O
the O
so-called O
salience O
network O
, O
and O
the O
nucleus O
accumbens O
, O
we O
applied O
small O
volume O
correction O
at O
the O
voxel O
level O
for O
the O
respective O
bilateral O
anatomical O
masks O
derived O
from O
the O
WFU O
PickAtlas O
( O
http O
: O
/ O
/ O
fmri.wfubmc.edu O
/ O
software O
/ O
pickatlas O
) O
. O

Thus O
, O
three O
VOIs O
were O
used O
for O
small O
volume O
correction O
at O
pFWE O
< O
0.05 O
and O
we O
indicate O
which O
results O
survive O
Bonferroni O
correction O
for O
three O
tests O
. O

Time‐dependent O
neuronal O
changes O
associated O
with O
craving O
in O
opioid B-OpioidAbuse
dependence I-OpioidAbuse
: O
an O
fMRI B-FunctionalMagneticResonanceImaging
study O
Abstract O
Relapse O
after O
initially O
successful O
treatment O
is O
a O
significant O
problem O
facing O
the O
treatment O
of O
opioid B-OpioidAbuse
dependence I-OpioidAbuse
. O

Evidence O
suggests O
craving O
elicited O
by O
re‐exposure O
to O
drug O
cues O
may O
precipitate O
relapse O
. O

Attempts O
to O
identify O
neural O
biomarkers O
of O
cue‐elicited O
craving O
have O
yielded O
inconsistent O
findings O
. O

We O
aimed O
to O
apply O
a O
novel O
continuous O
functional B-FunctionalMagneticResonanceImaging
magnetic I-FunctionalMagneticResonanceImaging
resonance I-FunctionalMagneticResonanceImaging
imaging I-FunctionalMagneticResonanceImaging
technique O
to O
follow O
the O
minute‐to‐minute O
evolution O
of O
brain O
responses O
, O
which O
correlate O
with O
the O
waxing O
and O
waning O
of O
craving O
. O

Newly B-OpioidAbuse
detoxified I-OpioidAbuse
male I-OpioidAbuse
opioid‐dependent I-OpioidAbuse
patients I-OpioidAbuse
and O
healthy B-NoKnownDisorder
control I-NoKnownDisorder
participants I-NoKnownDisorder
attended O
two O
separate O
, O
counterbalanced O
, O
functional B-FunctionalMagneticResonanceImaging
magnetic I-FunctionalMagneticResonanceImaging
resonance I-FunctionalMagneticResonanceImaging
imaging I-FunctionalMagneticResonanceImaging
scanning B-TaskParadigmImaging
sessions I-TaskParadigmImaging
during I-TaskParadigmImaging
which I-TaskParadigmImaging
they I-TaskParadigmImaging
viewed I-TaskParadigmImaging
a I-TaskParadigmImaging
10 I-TaskParadigmImaging
‐ I-TaskParadigmImaging
minute I-TaskParadigmImaging
video I-TaskParadigmImaging
( I-TaskParadigmImaging
drug I-TaskParadigmImaging
cue I-TaskParadigmImaging
or I-TaskParadigmImaging
neutral I-TaskParadigmImaging
cue I-TaskParadigmImaging
) I-TaskParadigmImaging
followed I-TaskParadigmImaging
by I-TaskParadigmImaging
5 I-TaskParadigmImaging
  I-TaskParadigmImaging
minutes I-TaskParadigmImaging
of I-TaskParadigmImaging
fixation I-TaskParadigmImaging
. O

Participants O
rated O
the O
intensity O
of O
their O
craving O
throughout O
each O
session O
. O

We O
hypothesized O
that O
subcortical O
/ O
ventral O
prefrontal O
cortex O
( O
PFC O
) O
regions O
and O
dorsal O
PFC O
regions O
would O
show O
different O
associations O
with O
craving O
reflecting O
their O
putative O
roles O
in O
appetitive O
processing O
versus O
cognitive O
control O
. O

Compared O
with O
controls B-NoKnownDisorder
, O
drug O
cue O
( O
minus O
neutral O
cue O
) O
video O
recruited O
the O
left O
amygdala O
and O
was O
temporally O
correlated O
with O
craving O
. O

In O
contrast O
, O
dorsal O
anterior O
cingulate O
blood‐oxygen‐level‐dependent O
signal O
time O
course O
was O
higher O
than O
controls B-NoKnownDisorder
only O
during O
a O
period O
after O
cue O
exposure O
when O
craving O
levels O
were O
declining O
. O

Against O
expectations O
, O
neither O
the O
ventral O
striatum O
nor O
ventral O
PFC O
was O
significantly O
recruited O
by O
drug O
cue O
exposure O
. O

Findings O
suggest O
that O
the O
amygdala O
has O
a O
central O
role O
in O
craving O
, O
whereas O
the O
dorsal O
anterior O
cingulate O
may O
control O
craving O
in O
treatment‐seeking O
patients O
. O

Time O
course O
analysis O
yielded O
new O
insights O
into O
the O
neural O
substrates O
of O
craving O
that O
could O
objectively O
validate O
development O
of O
psychological O
and O
pharmacological O
approaches O
to O
sustained O
abstinence O
. O

Methods B-StudyMethod
and I-StudyMethod
Materials I-StudyMethod
Participants O
Opioid‐dependent B-OpioidAbuse
individuals I-OpioidAbuse
( O
n O
  O
= O
  O
18 O
) O
This O
study O
was O
approved O
by O
the O
NHS O
Research O
Ethics O
Committee O
. O

Participants O
with O
OD B-OpioidAbuse
were O
recruited O
from O
a O
residential O
detoxification O
unit O
within O
Greater O
Manchester O
( O
see O
Table O
  O
1 O
for O
demographic O
information O
) O
. O

Treatment O
involved O
a O
4 O
‐ O
week O
residential O
stay O
with O
a O
10 O
‐ O
day O
methadone O
stabilization O
and O
reduction O
, O
followed O
by O
10 O
  O
days O
of O
lofexidine O
treatment O
, O
an O
alpha O
‐ O
2 O
adrenergic O
receptor O
agonist O
used O
to O
treat O
opioid O
withdrawal O
symptoms O
. O

Participants O
took O
part O
in O
the O
study O
during O
the O
last O
week O
of O
their O
residential O
stay O
when O
they O
were O
opioid O
free O
( O
confirmed O
by O
urine O
drug O
screen O
) O
. O

Lofexidine O
was O
extended O
at O
low O
doses O
for O
participants O
still O
experiencing O
withdrawal O
symptoms O
during O
this O
final O
week O
, O
and O
some O
ODs B-OpioidAbuse
were O
receiving O
other O
psychoactive O
medications O
as O
indicated O
by O
Supporting O
Information O
Table O
  O
S1 O
. O

The O
OD B-OpioidAbuse
group I-OpioidAbuse
was O
recruited O
according O
to O
the O
following O
inclusion O
criteria O
: O
male O
, O
aged O
18 O
– O
55 O
; O
current O
DSM B-OpioidAbuse
IV I-OpioidAbuse
heroin I-OpioidAbuse
dependence I-OpioidAbuse
( O
the O
majority O
of O
patients O
also O
met O
criteria O
for O
current O
or O
past O
dependence O
on O
other O
substances O
; O
Table O
  O
1 O
) O
; O
no O
history O
of O
serious O
psychiatric O
, O
neurological O
or O
physical O
illness O
; O
no O
contraindications O
for O
MRI B-MagneticResonanceImaging
; O
and O
IQ O
of O
≥ O
85 O
[ O
determined O
using O
the O
Wechsler O
Test O
of O
Adult O
Reading O
( O
Holdnack O
2001 O
) O
] O
. O

Participants O
were O
identified O
and O
approached O
by O
members O
of O
the O
clinical O
team O
on O
the O
basis O
of O
detailed O
physical O
and O
mental O
health O
assessments O
on O
admission O
to O
the O
unit O
. O

All O
participants O
meeting O
the O
inclusion O
criteria O
were O
approached O
to O
take O
part O
in O
the O
study O
. O

A O
total O
of O
39 O
patients O
were O
enrolled O
in O
the O
craving O
study O
; O
however O
, O
19 O
were O
discharged O
from O
the O
unit O
before O
any O
testing O
could O
take O
place O
( O
mainly O
self‐discharge O
or O
early O
discharge O
due O
to O
use O
of O
prohibited O
substances O
) O
. O

Twenty O
patients O
were O
scanned O
as O
part O
of O
the O
study O
, O
although O
two O
were O
excluded O
from O
analysis O
because O
of O
excessive O
movement O
( O
see O
Preprocessing O
section O
for O
further O
details O
) O
, O
leaving O
n O
  O
= O
  O
18 O
who O
were O
included O
in O
analysis O
. O

Handedness O
was O
assessed O
with O
the O
Edinburgh B-EdinburghHandednessInventoryQuestionnaire
Handedness I-EdinburghHandednessInventoryQuestionnaire
Inventory I-EdinburghHandednessInventoryQuestionnaire
( O
Oldfield O
1971 O
) O
. O

Demographic O
and O
clinical O
information O
of O
OD B-OpioidAbuse
( O
n O
  O
= O
  O
18 O
) O
and O
HC B-NoKnownDisorder
( O
n O
  O
= O
  O
20 O
) O
groups O
included O
in O
the O
analysis O
. O

OD O
group O
HC O
group O
p‐value O
Age O
34.8 O
( O
6.3 O
) O
31.6 O
( O
7.2 O
) O
0.15 O
IQ O
103.1.9 O
( O
7.7 O
) O
114.1 O
( O
4.7 O
) O
< O
0.05 O
Years O
of O
education O
11.5 O
( O
2.2 O
) O
16.5 O
( O
3.3 O
) O
< O
0.05 O
No O
. O
of O
right O
handers O
16 O
( O
89 O
percent O
) O
18 O
( O
90 O
percent O
) O
0.91 O
No O
. O
of O
smokers O
( O
nicotine O
) O
13 O
( O
72 O
percent O
) O
9 O
( O
45 O
percent O
) O
0.09 O
Clinical O
Variables O
for O
OD O
group O
Years O
of O
opioid O
dependence O
12.8 O
( O
7.7 O
) O
— O
Average O
daily O
opioid O
use O
( O
g O
) O
0.7 O
( O
0.6 O
) O
— O
Age O
of O
first O
use O
( O
years O
) O
20.3 O
( O
4.3 O
) O
No O
. O
who O
primarily O
smoke O
/ O
inject O
/ O
or O
use O
both O
methods O
for O
heroin O
administration O
5 O
( O
28 O
percent O
) O
/ O
5 O
( O
28 O
percent O
) O
/ O
8 O
( O
44 O
percent O
) O
— O
No O
. O
of O
OD O
group O
with O
current O
/ O
past O
history O
of O
: O
— O
Alcohol O
dependence O
7 O
( O
39 O
percent O
) O
— O
Cocaine O
dependence O
7 O
( O
39 O
percent O
) O
Amphetamine O
dependence O
1 O
( O
6 O
percent O
) O
— O
Benzodiazepine O
dependence O
3 O
( O
17 O
percent O
) O
— O
Heroin O
dependence O
only O
( O
except O
nicotine O
) O
6 O
( O
33 O
percent O
) O
— O
Age O
, O
IQ O
, O
years O
of O
education O
, O
years O
of O
dependence O
, O
average O
daily O
amount O
used O
and O
age O
of O
first O
use O
expressed O
as O
mean O
and O
standard O
deviation O
( O
in O
brackets O
) O
. O

All O
other O
variables O
expressed O
as O
frequency O
and O
proportion O
of O
group O
( O
in O
brackets O
) O
. O

P‐values O
taken O
from O
independent O
t‐tests O
for O
continuous O
data O
and O
chi‐squared O
tests O
for O
frequency O
data O
. O

Healthy O
controls O
( O
n O
  O
= O
  O
20 O
) O
Healthy B-NoKnownDisorder
controls I-NoKnownDisorder
( I-NoKnownDisorder
HCs I-NoKnownDisorder
) I-NoKnownDisorder
were O
recruited O
who O
were O
familiar O
with O
graphic O
scenes O
of O
drug O
use O
because O
of O
occupational O
experience O
( O
e.g O
. O
drug O
treatment O
workers O
and O
other O
health O
professionals O
) O
. O

The O
HC B-NoKnownDisorder
group I-NoKnownDisorder
met O
the O
same O
inclusion O
criteria O
outlined O
previously O
and O
additionally O
had O
no O
current O
or O
past O
history O
of O
drug O
dependence O
or O
misuse O
( O
except O
nicotine O
) O
and O
had O
never O
used O
heroin O
in O
their O
lifetime O
. O

No O
healthy B-NoKnownDisorder
volunteers I-NoKnownDisorder
were O
receiving O
psychoactive O
medications O
. O

Participants O
were O
screened O
with O
the O
Mini B-MentalHealthDiagnosisScale
International I-MentalHealthDiagnosisScale
Neuropsychiatric I-MentalHealthDiagnosisScale
Interview I-MentalHealthDiagnosisScale
( O
Sheehan O
et O
al O
. O
1998 O
) O
, O
Wechsler B-NeurocognitiveTest
Test I-NeurocognitiveTest
of I-NeurocognitiveTest
Adult I-NeurocognitiveTest
Reading I-NeurocognitiveTest
and O
Edinburgh B-EdinburghHandednessInventoryQuestionnaire
Handedness I-EdinburghHandednessInventoryQuestionnaire
Inventory I-EdinburghHandednessInventoryQuestionnaire
. O

All O
participants O
provided O
written O
consent O
and O
were O
paid O
for O
their O
participation O
with O
vouchers O
. O

Procedures O
Participants O
attended O
two O
separate O
, O
counterbalanced O
sessions O
. O

Patients B-MagneticResonanceImaging
were I-MagneticResonanceImaging
scanned I-MagneticResonanceImaging
in O
the O
last O
week O
of O
their O
residential O
stay O
when O
they O
were O
opioid O
free O
. O

On O
each O
occasion O
, O
participants B-TaskParadigmImagingProtocol
underwent I-TaskParadigmImagingProtocol
fMRI B-FunctionalMagneticResonanceImaging
, B-TaskParadigmImagingProtocol
once I-TaskParadigmImagingProtocol
whilst I-TaskParadigmImagingProtocol
viewing I-TaskParadigmImagingProtocol
a I-TaskParadigmImagingProtocol
10 I-TaskParadigmImagingProtocol
‐ I-TaskParadigmImagingProtocol
minute I-TaskParadigmImagingProtocol
heroin I-TaskParadigmImagingProtocol
video I-TaskParadigmImagingProtocol
( I-TaskParadigmImagingProtocol
drug I-TaskParadigmImagingProtocol
cue I-TaskParadigmImagingProtocol
session I-TaskParadigmImagingProtocol
) I-TaskParadigmImagingProtocol
and I-TaskParadigmImagingProtocol
once I-TaskParadigmImagingProtocol
whilst I-TaskParadigmImagingProtocol
viewing I-TaskParadigmImagingProtocol
a I-TaskParadigmImagingProtocol
10 I-TaskParadigmImagingProtocol
‐ I-TaskParadigmImagingProtocol
minute I-TaskParadigmImagingProtocol
video I-TaskParadigmImagingProtocol
containing I-TaskParadigmImagingProtocol
scenes I-TaskParadigmImagingProtocol
matched I-TaskParadigmImagingProtocol
for I-TaskParadigmImagingProtocol
visual I-TaskParadigmImagingProtocol
complexity I-TaskParadigmImagingProtocol
but I-TaskParadigmImagingProtocol
lacking I-TaskParadigmImagingProtocol
emotionally I-TaskParadigmImagingProtocol
arousing I-TaskParadigmImagingProtocol
content I-TaskParadigmImagingProtocol
( I-TaskParadigmImagingProtocol
neutral I-TaskParadigmImagingProtocol
session I-TaskParadigmImagingProtocol
) I-TaskParadigmImagingProtocol
. I-TaskParadigmImagingProtocol

Videos O
were O
preceded O
and O
followed O
by O
5 O
  O
minutes O
of O
fixation O
( O
Fig O
. O
  O
1 O
) O
. O

Images O
were O
presented O
using O
e‐prime O
( O
Psychology O
Software O
Tools O
, O
Inc O
, O
Sharpsburg O
, O
USA O
) O
( O
version O
2.0 O
) O
. O

Diagram O
illustrating O
1 O
‐ O
minute O
time‐bins O
for O
the O
drug O
cue O
and O
neutral O
sessions O
. O

The O
480 O
scans O
were O
divided O
into O
1 O
  O
minute O
time‐bins O
. O

T0 O
was O
the O
5th O
minute O
of O
the O
pre‐video O
baseline O
, O
T1 O
– O
T10 O
were O
the O
time‐bins O
acquired O
during O
the O
video O
and O
T11 O
‐ O
T15 O
were O
the O
post‐video O
time‐bins O
. O

The O
arrows O
indicate O
the O
time O
points O
of O
the O
presentation O
of O
the O
Likert‐like O
subjective O
rating O
scales O
Measures O
Participants O
were O
presented O
with O
Likert‐like O
subjective O
rating O
scales O
throughout O
the O
scanning O
session O
. O

Participants O
were O
prompted O
to O
respond O
by O
a O
screen O
displaying O
the O
following O
text O
‘ O
do O
you O
feel O
you O
are O
… O
’ O
, O
which O
was O
presented O
for O
3 O
  O
seconds O
before O
slides O
stating O
‘ O
Craving O
? O
’ O

, O
‘ O
Withdrawing O
? O
’ O

, O
‘ O
Anxious O
? O
’ O

or O
‘ O
High O
? O
’ O

, O
were O
presented O
for O
4 O
  O
seconds O
along O
with O
the O
following O
scale O
: O
1 O
( O
not O
all O
) O
, O
2 O
( O
slightly O
) O
, O
3 O
( O
moderately O
) O
and O
4 O
( O
extremely O
) O
. O

Participants O
responded O
via O
a O
button O
box O
. O

The O
scales O
were O
presented O
at O
3 O
‐ O
minute O
intervals O
in O
each O
session O
( O
Fig O
. O
  O
1 O
) O
Behavioural O
data O
Mixed O
ANOVAs O
were O
carried O
out O
for O
each O
of O
the O
four O
subjective O
rating O
scales O
with O
time O
of O
rating O
( O
six O
levels O
including O
a O
pre‐video O
baseline O
rating O
, O
three O
during O
the O
video O
and O
two O
post‐video O
ratings O
) O
and O
session O
( O
drug O
cue O
, O
neutral O
) O
as O
within‐subject O
factors O
and O
group O
( O
HC B-NoKnownDisorder
, O
OD B-OpioidAbuse
) O
as O
the O
between‐subject O
factor O
. O

Session O
order O
was O
included O
as O
a O
covariate O
. O

The O
pre‐video O
rating O
taken O
during O
the O
last O
minute O
of O
the O
baseline O
period O
( O
T0 O
) O
was O
used O
as O
the O
pre‐video O
baseline O
rating O
. O

A O
Greenhouse‐Geisser O
correction O
was O
applied O
when O
Mauchley's O
assumption O
of O
sphericity O
was O
violated O
. O

Ratings O
from O
one O
HC B-NoKnownDisorder
were O
not O
included O
as O
the O
participant O
could O
not O
see O
the O
rating O
scales O
. O

Scanning O
and O
analysis O
Whole O
brain O
T2 B-T2WeightedImaging
* I-T2WeightedImaging
weighted I-T2WeightedImaging
images I-T2WeightedImaging
were O
acquired O
on O
a O
3 B-MagneticResonanceImaging
Tesla I-MagneticResonanceImaging
Philips I-MagneticResonanceImaging
Achieva I-MagneticResonanceImaging
scanner I-MagneticResonanceImaging
with O
single B-FunctionalImagingProtocol
shot I-FunctionalImagingProtocol
, I-FunctionalImagingProtocol
multi‐slice I-FunctionalImagingProtocol
echo I-FunctionalImagingProtocol
planar I-FunctionalImagingProtocol
( I-FunctionalImagingProtocol
EPI I-FunctionalImagingProtocol
) I-FunctionalImagingProtocol
pulse I-FunctionalImagingProtocol
sequence I-FunctionalImagingProtocol
. O

Each O
volume O
comprised O
34 O
contiguous O
axial O
slices O
( O
TR O
  O
= O
  O
2.5 O
  O
s O
, O
TE O
  O
= O
  O
35 O
  O
ms O
, O
96 O
  O
× O
  O
96 O
matrix O
, O
in‐plane O
voxel O
size O
3.0 O
  O
mm O
  O
× O
  O
3.0 O
  O
mm O
, O
slice O
thickness O
3.5 O
  O
mm O
) O
. O

A O
high‐resolution O
T1 B-T1WeightedImaging
‐ I-T1WeightedImaging
weighted I-T1WeightedImaging
structural I-T1WeightedImaging
image I-T1WeightedImaging
was O
also O
acquired O
for O
each O
participant O
for O
coregistration O
during O
preprocessing O
and O
to O
exclude O
any O
structural O
abnormality O
. O

Preprocessing O
Functional O
data O
were O
analysed O
using O
statistical O
parametric O
mapping O
( O
SPM8 O
; O
The O
Wellcome O
Department O
of O
Cognitive O
Neurology O
, O
London O
, O
UK O
) O
running O
in O
MATLAB O
( O
Matlab O
, O
R2012a O
; O
Mathworks O
, O
Natick O
, O
Massachusetts O
, O
U.S.A O
. O
) O
. O

Functional O
images O
were O
realigned O
and O
coregistered O
with O
the O
T1 O
structural O
image O
before O
normalization O
of O
the O
functional O
images O
into O
standard O
space O
was O
carried O
out O
using O
the O
unified O
segmentation O
approach O
( O
Ashburner O
& O
Friston O
2005 O
) O
. O

Normalized O
images O
were O
smoothed O
using O
an O
8 O
‐ O
mm O
Gaussian O
kernel O
. O

The O
smoothed O
functional O
images O
of O
the O
participants O
who O
moved O
more O
than O
1 O
  O
voxel O
were O
repaired O
by O
an O
interpolation O
method O
using O
the O
artefact O
repair O
toolbox O
( O
http O
: O
/ O
/ O
cibsr.stanford.edu O
/ O
tools O
/ O
ArtRepair O
/ O
ArtRepair.htm O
) O
. O

Two O
ODs O
with O
excessive O
movement O
were O
excluded O
( O
> O
10 O
percent O
volumes O
needing O
repairing O
) O
. O

Eighteen O
ODs O
and O
20 O
HCs O
were O
entered O
into O
subsequent O
analyses O
. O

First‐level O
analysis O
For O
both O
the O
drug O
cue O
and O
the O
neutral O
session O
, O
data O
were O
acquired O
continuously O
for O
20 O
  O
minutes O
( O
5 O
  O
minutes O
before O
the O
start O
of O
each O
video O
to O
allow O
participants O
to O
acclimatize O
to O
the O
scanner O
environment O
, O
10 O
  O
minutes O
during O
presentation O
of O
the O
video O
and O
an O
additional O
5 O
  O
minutes O
after O
the O
end O
of O
the O
video O
) O
( O
Fig O
. O
  O
1 O
) O
. O

The O
resultant O
480 O
acquired O
scans O
were O
divided O
into O
1 O
‐ O
minute O
time‐bins O
( O
20 O
time‐bins O
in O
total O
) O
. O

The O
5th O
minute O
of O
the O
pre‐video O
baseline O
was O
treated O
as O
the O
baseline O
time‐bin O
T0 O
, O
with O
each O
subsequent O
time‐bin O
( O
T1 O
– O
15 O
) O
compared O
with O
T0 O
using O
regression O
analysis O
within O
a O
general O
linear O
model O
framework O
. O

The O
exact O
shape O
of O
the O
signal O
of O
interest O
was O
unknown O
; O
therefore O
, O
no O
high‐pass O
filter O
was O
used O
. O

The O
neutral O
session O
averages O
were O
subtracted O
from O
the O
time O
equivalent O
drug O
cue O
session O
averages O
, O
resulting O
in O
‘ O
drug O
cue O
session–neutral O
session O
’ O
contrast O
images O
. O

Region‐of‐interest O
analysis O
A O
region‐of‐interest O
( O
ROI O
) O
approach O
was O
used O
to O
extract O
time O
course O
signals O
from O
key O
brain O
regions O
involved O
in O
drug O
cue O
reactivity O
based O
on O
recent O
meta‐analyses O
( O
Chase O
et O
al O
. O
2011 O
; O
Kuhn O
& O
Gallinat O
2011 O
) O
. O

These O
composed O
of O
spheres O
of O
7 O
‐ O
mm O
radius O
centred O
around O
the O
bilateral O
ventral O
striatum O
, O
amygdala O
and O
VmPFC O
, O
coordinates O
from O
Chase O
et O
al O
. O
( O
2011 O
) O
, O
and O
anterior O
cingulate O
cortex O
, O
coordinates O
from O
Kuhn O
& O
Gallinat O
( O
2011 O
) O
, O
as O
displayed O
in O
Fig O
. O
  O
3 O
. O

Mean O
drug O
cue‐neutral O
session O
contrast O
estimates O
were O
extracted O
from O
each O
of O
the O
six O
ROIs O
using O
the O
Easy O
ROI O
toolbox O
implemented O
in O
SPM O
( O
http O
: O
/ O
/ O
www.sbirc.ed.ac.uk O
/ O
LCL O
/ O
LCL_M1 O
. O
html O
) O
and O
entered O
into O
mixed O
ANOVAs O
in O
SPSS O
( O
version O
20 O
) O
to O
investigate O
effects O
of O
time O
and O
group O
on O
drug O
cue‐neutral O
session O
BOLD O
signal O
. O

Investigations O
were O
carried O
out O
for O
the O
whole O
session O
( O
T0 O
to O
T15 O
) O
and O
for O
the O
video O
time‐bins O
( O
T1 O
– O
T10 O
) O
and O
post‐video O
time‐bins O
separately O
( O
T11 O
to O
T15 O
) O
with O
session O
order O
included O
as O
a O
covariate O
. O

A O
Greenhouse‐Geisser O
correction O
was O
applied O
when O
Mauchley's O
assumption O
of O
sphericity O
was O
violated O
. O

A O
Bonferroni O
correction O
for O
the O
six O
separate O
ROIs O
results O
in O
a O
significance O
value O
of O
p O
  O
< O
  O
0.008 O
for O
this O
analysis O
. O

However O
, O
this O
is O
a O
conservative O
approach O
, O
which O
may O
result O
in O
false O
negatives O
. O

Results O
are O
therefore O
reported O
significant O
at O
p O
  O
< O
  O
0.05 O
with O
results O
surviving O
Bonferroni O
correction O
highlighted O
. O

ROI O
BOLD O
signal O
time O
course O
and O
subjective O
rating O
time O
course O
temporal O
correlation O
analysis O
In O
participants O
reporting O
a O
subjective O
rating O
change O
in O
response O
to O
the O
drug O
cue O
session O
, O
we O
investigated O
whether O
their O
subjective O
rating O
time O
course O
was O
temporally O
correlated O
with O
fMRI O
signal O
in O
the O
ROIs O
. O

Analyses O
were O
restricted O
to O
subjective O
ratings O
and O
ROI O
BOLD O
signal O
time O
courses O
, O
demonstrating O
significant O
effects O
in O
the O
ANOVAs O
. O

Before O
correlations O
were O
carried O
out O
, O
the O
pre‐video O
baseline O
subjective O
rating O
was O
subtracted O
from O
each O
video O
and O
post‐video O
rating O
for O
each O
session O
. O

The O
neutral O
session O
ratings O
were O
then O
subtracted O
from O
the O
drug O
cue O
session O
ratings O
. O

This O
was O
to O
ensure O
both O
the O
fMRI O
and O
subjective O
rating O
data O
reflected O
drug O
cue O
session O
changes O
from O
baseline O
minus O
neutral O
session O
changes O
from O
baseline O
( O
fMRI O
data O
already O
in O
this O
format O
after O
first‐level O
analysis O
) O
. O

Finally O
, O
the O
fMRI O
BOLD O
signal O
data O
were O
averaged O
over O
3 O
‐ O
minute O
intervals O
to O
reflect O
the O
3 O
‐ O
minute O
interval O
of O
subjective O
rating O
presentation O
during O
each O
session O
. O

Correlational O
analyses O
were O
carried O
out O
between O
each O
individual's O
subjective O
rating O
and O
ROI O
BOLD O
signal O
time O
courses O
using O
Pearson's O
product O
moment O
correlation O
coefficient O
. O

Resultant O
correlation O
coefficients O
were O
Fisher's O
z‐transformed O
and O
entered O
into O
one‐sample O
t‐tests O
to O
determine O
group O
level O
significance O
. O

Interhemispheric O
connectivity O
and O
hemispheric O
specialization O
in O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
and O
their O
unaffected B-NoKnownDisorder
siblings I-NoKnownDisorder
Hemispheric O
integration O
and O
specialization O
are O
two O
prominent O
organizational O
principles O
for O
macroscopic O
brain O
function O
. O

Impairments O
of O
interhemispheric O
cooperation O
have O
been O
reported O
in O
schizophrenia O
patients O
, O
but O
whether O
such O
abnormalities O
should O
be O
attributed O
to O
effects O
of O
illness O
or O
familial O
risk O
remains O
inconclusive O
. O

Moreover O
, O
it O
is O
unclear O
how O
abnormalities O
in O
interhemispheric O
connectivity O
impact O
hemispheric O
specialization O
. O

To O
address O
these O
questions O
, O
we O
performed O
magnetic B-MagneticResonanceImaging
resonance I-MagneticResonanceImaging
imaging I-MagneticResonanceImaging
( I-MagneticResonanceImaging
MRI I-MagneticResonanceImaging
) I-MagneticResonanceImaging
in O
a O
large O
cohort O
of O
253 O
participants O
, O
including O
84 O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
, O
106 O
of O
their O
unaffected B-NoKnownDisorder
siblings I-NoKnownDisorder
and O
63 O
healthy B-NoKnownDisorder
controls I-NoKnownDisorder
. O

Interhemispheric O
connectivity O
and O
hemispheric O
specialization O
were O
calculated O
from O
resting-state B-RestingStateImaging
functional O
connectivity O
, O
and O
compared O
across O
groups O
. O

Results B-Schizophrenia
showed I-Schizophrenia
that I-Schizophrenia
schizophrenia I-Schizophrenia
patients I-Schizophrenia
exhibit O
lower O
interhemispheric O
connectivity O
as O
compared O
to O
controls B-NoKnownDisorder
and I-NoKnownDisorder
siblings I-NoKnownDisorder
. O

In O
addition O
, O
patients O
showed O
higher O
levels O
of O
hemispheric O
specialization O
as O
compared O
to O
siblings O
. O

Level O
of O
interhemispheric O
connectivity O
and O
hemispheric O
specialization O
correlated O
with O
duration O
of O
illness O
in O
patients O
. O

No O
significant O
alterations O
were O
identified O
in O
siblings O
relative O
to O
controls O
on O
both O
measurements O
. O

Furthermore O
, O
alterations O
in O
interhemispheric O
connectivity O
correlated O
with O
changes O
in O
hemispheric O
specialization O
in O
patients O
relative O
to O
controls O
and O
siblings O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
lower O
interhemispheric O
connectivity O
and O
associated O
abnormalities O
in O
hemispheric O
specialization O
are O
features O
of O
established O
illness O
, O
rather O
than O
an O
expression O
of O
preexistent O
familial O
risk O
for O
schizophrenia O
. O

Highlights O
Schizophrenia O
patients O
show O
lower O
interhemispheric O
connectivity O
( O
IC O
) O
compared O
to O
siblings O
and O
controls O
. O

Lower O
IC O
is O
associated O
with O
higher O
hemispheric O
specialization O
( O
HS O
) O
in O
patients O
. O

Siblings O
do O
not O
show O
changes O
on O
IC O
and O
HS O
relative O
to O
controls O
. O

Connectivity O
metrics O
( O
IC O
, O
HS O
) O
correlate O
with O
duration O
of O
illness O
in O
patients O
. O

Material B-StudyMethod
and I-StudyMethod
methods I-StudyMethod
Participants O
A O
total O
of O
253 O
participants O
, O
including O
84 O
schizophrenia B-Schizophrenia
patients I-Schizophrenia
, O
106 O
of O
their O
unaffected B-NoKnownDisorder
siblings I-NoKnownDisorder
and O
63 O
healthy B-NoKnownDisorder
controls I-NoKnownDisorder
, O
were O
recruited O
at O
the O
University O
Medical O
Center O
Utrecht O
between O
September O
2004 O
and O
April O
2008 O
, O
as O
part O
of O
the O
Genetic O
Risk O
and O
Outcome O
of O
Psychosis O
( O
GROUP O
) O
study O
. O

The O
GROUP O
study O
was O
conducted O
by O
four O
university O
psychiatric O
centers O
and O
their O
affiliated O
mental O
health O
care O
institutions O
in O
the O
Netherlands O
. O

The O
medical O
ethics O
committee O
of O
the O
University O
Medical O
Center O
Utrecht O
approved O
the O
current O
study O
. O

All O
subjects O
provided O
written O
informed O
consent O
prior O
to O
participation O
. O

For O
all O
participants O
, O
presence O
or O
absence O
of O
current O
and O
lifetime O
psychopathology O
was O
established O
using O
the O
Comprehensive B-ComprehensiveAssessmentofSymptomsandHistory
Assessment I-ComprehensiveAssessmentofSymptomsandHistory
of I-ComprehensiveAssessmentofSymptomsandHistory
Symptoms I-ComprehensiveAssessmentofSymptomsandHistory
and I-ComprehensiveAssessmentofSymptomsandHistory
History I-ComprehensiveAssessmentofSymptomsandHistory
( I-ComprehensiveAssessmentofSymptomsandHistory
CASH I-ComprehensiveAssessmentofSymptomsandHistory
) I-ComprehensiveAssessmentofSymptomsandHistory
. O

This O
semi-structured O
interview O
is O
designed O
to O
obtain O
comprehensive O
information O
on O
current O
and O
past O
signs O
and O
symptoms O
of O
major O
psychiatric O
disorders O
, O
premorbid O
functioning O
, O
sociodemographic O
status O
, O
treatment O
, O
and O
course O
of O
illness O
. O

Patients O
were O
included O
if O
they O
met O
Diagnostic O
and O
Statistical O
Manual O
of O
Mental O
Disorders O
fourth O
edition O
( O
DSM-IV O
) O
criteria O
for O
schizophrenia O
or O
schizoaffective O
disorder O
. O

Symptom O
severity O
was O
assessed O
using O
the O
Positive B-PositiveandNegativeSyndromeScale
and I-PositiveandNegativeSyndromeScale
Negative I-PositiveandNegativeSyndromeScale
Syndrome I-PositiveandNegativeSyndromeScale
Scale I-PositiveandNegativeSyndromeScale
( I-PositiveandNegativeSyndromeScale
PANSS I-PositiveandNegativeSyndromeScale
) I-PositiveandNegativeSyndromeScale
. I-PositiveandNegativeSyndromeScale

The O
dosage O
of O
antipsychotic O
medication O
patients O
were O
taking O
at O
the O
time O
of O
scanning O
were O
converted O
to O
a O
chlorpromazine O
equivalent O
dosage O
. O

Demographic O
and O
clinical O
information O
of O
the O
three O
groups O
of O
participants O
( O
controls O
, O
siblings O
, O
schizophrenia O
N O
  O
= O
  O
63 O
, O
106 O
, O
84 O
) O
. O

Table O
1 O
Controls O
Siblings O
Patients O
Statisticsa O
Age O
29.16 O
  O
± O
  O
7.59 O
29.50 O
  O
± O
  O
7.65 O
29.86 O
  O
± O
  O
5.27 O
F O
( O
2,250 O
) O
  O
= O
  O
0.18 O
, O
p O
  O
= O
  O
.83 O
Sex O
( O
M O
/ O
F O
) O
29 O
/ O
34 O
49 O
/ O
57 O
70 O
/ O
14 O
χ O
( O
2 O
) O
2 O
  O
= O
  O
31.95 O
, O
p O
  O
< O
  O
.001 O
IQ O
113.76 O
  O
± O
  O
15.66 O
105.96 O
  O
± O
  O
17.10 O
95.99 O
  O
± O
  O
15.21 O
F O
( O
2,250 O
) O
  O
= O
  O
20.54 O
, O
p O
  O
< O
  O
.001 O
Handedness O
( O
right O
/ O
left O
/ O
mixed O
) O
44 O
/ O
8 O
/ O
1 O
94 O
/ O
6 O
/ O
6 O
70 O
/ O
5 O
/ O
4 O
χ O
( O
2 O
) O
2 O
  O
= O
  O
5.63 O
, O
p O
  O
= O
  O
.23 O
Scanner O
( O
#1 O
/ O
#2 O
) O
28 O
/ O
28 O
59 O
/ O
47 O
49 O
/ O
33 O
χ O
( O
2 O
) O
2 O
  O
= O
  O
1.28 O
, O
p O
  O
= O
  O
.53 O
Illness O
duration O
( O
years O
) O
b O
– O
– O
5.91 O
( O
4.12 O
) O
– O
Chlorpromazine O
dosage O
( O
mg O
/ O
day O
) O
– O
– O
300 O
( O
200 O
, O
600 O
) O
– O
PANSS O
total O
– O
– O
48.38 O
  O
± O
  O
14.89 O
– O
PANSS O
positive O
– O
– O
11.58 O
  O
± O
  O
5.42 O
– O
PANSS O
negative O
– O
– O
12.23 O
  O
± O
  O
4.35 O
– O
PANSS O
general O
psychopathology O
– O
– O
24.57 O
  O
± O
  O
7.05 O
– O
Group O
comparison O
of O
continuous O
variables O
( O
Age O
, O
IQ O
) O
are O
tested O
with O
one-way O
analysis O
of O
variance O
( O
ANOVA O
) O
. O

Nominal O
variables O
( O
sex O
, O
handedness O
, O
scanner O
) O
were O
compared O
using O
chi-square O
statistics O
. O

Distribution O
of O
illness O
duration O
and O
medication O
is O
skewed O
, O
therefore O
median O
and O
inter-quartile O
range O
was O
reported O
. O

Patients O
and O
siblings O
originated O
from O
120 O
unique O
families O
and O
included O
48 O
patient-sibling O
pairs O
or O
triplets O
. O

The B-NoKnownDisorder
control I-NoKnownDisorder
group I-NoKnownDisorder
comprised O
63 O
subjects O
from O
57 O
families O
. O

A O
family O
identification O
code O
( O
family O
ID O
) O
was O
assigned O
to O
every O
subject O
to O
keep O
track O
of O
their O
pedigrees O
. O

Siblings B-NoKnownDisorder
and I-NoKnownDisorder
healthy I-NoKnownDisorder
controls I-NoKnownDisorder
were O
excluded O
for O
any O
current O
or O
previous O
psychotic O
disorder O
. O

In O
addition O
, O
controls O
were O
examined O
with O
the O
Family B-FamilyHistoryAssessmentModule
Interview I-FamilyHistoryAssessmentModule
for I-FamilyHistoryAssessmentModule
Genetic I-FamilyHistoryAssessmentModule
Studies I-FamilyHistoryAssessmentModule
, O
to O
exclude O
a O
family O
history O
of O
psychotic O
disorders O
( O
in O
first O
- O
or O
second-degree O
relatives O
) O
. O

Exclusion O
criteria O
for O
all O
participants O
included O
a O
history O
of O
head O
trauma O
or O
major O
medical O
or O
neurological O
illness O
. O

All O
participants O
were O
between O
18 O
and O
60 O
  O
years O
of O
age O
at O
the O
time O
of O
inclusion O
. O

Demographics O
and O
clinical O
information O
are O
described O
in O
Table O
1 O
. O

Data O
acquisition O
MRI B-MagneticResonanceImaging
scans I-MagneticResonanceImaging
were O
acquired O
on O
two O
1.5 O
  O
T O
Philips O
Achieva O
scanners O
at O
the O
University O
Medical O
Center O
Utrecht O
, O
with O
the O
same O
acquisition O
protocol O
. O

The O
scanner O
information O
was O
included O
as O
a O
covariate O
in O
further O
group-comparisons O
. O

For O
each O
subject O
, O
resting-state B-RestingStateImaging
functional I-RestingStateImaging
magnetic I-RestingStateImaging
resonance I-RestingStateImaging
imaging I-RestingStateImaging
( I-RestingStateImaging
fMRI I-RestingStateImaging
) I-RestingStateImaging
time O
series O
were O
acquired O
with O
a O
three O
dimensional O
( O
3D O
) O
echo O
shifting O
with O
a O
train O
of O
observations O
( O
PRESTO O
) O
acquisition O
scheme O
. O

The B-FunctionalImagingProtocol
PRESTO I-FunctionalImagingProtocol
protocol I-FunctionalImagingProtocol
combines O
the O
echo O
shifting O
technique O
with O
multiple O
gradient O
echoes O
per O
excitation O
to O
allow O
for O
a O
repetition O
time O
shorter O
than O
echo O
time O
. O

The O
acquisition O
parameters O
were O
: O
TR O
/ O
TE O
  O
= O
  O
21.1 O
/ O
31.1 O
  O
ms O
; O
flip O
angle O
  O
= O
  O
90 O
° O
; O
field O
of O
view O
  O
= O
  O
256 O
  O
× O
  O
256 O
  O
mm2 O
, O
voxel O
size O
  O
= O
  O
4 O
  O
× O
  O
4 O
  O
× O
  O
4 O
  O
mm3 O
, O
900 O
time O
frames O
, O
consisting O
of O
32 O
slices O
covering O
whole O
brain O
. O

In O
addition O
, O
a O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
scan O
was O
collected O
as O
anatomical B-StructuralImaging
reference I-StructuralImaging
with O
the O
following O
scanning O
parameters O
: O
TR O
/ O
TE O
  O
= O
  O
30 O
/ O
4.6 O
  O
ms O
; O
flip O
angle O
  O
= O
  O
30 O
° O
; O
field O
of O
view O
  O
= O
  O
256 O
  O
× O
  O
256 O
  O
mm2 O
, O
voxel O
size O
  O
= O
  O
1 O
  O
× O
  O
1 O
  O
× O
  O
1.2 O
  O
mm3 O
. O

Data O
preprocessing O
Resting-state B-RestingStateImaging
fMRI I-RestingStateImaging
data I-RestingStateImaging
were O
preprocessed O
using O
the O
Data O
Processing O
and O
Analysis O
for O
Brain O
Imaging O
( O
DPABI O
) O
toolbox O
on O
MATLAB O
v O
. O

R2016a O
( O
Mathworks O
) O
. O

For O
every O
subject O
, O
the O
first O
10 O
functional O
volumes O
were O
removed O
to O
allow O
for O
signal O
stabilization O
. O

The O
rest O
of O
the O
functional O
images O
were O
realigned O
, O
co-registered O
with O
their O
individual O
anatomic O
image O
, O
and O
corrected O
for O
nuisance O
variables O
( O
six O
rigid O
realignment O
parameters O
, O
signal O
drift O
, O
averaged O
signal O
from O
white O
matter O
and O
cerebrospinal O
fluid O
) O
using O
a O
linear O
regression O
model O
. O

Band-pass O
filtering O
( O
0.01 O
– O
0.1 O
  O
Hz O
) O
was O
applied O
to O
fMRI O
time-series O
to O
reduce O
effects O
of O
low-frequency O
drifts O
and O
high-frequency O
noise O
. O

Subsequently O
, O
the O
functional O
scans O
were O
spatially O
normalized O
to O
MNI O
space O
using O
a O
symmetric O
group-specific O
T1 O
template O
, O
and O
resampled O
to O
3 O
  O
× O
  O
3 O
  O
× O
  O
3 O
  O
mm3 O
voxels O
. O

Spatial O
smoothing O
was O
applied O
to O
normalized O
images O
with O
a O
4 O
  O
mm O
full-width O
half-maximum O
( O
FWHM O
) O
Gaussian O
kernel O
. O

In O
view O
of O
recent O
findings O
on O
the O
influence O
of O
in-scanner O
head O
motion O
on O
fMRI O
signals O
, O
images O
with O
excessive O
movement O
( O
frame-wise O
displacement O
> O
0.5 O
  O
mm O
) O
and O
1 O
backward O
and O
2 O
forward O
scans O
relative O
to O
the O
marked O
frame O
, O
were O
scrubbed O
. O

The O
scrubbing O
procedure O
negated O
group-differences O
in O
head O
motion O
( O
before O
scrubbing O
χ O
( O
2 O
) O
2 O
  O
= O
  O
6.20 O
, O
p O
  O
= O
  O
.04 O
and O
after O
scrubbing O
χ O
( O
2 O
) O
2 O
  O
= O
  O
4.09 O
, O
p O
  O
= O
  O
.13 O
, O
Supplementary O
Table O
1 O
) O
, O
and O
did O
not O
lead O
to O
differences O
on O
the O
number O
of O
images O
rejected O
among O
the O
three O
subject O
groups O
( O
χ O
( O
2 O
) O
2 O
  O
= O
  O
3.54 O
, O
p O
  O
= O
  O
.17 O
) O
. O

The O
Harvard-Oxford O
atlas O
was O
applied O
to O
whole-brain O
functional O
data O
in O
order O
to O
parcellate O
the O
brain O
into O
112 O
bilateral O
regions O
( O
48 O
cortical O
and O
8 O
subcortical O
regions O
per O
hemisphere O
) O
. O

Region O
names O
, O
abbreviations O
, O
anatomic O
classification O
( O
frontal O
, O
temporal O
, O
parietal O
, O
occipital O
lobe O
, O
cingulate O
cortex O
and O
subcortical O
regions O
) O
and O
functional O
hierarchy O
( O
primary O
sensorimotor O
regions O
, O
unimodal O
, O
heteromodal O
association O
areas O
, O
( O
para O
) O
limbic O
and O
subcortical O
regions O
) O
are O
referenced O
in O
Supplementary O
Table O
2 O
. O

The O
functional O
hierarchy O
subdivision O
scheme O
is O
based O
on O
previous O
studies O
. O

Regional O
time-series O
were O
averaged O
across O
voxels O
, O
and O
cross-correlated O
for O
each O
pair O
of O
brain O
regions O
using O
Pearson's O
correlation O
. O

Correlation O
coefficients O
were O
converted O
to O
z O
scores O
using O
Fisher's O
z O
transformation O
, O
serving O
as O
a O
measure O
of O
functional O
connectivity O
strength O
between O
two O
regions O
. O

Interhemispheric O
connectivity O
The O
level O
of O
functional O
connectivity O
between O
56 O
regions O
in O
one O
hemisphere O
and O
their O
corresponding O
areas O
in O
the O
other O
hemisphere O
is O
used O
here O
as O
the O
measure O
of O
interhemispheric O
connectivity O
. O

Interhemispheric O
connections O
between O
homotopic O
regions O
are O
among O
the O
strongest O
functional O
associations O
in O
cortical-cortical O
interactions O
and O
have O
reliably O
been O
identified O
in O
both O
healthy O
and O
clinical O
populations O
. O

As O
a O
supplementary O
analysis O
, O
group-differences O
in O
heterotopic O
interhemispheric O
connectivity O
and O
left O
and O
right O
intrahemispheric O
connectivity O
were O
examined O
in O
the O
same O
manner O
as O
homotopic O
interhemispheric O
connectivity O
. O

Moreover O
, O
to O
assess O
the O
consistency O
of O
interhemispheric O
connectivity O
measurements O
between O
studies O
, O
we O
performed O
an O
additional O
analysis O
examining O
the O
correlation O
in O
regional O
interhemispheric O
connectivity O
in O
controls O
between O
this O
study O
and O
the O
study O
of O
. O

Hemispheric O
specialization O
Hemispheric O
specialization O
is O
calculated O
here O
as O
the O
difference O
in O
connectivity O
strength O
between O
intrahemispheric O
and O
heterotopic O
interhemispheric O
connections O
of O
each O
brain O
region O
. O

Homotopic O
interhemispheric O
connections O
were O
not O
used O
in O
the O
calculation O
of O
hemispheric O
specialization O
so O
that O
we O
could O
examine O
relationship O
between O
hemispheric O
specialization O
and O
interhemispheric O
connectivity O
in O
the O
following O
analysis O
. O

A O
positive O
value O
of O
hemispheric O
specialization O
indicates O
that O
a O
region O
or O
hemisphere O
is O
preferentially O
connected O
to O
other O
regions O
within O
its O
own O
hemisphere O
, O
whereas O
a O
negative O
value O
suggests O
that O
a O
region O
or O
hemisphere O
is O
more O
strongly O
connected O
to O
regions O
in O
the O
contralateral O
hemisphere O
. O

The O
method O
used O
to O
compute O
hemispheric O
specialization O
using O
intrinsic O
functional O
connectivity O
has O
been O
described O
in O
previous O
studies O
using O
a O
voxel-based O
analysis O
. O

Statistical O
analysis O
Effects O
of O
group O
and O
covariates O
on O
interhemispheric O
connectivity O
and O
hemispheric O
specialization O
were O
assessed O
using O
linear-mixed O
effect O
models O
. O

For O
interhemispheric O
connectivity O
, O
fixed-effects O
include O
: O
group O
status O
( O
controls O
, O
siblings O
, O
patients O
) O
, O
age O
, O
sex O
, O
handedness O
( O
right O
/ O
left O
/ O
mixed O
) O
, O
scanner O
( O
#1 O
/ O
#2 O
) O
and O
head O
motion O
. O

To O
control O
for O
potential O
group-differences O
in O
global O
connectivity O
, O
mean O
connectivity O
strength O
of O
all O
non-homotopic O
connections O
( O
i.e O
. O
, O
all O
intrahemispheric O
and O
heterotopic O
interhemispheric O
connections O
) O
was O
included O
as O
a O
fixed-effect O
term O
( O
global O
FC O
) O
. O

Family O
ID O
, O
encoding O
the O
subjects O
' O
pedigree O
information O
, O
was O
included O
as O
random-effect O
term O
to O
control O
for O
family O
ties O
between O
subjects O
( O
Eq O
. O
( O
1 O
) O
) O
. O

The O
model O
has O
237 O
observations O
( O
number O
of O
subjects O
with O
complete O
information O
) O
, O
and O
10 O
fixed O
term O
predictors O
( O
constant O
, O
group_sibling O
, O
group_patient O
, O
age O
, O
gender_female O
, O
handedness_left O
, O
handedness_mixed O
, O
scanner O
_ O
#2 O
, O
motion O
, O
global O
FC O
) O
, O
leaving O
  O
= O
  O
237 O
– O
10 O
  O
= O
  O
227 O
residual O
degrees O
of O
freedom O
. O

Equation O
1 O
: O
For O
hemispheric O
specialization O
, O
group O
status O
, O
age O
, O
sex O
, O
handedness O
, O
scanner O
and O
head O
motion O
were O
again O
included O
as O
fixed-effect O
terms O
. O

Additionally O
, O
we O
included O
hemisphere O
as O
a O
fixed O
factor O
to O
examine O
potential O
differences O
in O
connectivity O
patterns O
between O
the O
two O
hemispheres O
. O

Random O
effect O
terms O
include O
family O
ID O
and O
subject O
ID O
nested O
within O
family O
ID O
. O

The O
number O
of O
fixed O
term O
predictors O
is O
10 O
( O
constant O
, O
group_sibling O
, O
group_patient O
, O
age O
, O
gender_female O
, O
handedness_left O
, O
handedness_mixed O
, O
scanner O
_ O
#2 O
, O
motion O
, O
hemisphere_RH O
) O
, O
and O
residual O
degrees O
of O
freedom O
is O
237 O
  O
× O
  O
2 O
( O
hemisphere O
) O
– O
10 O
  O
= O
  O
464 O
. O

Equation O
2 O
: O
Linear-mixed O
effects O
analysis O
was O
first O
applied O
to O
overall O
interhemispheric O
connectivity O
and O
hemispheric O
specialization O
( O
p O
  O
< O
  O
.05 O
) O
, O
and O
then O
to O
each O
of O
56 O
regional O
measurements O
, O
controlling O
for O
multiple O
comparisons O
( O
p O
  O
< O
  O
.05 O
, O
Bonferroni O
corrected O
) O
. O

Overall O
and O
regional O
measurements O
with O
significant O
group O
effects O
were O
subjected O
to O
post-hoc O
bivariate O
comparisons O
between O
each O
pair O
of O
subject O
groups O
( O
p O
  O
< O
  O
.05 O
) O
. O

Relationship O
between O
interhemispheric O
connectivity O
and O
hemispheric O
specialization O
To O
test O
whether O
schizophrenia-related O
changes O
in O
interhemispheric O
connectivity O
co-vary O
with O
alterations O
in O
hemispheric O
specialization O
, O
we O
calculated O
the O
mean O
difference O
between O
controls O
and O
patients O
on O
both O
measurements O
for O
each O
brain O
region O
. O

Pearson's O
correlation O
analysis O
was O
performed O
on O
group-differences O
of O
interhemispheric O
connectivity O
and O
hemispheric O
specialization O
across O
regions O
( O
p O
  O
< O
  O
.05 O
) O
. O

The O
same O
analysis O
was O
performed O
for O
siblings O
as O
compared O
to O
patients O
, O
and O
for O
controls O
compared O
to O
siblings O
. O

Correlation O
between O
connectivity O
alteration O
and O
clinical O
factors O
To O
examine O
the O
potential O
clinical O
relevance O
of O
connectivity O
changes O
in O
patients O
, O
the O
level O
of O
interhemispheric O
connectivity O
and O
hemispheric O
specialization O
were O
correlated O
with O
illness O
duration O
and O
PANSS O
total O
scores O
in O
patients O
( O
p O
  O
< O
  O
.05 O
) O
. O

Moreover O
, O
antipsychotic O
medication O
was O
examined O
as O
a O
potential O
confounder O
of O
functional O
connectivity O
measurements O
by O
correlating O
daily O
medication O
in O
chlorpromazine O
equivalent O
dose O
with O
interhemispheric O
connectivity O
and O
hemispheric O
specialization O
. O

Bayesian O
computational O
markers O
of O
relapse O
in O
methamphetamine B-MethamphetamineDependence
dependence I-MethamphetamineDependence
Methamphetamine O
use O
disorder O
is O
associated O
with O
a O
high O
likelihood O
of O
relapse O
. O

Identifying O
robust O
predictors O
of O
relapse O
that O
have O
explanatory O
power O
is O
critical O
to O
develop O
secondary O
prevention O
based O
on O
a O
mechanistic O
understanding O
of O
relapse O
. O

Computational O
approaches O
have O
the O
potential O
to O
identify O
such O
predictive O
markers O
of O
psychiatric O
illness O
, O
with O
the O
advantage O
of O
providing O
a O
finer O
mechanistic O
explanation O
of O
the O
cognitive O
processes O
underlying O
psychiatric O
vulnerability O
. O

In O
this O
study O
, O
sixty-two O
recently O
sober O
methamphetamine-dependent B-MethamphetamineDependence
individuals I-MethamphetamineDependence
were O
recruited O
from O
a O
28 O
- O
day O
inpatient O
treatment O
program O
, O
and O
completed B-TaskParadigmImaging
a I-TaskParadigmImaging
Stop I-TaskParadigmImaging
Signal I-TaskParadigmImaging
Task I-TaskParadigmImaging
( I-TaskParadigmImaging
SST I-TaskParadigmImaging
) I-TaskParadigmImaging
while I-TaskParadigmImaging
undergoing I-TaskParadigmImaging
functional I-TaskParadigmImaging
magnetic I-TaskParadigmImaging
resonance I-TaskParadigmImaging
imaging I-TaskParadigmImaging
( I-TaskParadigmImaging
fMRI I-TaskParadigmImaging
) I-TaskParadigmImaging
. O

These O
individuals O
were O
prospectively O
followed O
for O
1 O
  O
year O
and O
assessed O
for O
relapse O
to O
methamphetamine O
use O
. O

Thirty-three O
percent O
of O
followed O
participants O
reported O
relapse O
. O

We O
found O
that O
neural O
activity O
associated O
with O
two O
types O
of O
Bayesian O
prediction O
error O
, O
i.e O
. O
the O
difference O
between O
actual O
and O
expected O
need O
to O
stop O
on O
a O
given O
trial O
, O
significantly O
differentiated O
those O
individuals O
who O
remained O
abstinent O
and O
those O
who O
relapsed O
. O

Specifically O
, O
relapsed O
individuals O
exhibited O
smaller O
neural O
activations O
to O
such O
Bayesian O
prediction O
errors O
relative O
to O
those O
individuals O
who O
remained O
abstinent O
in O
the O
left O
temporoparietal O
junction O
( O
Cohen's O
d O
  O
= O
  O
0.91 O
) O
, O
the O
left O
inferior O
frontal O
gyrus O
( O
Cohen's O
d O
  O
= O
  O
0.57 O
) O
, O
and O
left O
anterior O
insula O
( O
Cohen's O
d O
  O
= O
  O
0.63 O
) O
. O

In O
contrast O
, O
abstinent O
and O
relapsed O
participants O
did O
not O
differ O
in O
neural O
activation O
to O
non-model O
based O
task O
contrasts O
or O
on O
various O
self-report O
clinical O
measures O
. O

In O
conclusion O
, O
Bayesian O
cognitive O
models O
may O
help O
identify O
predictive O
biomarkers O
of O
relapse O
, O
while O
providing O
a O
computational O
explanation O
of O
belief O
processing O
and O
updating O
deficits O
in O
individuals O
with O
methamphetamine O
use O
disorder O
. O

Highlights O
Methamphetamine-dependent B-MethamphetamineDependence
individuals I-MethamphetamineDependence
( I-MethamphetamineDependence
MDI I-MethamphetamineDependence
) I-MethamphetamineDependence
face O
a O
high O
rate O
of O
relapse O
after O
treatment O
. O

Can O
a O
Bayesian O
learning O
modeling O
and O
fMRI O
be O
used O
to O
identify O
markers O
of O
relapse O
? O

MDI O
who O
relapsed O
within O
1 O
  O
year O
have O
smaller O
activation O
to O
Bayesian O
model-based O
prediction O
errors O
. O

Such O
neural O
pattern O
was O
observed O
in O
left O
temporo-parietal O
junction O
, O
IFG O
, O
and O
anterior O
insula O
. O

MDI B-MethamphetamineDependence
more O
likely O
to O
relapse O
show O
weaker O
tracking O
of O
uncertainty O
and O
updating O
of O
their O
belief O
model O
. O

Methods B-StudyMethod
Participants O
The O
study O
protocol O
was O
approved O
by O
the O
UCSD O
Human O
Research O
Protections O
Program O
and O
all O
subjects O
gave O
written O
informed O
consent O
. O

Sixty-two O
( O
21% O
female O
) O
recently O
sober O
methamphetamine-dependent B-MethamphetamineDependence
individuals I-MethamphetamineDependence
were O
recruited O
from O
a O
28 O
- O
day O
inpatient O
Alcohol O
and O
Drug O
Treatment O
Program O
at O
the O
Veterans O
Affairs O
San O
Diego O
Healthcare O
System O
and O
Scripps O
Green O
Hospital O
( O
La O
Jolla O
, O
CA O
; O
cross-sectional O
analysis O
of O
these O
data O
published O
elsewhere O
) O
. O

All O
study O
procedures O
, O
including O
the B-TaskParadigmImaging
neuroimaging I-TaskParadigmImaging
session I-TaskParadigmImaging
examining I-TaskParadigmImaging
brain I-TaskParadigmImaging
and I-TaskParadigmImaging
behavior I-TaskParadigmImaging
responses I-TaskParadigmImaging
during I-TaskParadigmImaging
the I-TaskParadigmImaging
SST I-TaskParadigmImaging
, O
occurred O
during O
the O
third O
or O
fourth O
week O
of O
treatment O
for O
all O
participants O
( O
i.e O
. O
, O
all O
had O
been O
abstinent O
from O
methamphetamine O
or O
any O
other O
drugs O
, O
including O
alcohol O
, O
for O
3 O
– O
4 O
  O
weeks O
) O
. O

To O
maintain O
sobriety O
during O
the O
program O
, O
participants O
were O
screened O
for O
the O
presence O
of O
drugs O
via O
random O
urine O
toxicology O
or O
whenever O
they O
left O
the O
facility O
, O
and O
were O
terminated O
from O
the O
program O
if O
tested O
positive O
. O

Participants O
also O
performed O
the O
North B-NationalAdultReadingTest
American I-NationalAdultReadingTest
Adult I-NationalAdultReadingTest
Reading I-NationalAdultReadingTest
Test I-NationalAdultReadingTest
as O
a O
measure O
of O
verbal O
intelligence O
, O
and O
completed O
self-report O
measures O
of O
personality O
and O
affective O
measures O
previously O
associated O
with O
stimulant O
addiction O
vulnerability O
, O
including O
the O
Barratt B-BarrattImpulsivenessQuestionnaire
Impulsiveness I-BarrattImpulsivenessQuestionnaire
Scale I-BarrattImpulsivenessQuestionnaire
( I-BarrattImpulsivenessQuestionnaire
BIS I-BarrattImpulsivenessQuestionnaire
- I-BarrattImpulsivenessQuestionnaire
11 I-BarrattImpulsivenessQuestionnaire
) I-BarrattImpulsivenessQuestionnaire
, O
the B-PersonalityRatingScale
Sensation I-PersonalityRatingScale
Seeking I-PersonalityRatingScale
Scale I-PersonalityRatingScale
( I-PersonalityRatingScale
SSS-V I-PersonalityRatingScale
) I-PersonalityRatingScale
, O
and O
the O
Beck B-BeckDepressionInventory
Depression I-BeckDepressionInventory
Inventory I-BeckDepressionInventory
( I-BeckDepressionInventory
BDI I-BeckDepressionInventory
) I-BeckDepressionInventory
. O

Lifetime O
DSM-IV O
Axis O
I O
and O
II O
diagnoses O
at O
baseline O
were O
assessed O
with O
the O
Semi B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
Structured B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
Assessment B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
for B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
the B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
Genetics B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
of B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
Alcoholism B-Semi-StructuredAssessmentfortheGeneticsofAlcoholism
and O
based O
on O
consensus O
meetings O
with O
the O
supervising O
clinician O
and O
trained O
study O
personnel O
, O
including O
a O
Masters-level O
research O
assistant O
and O
postdoctoral-level O
psychologist O
( O
see O
Supplementary O
Text O
1 O
for O
exclusion O
criteria O
) O
. O

Methamphetamine B-MethamphetamineDependence
dependence I-MethamphetamineDependence
, O
and O
not O
DSM O
- O
5 O
diagnosis O
of O
methamphetamine O
use O
disorder O
, O
was O
assessed O
because O
DSM-IV O
was O
in O
effect O
at O
the O
start O
of O
the O
study O
. O

Participants O
were O
contacted O
one O
year O
later O
for O
a O
brief O
structured O
phone O
interview O
to O
assess O
for O
any O
use O
of O
methamphetamine O
, O
level O
of O
use O
, O
and O
time O
of O
relapse O
. O

At O
baseline O
, O
we O
also O
assessed O
for O
use O
and O
abuse O
/ O
dependence O
criteria O
for O
other O
drugs O
( O
i.e O
. O
, O
sedatives O
, O
hallucinogens O
, O
marijuana O
, O
cocaine O
or O
opiates O
) O
in O
the O
past O
year O
, O
as O
part O
of O
a O
larger O
longitudinal O
study O
, O
which O
also O
followed O
individuals O
with O
other O
primary O
drugs O
of O
abuse O
. O

For O
all O
participants O
in O
this O
study O
, O
methamphetamine B-MethamphetamineDependence
was I-MethamphetamineDependence
confirmed I-MethamphetamineDependence
as I-MethamphetamineDependence
participants I-MethamphetamineDependence
' I-MethamphetamineDependence
drug I-MethamphetamineDependence
of I-MethamphetamineDependence
choice I-MethamphetamineDependence
. O

Relapse O
was O
defined O
as O
use O
of O
methamphetamine O
at O
any O
point O
during O
the O
follow-up O
period O
, O
while O
some O
participants O
may O
have O
additionally O
relapsed O
to O
any O
of O
these O
other O
substances O
( O
not O
assessed O
at O
follow-up O
) O
. O

Based O
on O
interview O
responses O
, O
thirty-nine O
methamphetamine-dependent B-MethamphetamineDependence
individuals O
remained O
abstinent O
from O
methamphetamine O
from O
the O
time O
of O
treatment O
to O
one-year O
follow-up O
. O

Nineteen O
individuals O
reported O
that O
they O
relapsed O
. O

Four O
participants O
could O
not O
be O
tracked O
. O

Stop B-TaskParadigmImaging
signal I-TaskParadigmImaging
task I-TaskParadigmImaging
Participants I-TaskParadigmImaging
completed I-TaskParadigmImaging
a I-TaskParadigmImaging
stop-signal I-TaskParadigmImaging
task I-TaskParadigmImaging
( I-TaskParadigmImaging
6 I-TaskParadigmImaging
blocks I-TaskParadigmImaging
of I-TaskParadigmImaging
48 I-TaskParadigmImaging
trials I-TaskParadigmImaging
) I-TaskParadigmImaging
while I-TaskParadigmImaging
undergoing I-TaskParadigmImaging
fMRI B-FunctionalMagneticResonanceImaging
. O

On O
216 O
go O
trials O
( O
75% O
of O
all O
trials O
) O
, O
they O
had O
to O
press O
as O
fast O
as O
possible O
the O
left O
button O
when O
an O
‘ O
X O
' O
appeared O
or O
the O
right O
button O
when O
an O
‘ O
O O
' O
appeared O
. O

On O
72 O
stop O
trials O
( O
25% O
of O
all O
trials O
) O
, O
they O
heard O
a O
tone O
shortly O
after O
onset O
of O
the O
go O
stimulus O
, O
which O
instructed O
them O
not O
to O
press O
either O
button O
. O

Each O
trial O
lasted O
around O
1300 O
  O
ms O
, O
and O
trials O
were O
separated O
by O
a O
200 O
- O
ms O
inter-stimulus O
intervals O
( O
blank O
screen O
) O
. O

Individuals O
' O
reaction O
time O
( O
time O
from O
stimulus O
onset O
to O
button O
press O
) O
provided O
a O
natural O
jitter O
. O

The O
sequence O
of O
trial O
types O
presented O
was O
pseudo-randomized O
. O

Finally O
, O
prior O
to O
scanning O
, O
participants O
completed O
the O
SST O
outside O
the O
scanner O
to O
determine O
their O
mean O
‘ O
Go O
’ O
reaction O
time O
( O
MRT O
) O
. O

This O
measure O
was O
then O
used O
to O
determine O
the O
stop O
signal O
delay O
( O
SSD O
) O
for O
six O
different O
types O
stop O
trial O
of O
increasing O
difficulty O
, O
providing O
a O
subject-dependent O
jittered O
reference O
function O
. O

Specifically O
, O
stop O
signals O
were O
delivered O
in O
equal O
amounts O
at O
MRT O
- O
0 O
  O
ms O
, O
MRT O
- O
100 O
  O
ms O
, O
MRT O
- O
200 O
  O
ms O
, O
MRT O
- O
300 O
  O
ms O
, O
MRT O
- O
400 O
  O
ms O
, O
and O
MRT O
- O
500 O
  O
ms O
providing O
an O
individually O
customized O
range O
of O
difficulty O
; O
see O
Supplementary O
Text O
2 O
for O
task O
instructions O
) O
. O

Bayesian O
model O
of O
the O
inhibitory O
response O
expectation O
To O
model O
behavior O
, O
we O
used O
a O
Bayes-optimal O
Dynamic O
Belief O
Model O
, O
which O
has O
been O
robustly O
established O
to O
capture O
behavioral O
adjustments O
in O
the O
SST O
in O
both O
healthy O
individuals O
and O
substance O
users O
. O

The O
model O
assumes O
that O
one O
1 O
) O
updates O
the O
prior O
probability O
of O
encountering O
stop O
trials O
, O
P O
( O
stop O
) O
, O
on O
a O
trial-by-trial O
basis O
based O
on O
trial O
history O
, O
and O
2 O
) O
adjusts O
behavior O
as O
a O
function O
of O
P O
( O
stop O
) O
with O
higher O
predicted O
P O
( O
stop O
) O
prompting O
slower O
Go O
RT O
and O
higher O
likelihood O
of O
correctly O
stopping O
on O
a O
stop O
trial O
. O

Mathematically O
, O
on O
each O
trial O
k O
, O
Pk O
( O
stop O
) O
is O
the O
mean O
of O
the O
predictive O
distribution O
p O
( O
rk O
| O
sk O
- O
1 O
) O
, O
which O
is O
a O
mixture O
of O
the O
previous O
posterior O
distribution O
and O
a O
fixed O
prior O
distribution O
, O
with O
α O
and O
1 O
  O
− O
  O
α O
acting O
as O
the O
mixing O
coefficients O
, O
respectively O
, O
and O
where O
Sk O
  O
= O
  O
( O
s1 O
, O
… O
, O
sk O
) O
is O
1 O
on O
stop O
trials O
and O
0 O
on O
go O
trials O
: O
with O
the O
posterior O
distribution O
being O
updated O
according O
to O
Bayes O
' O
Rule O
: O
A O
. O

P O
( O
stop O
) O
as O
a O
function O
of O
trial O
sequence O
. O

Top O
: O
for O
the O
sequence O
of O
go O
( O
green O
dots O
, O
outcome O
  O
= O
  O
0 O
) O
and O
stop O
( O
blue O
dots O
, O
outcome O
  O
= O
  O
1 O
) O
trials O
, O
Bayesian O
prior O
belief O
about O
encountering O
a O
stop O
trial O
( O
P O
( O
stop O
) O
, O
red O
line O
) O
, O
as O
predicted O
by O
the O
Dynamic O
Belief O
Model O
. O

P O
( O
stop O
) O
increases O
after O
each O
stop O
trial O
, O
and O
decreases O
after O
each O
go O
trial O
. O

Bottom O
: O
The O
corresponding O
signed O
prediction O
error O
( O
SPE O
, O
red O
line O
, O
solid O
) O
, O
SPE O
  O
= O
  O
stimulus O
outcome O
− O
P O
( O
stop O
) O
, O
and O
unsigned O
prediction O
error O
( O
UPE O
, O
blue O
, O
dashed O
) O
, O
SPE O
  O
= O
  O
| O
stimulus O
outcome O
− O
P O
( O
stop O
) O
| O
. O

B O
. O

Model O
fit O
for O
both O
methamphetamine O
dependent O
individuals O
who O
maintained O
abstinence O
over O
a O
1 O
  O
year O
( O
black O
; O
n O
  O
= O
  O
39 O
) O
and O
those O
who O
relapsed O
within O
1 O
  O
year O
of O
treatment O
( O
red O
; O
n O
  O
= O
  O
19 O
) O
; O
data O
collapsed O
across O
all O
subjects O
for O
relapsed O
and O
abstinent O
groups O
separately O
, O
where O
Go O
trials O
were O
binned O
by O
P O
( O
stop O
) O
and O
average O
RT O
calculated O
for O
each O
bin O
separately O
; O
as O
predicted O
by O
our O
Bayes O
optimal O
decision-making O
model O
, O
a O
significant O
positive O
relationship O
was O
observed O
between O
individuals O
' O
Go O
reaction O
times O
( O
RT O
) O
and O
trial-wise O
P O
( O
stop O
) O
model O
estimates O
in O
each O
group O
; O
black O
and O
red O
lines O
represent O
best O
linear O
regression O
fit O
to O
mean O
go O
reaction O
time O
for O
each O
group O
. O

Error O
bars O
  O
= O
  O
SEM O
. O

Fig O
. O
1 O
In O
this O
study O
, O
model O
parameters O
for O
the O
beta O
distribution O
p0 O
( O
r O
) O
and O
α O
were O
kept O
constant O
across O
all O
participants O
, O
based O
on O
prior O
simulations O
that O
sought O
to O
optimize O
behavioral O
fit O
at O
the O
group O
level O
, O
i.e O
. O
, O
maximizing O
the O
goodness-of-fit O
of O
the O
linear O
regression O
of O
P O
( O
Stop O
) O
on O
RT O
across O
all O
participants O
( O
see O
Supplementary O
Text O
3 O
) O
. O

A O
fixed O
setting O
of O
p0 O
  O
= O
  O
Beta O
( O
a O
  O
= O
  O
2.5 O
, O
b O
  O
= O
  O
7.5 O
; O
s O
  O
= O
  O
a O
  O
+ O
  O
b O
  O
= O
  O
10 O
; O
mean O
  O
= O
  O
0.25 O
) O
was O
used O
, O
and O
alpha O
was O
fit O
to O
participants O
' O
data O
( O
range O
tested O
: O
0.25 O
– O
1.0 O
; O
α O
  O
= O
  O
0.5 O
maximized O
overall O
fit O
across O
all O
participants O
; O
see O
Fig O
. O
1A O
for O
P O
( O
stop O
) O
sequence O
) O
. O

Image O
acquisition O
and O
preprocessing O
Using O
a O
fast O
event-related B-TaskParadigmImagingProtocol
fMRI I-TaskParadigmImagingProtocol
design I-TaskParadigmImagingProtocol
, O
six O
T2 B-FunctionalMagneticResonanceImaging
* I-FunctionalMagneticResonanceImaging
- I-FunctionalMagneticResonanceImaging
weighted I-FunctionalMagneticResonanceImaging
EPI I-FunctionalMagneticResonanceImaging
functional I-FunctionalMagneticResonanceImaging
runs I-FunctionalMagneticResonanceImaging
were O
collected O
for O
each O
participant O
, O
along O
with O
one O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
anatomical I-T1WeightedImaging
image I-T1WeightedImaging
. O

Each O
scanning O
session O
was O
conducted O
on O
a O
3 O
  O
T O
General O
Electric O
scanner O
with O
the O
following O
parameters O
: O
T2 O
* O
- O
weighted O
EPI O
, O
repetition O
time O
  O
= O
  O
2000 O
  O
ms O
, O
echo O
time O
  O
= O
  O
40 O
  O
ms O
, O
64 O
  O
× O
  O
64 O
matrix O
, O
30 O
4 O
- O
mm O
axial O
slices O
, O
FOV O
  O
= O
  O
220 O
  O
× O
  O
220 O
  O
mm O
, O
in-plane O
voxel O
size O
  O
= O
  O
3.437 O
, O
and O
flip O
angle O
  O
= O
  O
90o O
. O

Each O
run O
included O
256 O
repetitions O
for O
a O
length O
of O
8 O
  O
min O
and O
32 O
  O
s O
. O

Functional B-FunctionalMagneticResonanceImaging
volume I-FunctionalMagneticResonanceImaging
acquisitions I-FunctionalMagneticResonanceImaging
were O
time-locked O
to O
task O
onset O
. O

During O
the O
same O
experimental O
session O
, O
we O
collected O
a O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
image I-T1WeightedImaging
( I-T1WeightedImaging
MPRAGE I-T1WeightedImaging
, O
TR O
  O
= O
  O
11.4 O
  O
ms O
, O
TE O
  O
= O
  O
4.4 O
  O
ms O
, O
flip O
angle O
  O
= O
  O
10 O
degree O
, O
FOV O
  O
= O
  O
256 O
  O
× O
  O
256 O
, O
1 O
  O
mm3 O
voxels O
) O
to O
be O
used O
for O
anatomical O
reference O
. O

All O
structural B-FunctionalImagingProtocol
and I-FunctionalImagingProtocol
functional I-FunctionalImagingProtocol
image I-FunctionalImagingProtocol
processing I-FunctionalImagingProtocol
and O
analysis O
was O
performed O
with O
the O
Analysis O
of O
Functional O
Neuroimages O
( O
AFNI O
) O
software O
package O
, O
and O
MRI O
x-y O
slices O
were O
reconstructed O
into O
AFNI O
BRIK O
format O
. O

Echoplanar B-FunctionalImagingProtocol
images I-FunctionalImagingProtocol
underwent O
automatic O
coregistration O
to O
the O
anatomical B-StructuralImaging
image I-StructuralImaging
and O
each O
participant O
dataset O
was O
visually O
inspected O
to O
confirm O
successful O
alignment O
. O

Outlier O
voxels O
were O
identified O
in O
the O
aligned O
images O
based O
on O
whether O
a O
given O
time O
point O
greatly O
exceeded O
the O
mean O
number O
of O
voxel O
outliers O
for O
the O
time-series O
. O

Time O
points O
with O
high O
numbers O
of O
outlier O
voxels O
were O
excluded O
from O
subsequent O
analyses O
. O

First-level O
fMRI O
analyses O
In O
a O
first O
general O
linear O
model O
( O
GLM O
) O
, O
Go O
, O
Stop O
Success O
/ O
SS O
, O
and O
Stop O
Error O
/ O
SE O
trials O
were O
distinguished O
and O
convolved O
with O
a O
canonical O
hemodynamic O
response O
function O
( O
Go O
Error O
trials O
were O
scarce O
and O
not O
included O
in O
these O
analyses O
) O
. O

Each O
was O
entered O
as O
both O
categorical O
and O
P O
( O
stop O
) O
- O
modulated O
regressor O
( O
i.e O
. O
, O
Go O
, O
SS O
, O
SE O
, O
GoxPk O
( O
stop O
) O
, O
SSxPk O
( O
stop O
) O
, O
and O
SExPk O
( O
stop O
) O
) O
. O

To O
more O
specifically O
isolate O
neural O
activity O
related O
to O
belief O
updating O
processes O
vs O
uncertainty O
tracking O
, O
a O
second O
GLM O
was O
created O
with O
two O
types O
of O
trial-wise O
Bayesian O
prediction O
errors O
as O
parametric O
regressors O
, O
representing O
the O
discrepancy O
between O
expected O
likelihood O
of O
having O
to O
stop O
on O
the O
upcoming O
trial O
( O
i.e O
. O
, O
P O
( O
stop O
) O
) O
and O
actual O
trial O
type O
observed O
( O
i.e O
. O
, O
Go O
  O
= O
  O
0 O
, O
Stop O
  O
= O
  O
1 O
) O
. O

These O
regressors O
included O
in O
this O
order O
the O
signed O
prediction O
error O
( O
SPE O
  O
= O
  O
outcome-P O
( O
stop O
) O
  O
= O
  O
sk-Pk O
( O
stop O
) O
) O
and O
the O
unsigned O
prediction O
error O
( O
UPE O
  O
= O
  O
| O
outcome-Pk O
( O
stop O
) O
| O
  O
= O
  O
| O
sk-Pk O
( O
stop O
) O
| O
; O
see O
Fig O
. O
1A O
, O
bottom O
) O
, O
as O
well O
as O
trial O
error O
( O
0 O
  O
= O
  O
correct O
or O
1 O
  O
= O
  O
error O
) O
to O
control O
for O
performance O
error O
related O
activity O
. O

Each O
of O
these O
regressors O
were O
orthogonalized O
with O
respect O
to O
the O
preceding O
one O
given O
the O
non-trivial O
collinearity O
between O
them O
. O

Both O
GLMs O
included O
the O
following O
regressors O
of O
no-interest O
: O
a O
baseline O
regressor O
( O
inter-trial O
intervals O
) O
, O
three O
linear O
drift O
regressors O
( O
x O
, O
y O
, O
z O
) O
, O
and O
three O
motion O
regressors O
( O
pitch O
, O
yaw O
, O
roll O
) O
, O
and O
Go O
RTs O
( O
residualized O
with O
respect O
to O
P O
( O
stop O
) O
) O
to O
control O
for O
motor O
response O
confounds O
. O

Images O
were O
spatially O
filtered O
( O
Gaussian O
full O
width O
half O
maximum O
4 O
  O
mm O
) O
to O
account O
for O
individual O
anatomical O
differences O
. O

Automated O
Talairach O
transformations O
were O
applied O
to O
anatomical O
images O
and O
functional O
images O
were O
subsequently O
transformed O
into O
Talairach O
space O
. O

Percent O
signal O
change O
( O
% O
SC O
) O
was O
determined O
by O
dividing O
the O
signal O
for O
each O
regressor O
of O
interest O
by O
the O
baseline O
regressor O
. O

Second-level O
analyses O
At O
the O
between-subject O
level O
, O
two O
types O
of O
voxelwise O
mixed-effects O
linear O
models O
( O
LME O
) O
were O
fit O
to O
the O
coefficients O
of O
our O
first-level O
GLM O
. O

In O
the O
first O
LME O
, O
we O
first O
tested O
for O
the O
interaction O
of O
clinical O
status O
( O
abstinent O
vs O
relapsed O
) O
and O
modulation O
of O
P O
( O
Stop O
) O
under O
each O
Go O
vs O
Stop O
trials O
( O
i.e O
, O
GoxP O
( O
stop O
) O
vs O
StopxPk O
( O
stop O
) O
, O
SS O
and O
SE O
were O
averaged O
) O
, O
with O
subject O
treated O
as O
random O
intercept O
effect O
. O

Whole O
brain O
statistical O
maps O
were O
obtained O
for O
the O
group O
main O
effect O
( O
reflecting O
areas O
tracking O
a O
clinical O
status O
group O
difference O
in O
prior O
P O
( O
stop O
) O
value O
irrespective O
of O
trial O
type O
) O
and O
the O
clinical O
status O
X O
P O
( O
stop O
) O
modulated O
trial O
type O
interaction O
. O

In O
order O
to O
assess O
for O
potential O
group O
difference O
in O
the O
modulation O
of O
trial O
accuracy O
( O
i.e O
. O
, O
successful O
vs O
failed O
inhibition O
) O
by O
P O
( O
stop O
) O
, O
a O
similar O
LME O
approach O
was O
used O
. O

Specifically O
, O
we O
obtained O
statistical O
maps O
for O
the O
main O
effect O
of O
clinical O
status O
( O
reflecting O
potential O
group O
difference O
in O
P O
( O
stop O
) O
activation O
on O
Stop O
trials O
irrespective O
of O
accuracy O
) O
and O
for O
the O
clinical O
status O
X O
P O
( O
stop O
) O
modulated O
trial O
type O
( O
SE O
vs O
SS O
) O
interaction O
. O

To O
correct O
for O
multiple O
comparisons O
, O
we O
used O
a O
cluster O
threshold O
adjustment O
based O
on O
Monte O
Carlo O
simulations O
( O
generated O
with O
AFNI's O
3dClustSim O
program O
) O
. O

We O
first O
calculated O
spatial O
autocorrelation O
function O
( O
acf O
) O
parameters O
from O
the O
1st O
glm O
model O
residuals O
, O
using O
the O
3dFHWMx O
function O
( O
which O
does O
not O
assume O
a O
purely O
Gaussian O
acf O
function O
, O
but O
rather O
a O
mixture O
of O
Gaussian O
and O
mono-exponential O
) O
. O

The O
obtained O
parameters O
, O
averaged O
across O
participants O
, O
were O
fed O
to O
the O
3dClustSim O
function O
to O
determine O
FWER O
corrected O
cluster O
size O
. O

Based O
on O
the O
simulations O
, O
a O
minimum O
cluster O
volume O
of O
896 O
  O
μL O
was O
found O
to O
be O
sufficient O
to O
correct O
for O
multiple O
comparisons O
at O
FWER O
  O
= O
  O
p O
  O
< O
  O
.05 O
with O
a O
minimum O
voxelwise O
significant O
threshold O
of O
p O
  O
< O
  O
.005 O
. O

While O
less O
conservative O
than O
using O
a O
p O
  O
< O
  O
.001 O
or O
p O
  O
< O
  O
.002 O
voxelwise O
threshold O
, O
this O
setting O
provides O
a O
balance O
of O
adequate O
correction O
for O
multiple O
comparisons O
while O
ensuring O
a O
substantial O
minimum O
cluster O
size O
. O

We O
also O
note O
that O
this O
threshold O
is O
still O
relatively O
conservative O
in O
light O
of O
previous O
work O
having O
applied O
this O
Bayesian O
computational O
model O
in O
similar O
populations O
and O
experimental O
settings O
, O
which O
would O
provide O
grounds O
for O
a O
more O
focused O
search O
within O
the O
brain O
based O
on O
regions O
of O
interest O
. O

Finally O
, O
within O
the O
regions O
identified O
with O
those O
LMEs O
, O
we O
identified O
those O
that O
were O
consistent O
with O
a O
potential O
group O
difference O
in O
either O
type O
of O
Bayesian O
prediction O
errors O
( O
UPE O
or O
SPE O
) O
, O
using O
our O
second O
GLM O
for O
regions O
of O
interest O
( O
ROI O
) O
analyses O
. O

Moreover O
, O
for O
regions O
consistent O
with O
a O
group O
main O
effect O
or O
group O
X O
trial O
type O
interaction O
, O
we O
specifically O
checked O
for O
convergence O
between O
results O
from O
the O
second O
GLM O
and O
the O
pattern O
of O
activation O
to O
P O
( O
Stop O
) O
as O
function O
of O
trial O
type O
( O
first O
GLM O
) O
. O

Specifically O
, O
regions O
with O
non-zero O
P O
( O
stop O
) O
activations O
of O
opposite O
signs O
or O
with O
the O
same O
signs O
across O
Go O
and O
Stop O
trials O
, O
should O
be O
consistent O
with O
a O
significant O
group O
difference O
in O
UPE O
and O
SPE O
activations O
, O
respectively O
. O

This O
is O
because O
an O
SPE O
is O
equal O
to O
0 O
- O
P O
( O
stop O
) O
  O
= O
  O
− O
P O
( O
stop O
) O
on O
Go O
trials O
, O
and O
SPE O
  O
= O
  O
1 O
– O
P O
( O
stop O
) O
on O
Stop O
trials O
, O
and O
thus O
negatively O
correlated O
with O
P O
( O
stop O
) O
on O
both O
type O
of O
trials O
. O

In O
contrast O
, O
UPE O
is O
equal O
to O
| O
0 O
- O
P O
( O
stop O
) O
| O
  O
= O
  O
P O
( O
stop O
) O
on O
Go O
trials O
and O
to O
| O
1 O
- O
P O
( O
stop O
) O
| O
  O
= O
  O
1 O
– O
P O
( O
stop O
) O
on O
Stop O
trials O
, O
and O
thus O
should O
be O
positively O
correlated O
on O
Go O
trials O
but O
negatively O
correlated O
with O
P O
( O
stop O
) O
on O
Stop O
trials O
( O
see O
. O

Transdiagnostic O
Effects O
of O
Ventromedial O
Prefrontal O
Cortex O
Transcranial O
Magnetic O
Stimulation O
on O
Cue O
Reactivity O
BACKGROUND O
: O
Elevated O
frontal O
and O
striatal O
reactivity O
to O
drug B-SubstanceDisorder
cues O
is O
a O
transdiagnostic O
hallmark O
of O
substance O
use O
disorders O
. O

The O
goal O
of O
these O
experiments O
was O
to O
determine O
if O
it O
is O
possible O
to O
decrease O
frontal O
and O
striatal O
reactivity O
to O
drug O
cues O
in O
both O
cocaine B-CocaineAbuse
users I-CocaineAbuse
and O
heavy B-AlcoholAbuse
alcohol I-AlcoholAbuse
users I-AlcoholAbuse
through O
continuous O
theta O
burst O
stimulation O
( O
cTBS O
) O
to O
the O
left O
ventromedial O
prefrontal O
cortex O
( O
VMPFC O
) O
. O

METHODS O
: O
Two B-StudyMethod
single-blinded I-StudyMethod
, I-StudyMethod
within-subject I-StudyMethod
, I-StudyMethod
active I-StudyMethod
sham–controlled I-StudyMethod
experiments I-StudyMethod
were I-StudyMethod
performed I-StudyMethod
wherein I-StudyMethod
neural I-StudyMethod
reactivity I-StudyMethod
to I-StudyMethod
drug I-StudyMethod
/ I-StudyMethod
alcohol I-StudyMethod
cues I-StudyMethod
versus I-StudyMethod
neutral I-StudyMethod
cues I-StudyMethod
was I-StudyMethod
evaluated I-StudyMethod
immediately I-StudyMethod
before I-StudyMethod
and I-StudyMethod
after I-StudyMethod
receiving I-StudyMethod
real I-StudyMethod
or I-StudyMethod
sham I-StudyMethod
cTBS I-StudyMethod
( I-StudyMethod
110% I-StudyMethod
resting I-StudyMethod
motor I-StudyMethod
threshold I-StudyMethod
, I-StudyMethod
3600 I-StudyMethod
pulses I-StudyMethod
, I-StudyMethod
Fp1 I-StudyMethod
location I-StudyMethod
; I-StudyMethod
N I-StudyMethod
= I-StudyMethod
49 I-StudyMethod
: I-StudyMethod
25 I-StudyMethod
cocaine B-CocaineAbuse
users I-CocaineAbuse
[ B-StudyMethod
experiment I-StudyMethod
1 I-StudyMethod
] I-StudyMethod
, I-StudyMethod
24 I-StudyMethod
alcohol B-NondependentAlcoholAbuse
users I-NondependentAlcoholAbuse
[ B-StudyMethod
experiment I-StudyMethod
2 I-StudyMethod
] I-StudyMethod
; I-StudyMethod
196 I-StudyMethod
total I-StudyMethod
functional B-FunctionalMagneticResonanceImaging
magnetic I-FunctionalMagneticResonanceImaging
resonance I-FunctionalMagneticResonanceImaging
imaging I-FunctionalMagneticResonanceImaging
scans I-FunctionalMagneticResonanceImaging
) B-StudyMethod
. I-StudyMethod

Generalized O
psychophysiological O
interaction O
and O
three-way O
repeated-measures O
analysis O
of O
variance O
were O
used O
to O
evaluate O
cTBS-induced O
changes O
in O
drug O
cue-associated O
functional O
connectivity O
between O
the O
left O
VMPFC O
and O
eight O
regions O
of O
interest O
: O
ventral O
striatum O
, O
left O
and O
right O
caudate O
, O
left O
and O
right O
putamen O
, O
left O
and O
right O
insula O
, O
and O
anterior O
cingulate O
cortex O
. O

RESULTS O
: O
In O
both O
experiments O
, O
there O
was O
a O
significant O
interaction O
between O
treatment O
( O
real O
/ O
sham O
) O
and O
time O
( O
pre O
/ O
post O
) O
. O

In O
both O
experiments O
, O
cue-related O
functional O
connectivity O
was O
significantly O
attenuated O
following O
real O
cTBS O
versus O
sham O
cTBS O
. O

There O
was O
no O
significant O
interaction O
with O
region O
of O
interest O
for O
either O
experiment O
. O

CONCLUSIONS O
: O
This O
is O
the O
first O
sham-controlled O
investigation O
to O
demonstrate O
, O
in O
two O
populations O
, O
that O
VMPFC O
cTBS O
can O
attenuate O
neural O
reactivity O
to O
drug O
and O
alcohol O
cues O
in O
frontostriatal O
circuits O
. O

These O
results O
provide O
an O
empirical O
foundation O
for O
future O
clinical O
trials O
that O
may O
evaluate O
the O
efficacy O
, O
durability O
, O
and O
clinical O
implications O
of O
VMPFC O
cTBS O
to O
treat O
addictions O
. O

METHODS B-StudyMethod
AND I-StudyMethod
MATERIALS I-StudyMethod
Experiment O
1 O
( O
Cocaine B-CocaineAbuse
Users I-CocaineAbuse
) O
and O
Experiment O
2 O
( O
Heavy B-NondependentAlcoholAbuse
Alcohol I-NondependentAlcoholAbuse
Users I-NondependentAlcoholAbuse
) O
Participants O
. O

Non–treatment-seeking B-CocaineAbuse
cocaine-dependent I-CocaineAbuse
individuals I-CocaineAbuse
( O
n O
= O
25 O
) O
and O
alcohol-dependent B-AlcoholAbuse
individuals I-AlcoholAbuse
( O
n O
= O
24 O
) O
were O
recruited O
from O
the O
Charleston O
, O
South O
Carolina O
, O
metropolitan O
area O
to O
participate O
in O
one O
of O
two O
single-blinded O
, O
active O
sham–controlled O
crossover O
studies O
. O

These O
studies O
were O
independent O
but O
were O
run O
in O
parallel O
by O
the O
same O
study O
coordinator O
using O
the O
same O
TMS O
equipment O
and O
facilities O
. O

Following O
informed O
consent O
procedures O
approved O
by O
the O
Medical O
University O
of O
South O
Carolina O
Institutional O
Review O
Board O
, O
participants O
completed O
screening O
assessments O
related O
to O
MRI O
and O
TMS O
protocol O
safety O
, O
mental O
status O
, O
and O
drug O
use O
to O
determine O
study O
eligibility O
( O
see O
Supplemental O
Methods O
for O
detailed O
inclusion O
/ O
exclusion O
information O
) O
. O

Eligible O
participants O
completed O
two O
MRI O
/ O
rTMS O
visits O
( O
each O
~ O
1 O
hour O
) O
. O

Before O
each O
study O
session O
, O
a O
multipanel O
urine O
drug O
screen O
( O
QuikVue O
6 O
- O
panel O
urine O
drug O
screen O
; O
Quidel O
, O
San O
Diego O
, O
CA O
) O
was O
given O
. O

Participants O
were O
told O
ahead O
of O
time O
that O
if O
they O
had O
positive O
urine O
drug O
screen O
for O
( O
meth O
) O
amphetamine O
, O
opiates O
, O
marijuana O
, O
or O
benzodiazepines O
they O
would O
not O
be O
eligible O
to O
participate O
on O
that O
day O
and O
that O
they O
would O
have O
one O
opportunity O
to O
reschedule O
. O

In O
this O
study O
, O
none O
of O
the O
participants O
had O
to O
reschedule O
for O
a O
positive O
urine O
drug O
screen O
. O

All O
participants O
received O
both O
real O
and O
sham O
VMPFC O
cTBS O
( O
one O
type O
per O
session O
) O
and O
were O
counterbalanced O
for O
the O
order O
in O
which O
they O
received O
stimulation O
( O
Fp1 O
landmark O
based O
on O
the O
International O
10 O
– O
20 O
system O
; O
110% O
resting O
motor O
threshold O
[ O
rMT O
] O
; O
six O
sessions O
of O
cTBS O
for O
each O
visit O
; O
3600 O
pulses O
total O
, O
with O
a O
60 O
- O
second O
break O
after O
the O
first O
1800 O
pulses O
) O
. O

Visit O
2 O
occurred O
between O
7 O
and O
14 O
days O
after O
visit O
1 O
. O
fMRI B-FunctionalMagneticResonanceImaging
drug O
/ O
alcohol O
cue B-TaskParadigmImaging
reactivity I-TaskParadigmImaging
task I-TaskParadigmImaging
data O
were O
collected O
immediately O
before O
and O
after O
cTBS O
stimulation O
( O
Figure O
1 O
) O
, O
with O
the O
fMRI B-FunctionalMagneticResonanceImaging
scan I-FunctionalMagneticResonanceImaging
initiated O
within O
20 O
minutes O
of O
receiving O
real O
or O
sham O
cTBS O
and O
completed O
no O
later O
than O
40 O
minutes O
after O
cTBS O
to O
maximize O
presumed O
effects O
of O
cTBS O
on O
cortical O
activity O
. O

Self-reported O
cocaine O
or O
alcohol O
craving O
( O
respectively O
) O
was O
assessed O
at O
five O
time O
points O
: O
upon O
visit O
initiation O
, O
before O
the O
baseline O
fMRI O
scan O
, O
before O
the O
cTBS O
session O
, O
immediately O
after O
cTBS O
, O
and O
after O
the O
second O
fMRI O
scan O
. O

Procedures O
: O
Clinical O
Assessments O
. O

Self-report O
assessments O
included O
the O
Structured B-StructuredClinicalInterviewforDSMDisorders
Clinical I-StructuredClinicalInterviewforDSMDisorders
Interview I-StructuredClinicalInterviewforDSMDisorders
for I-StructuredClinicalInterviewforDSMDisorders
DSM-IV I-StructuredClinicalInterviewforDSMDisorders
, O
Timeline B-SubstanceUseScale
Followback I-SubstanceUseScale
[ I-SubstanceUseScale
for I-SubstanceUseScale
cocaine I-SubstanceUseScale
, I-SubstanceUseScale
alcohol I-SubstanceUseScale
, I-SubstanceUseScale
marijuana I-SubstanceUseScale
, I-SubstanceUseScale
and I-SubstanceUseScale
nicotine I-SubstanceUseScale
] I-SubstanceUseScale
, O
Alcohol B-AlcoholUseDisordersIdentificationTest
Use I-AlcoholUseDisordersIdentificationTest
Disorders I-AlcoholUseDisordersIdentificationTest
Identification I-AlcoholUseDisordersIdentificationTest
Test I-AlcoholUseDisordersIdentificationTest
, O
Fagerström B-FagerstromTestforNicotineDependence
Smoking I-FagerstromTestforNicotineDependence
Inventory I-FagerstromTestforNicotineDependence
, O
Beck B-BeckDepressionInventory
Depression I-BeckDepressionInventory
Inventory-II I-BeckDepressionInventory
, O
and O
State-Trait B-MentalStateAssessmentScale
Anxiety I-MentalStateAssessmentScale
Inventory I-MentalStateAssessmentScale
. O

Timeline B-SubstanceUseScale
Followback I-SubstanceUseScale
was O
used O
to O
evaluate O
past O
week O
’ O
s O
substance O
use O
at O
all O
study O
visits O
. O

As O
typically O
done O
in O
cue-induced O
craving O
studies O
, O
study O
personnel O
ensured O
that O
craving O
levels O
were O
at O
or O
below O
baseline O
before O
participants O
were O
dismissed O
from O
each O
visit O
. O

Procedures O
: O
Drug B-TaskParadigmImaging
/ I-TaskParadigmImaging
Alcohol I-TaskParadigmImaging
Cue I-TaskParadigmImaging
Reactivity I-TaskParadigmImaging
fMRI B-FunctionalMagneticResonanceImaging
Task B-TaskParadigmImaging
. O

The O
drug B-TaskParadigmImaging
/ I-TaskParadigmImaging
alcohol I-TaskParadigmImaging
cue I-TaskParadigmImaging
reactivity I-TaskParadigmImaging
task I-TaskParadigmImaging
that O
has O
been O
used O
by O
our O
group O
in O
the O
past O
was O
administered O
in O
the O
MRI O
scanner O
as O
a O
block O
design O
using O
E-Prime O
2 O
software O
( O
Psychology O
Software O
Tools O
, O
Inc O
. O
, O
Sharpsburg O
, O
PA O
) O
. O

The O
total O
task O
time O
was O
12 O
minutes O
and O
consisted O
of O
six O
120 O
- O
second O
epochs O
. O

Each O
epoch O
included O
alternating O
24 O
- O
second O
blocks O
of O
four O
task O
conditions O
: O
drug O
, O
neutral O
, O
blur O
, O
and O
rest O
. O

Respectively O
, O
these O
task O
conditions O
included O
images O
of O
cocaine O
- O
or O
alcohol-related O
stimuli O
customized O
for O
each O
group O
( O
e.g O
. O
, O
crack O
pipe O
for O
cocaine B-CocaineAbuse
users I-CocaineAbuse
, I-CocaineAbuse
liquor O
bottles O
for O
alcohol B-AlcoholAbuse
users I-AlcoholAbuse
) O
, O
neutral O
stimuli O
( O
e.g O
. O
, O
glass O
of O
water O
, O
cooking O
utensils O
, O
people O
eating O
dinner O
) O
, O
blurred O
stimuli O
acting O
as O
visual O
controls O
by O
matching O
substance O
images O
in O
color O
and O
hue O
, O
and O
a O
fixation O
cross O
for O
alert O
rest O
periods O
. O

During O
each O
task O
block O
, O
five O
images O
were O
presented O
( O
4.8 O
seconds O
) O
. O

Procedures O
: O
Neuroimaging O
Acquisition O
. O

Participants O
were O
scanned O
using O
a O
Siemens O
3.0T O
TIM O
Trio O
( O
Siemens O
Corp O
. O
, O
Erlangen O
, O
Germany O
) O
MRI O
scanner O
with O
a O
32 O
- O
channel O
head O
coil O
. O

High-resolution O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
structural I-T1WeightedImaging
images I-T1WeightedImaging
were O
acquired O
using O
a O
magnetization O
prepared O
rapid O
acquisition O
gradient-echo O
sequence O
( O
repetition O
time O
/ O
echo O
time O
= O
1900 O
ms O
/ O
2.34 O
ms O
; O
field O
of O
view O
= O
220 O
mm O
; O
matrix O
= O
256 O
× O
256 O
voxels O
; O
192 O
slices O
; O
slice O
thickness O
= O
1.0 O
mm O
with O
no O
gap O
; O
final O
resolution O
= O
1 O
- O
mm3 O
voxels O
) O
. O

Functional B-FunctionalMagneticResonanceImaging
images I-FunctionalMagneticResonanceImaging
were I-FunctionalMagneticResonanceImaging
acquired I-FunctionalMagneticResonanceImaging
with I-FunctionalMagneticResonanceImaging
a I-FunctionalMagneticResonanceImaging
multislice I-FunctionalMagneticResonanceImaging
gradient-echo I-FunctionalMagneticResonanceImaging
echo-planar I-FunctionalMagneticResonanceImaging
imaging I-FunctionalMagneticResonanceImaging
( I-FunctionalMagneticResonanceImaging
EPI I-FunctionalMagneticResonanceImaging
) I-FunctionalMagneticResonanceImaging
sequence I-FunctionalMagneticResonanceImaging
( O
repetition O
time O
/ O
echo O
time O
= O
2200 O
ms O
/ O
35 O
ms O
; O
field O
of O
view O
= O
192 O
mm O
; O
matrix O
= O
64 O
× O
64 O
voxels O
; O
36 O
slices O
; O
slice O
thickness O
= O
3 O
mm O
with O
no O
gap O
; O
final O
resolution O
= O
3 O
mm3 O
voxels O
) O
. O

Each O
functional B-FunctionalMagneticResonanceImaging
run I-FunctionalMagneticResonanceImaging
consisted O
of O
328 O
time O
points O
. O

Procedures O
: O
cTBS O
Protocol—Real O
and O
Sham O
cTBS O
. O

Coil O
position O
was O
determined O
using O
standardized O
coordinates O
from O
the O
International O
10 O
– O
20 O
system O
( O
with O
Fp1 O
corresponding O
to O
the O
left O
VMPFC O
stimulation O
target O
) O
. O

The O
location O
and O
orientation O
of O
each O
participant O
’ O
s O
coil O
placement O
was O
indicated O
on O
a O
nylon O
cap O
that O
participants O
wore O
throughout O
visit O
1 O
and O
both O
MRI O
/ O
rTMS O
sessions O
. O

Participants O
’ O
rMT O
was O
identified O
via O
the O
standardized O
Parametric O
Estimation O
by O
Sequential O
Testing O
procedure O
. O

The O
cTBS O
was O
administered O
with O
a O
figure-of-eight O
Cool-B65 O
A O
/ O
P O
coil O
( O
MagVenture O
, O
Farum O
, O
Denmark O
) O
. O

Participants O
received O
two O
2 O
- O
minute O
trains O
of O
cTBS O
over O
Fp1 O
( O
one O
train O
= O
120 O
seconds O
; O
three O
pulse O
bursts O
at O
5 O
Hz O
; O
15 O
pulses O
/ O
s O
; O
1800 O
pulses O
/ O
train O
; O
60 O
- O
second O
intertrain O
interval O
; O
110% O
rMT O
) O
( O
see O
Supplemental O
Methods O
for O
details O
of O
rigorous O
active O
sham O
) O
. O

To O
enhance O
tolerability O
, O
stimulation O
intensity O
was O
gradually O
escalated O
in O
5% O
increments O
( O
from O
80% O
to O
110% O
rMT O
) O
over O
the O
first O
30 O
seconds O
of O
each O
train O
. O

Procedures O
: O
Cue O
Recollection O
During O
cTBS O
Administration O
. O

Before O
cTBS O
administration O
, O
participants O
were O
asked O
to O
recall O
the O
last O
time O
they O
used O
cocaine O
or O
alcohol O
( O
respectively O
) O
and O
, O
using O
a O
series O
of O
standardized O
questions O
from O
traditional O
Narrative O
Exposure O
Therapy O
practice O
, O
they O
were O
asked O
to O
describe O
the O
place O
they O
were O
using O
, O
a O
visual O
description O
of O
the O
scene O
, O
and O
a O
description O
of O
the O
sensory O
properties O
of O
the O
drug O
including O
taste O
, O
smell O
, O
and O
sensation O
. O

During O
cTBS O
administration O
, O
the O
participants O
were O
primed O
every O
20 O
seconds O
to O
“ O
Think O
about O
that O
scene O
you O
described O
wherein O
you O
were O
last O
using O
cocaine O
/ O
alcohol O
” O
( O
paraphrased O
so O
as O
to O
be O
tailored O
to O
the O
participant O
’ O
s O
description O
) O
. O

Data O
Analysis O
Self-reported O
Craving O
. O

Self-reported O
craving O
scores O
were O
entered O
into O
a O
two-way O
analysis O
of O
variance O
( O
ANOVA O
) O
( O
treatment O
type O
[ O
real O
/ O
sham O
] O
× O
time O
[ O
pre O
/ O
post O
] O
) O
and O
subsequent O
t O
tests O
to O
determine O
the O
effect O
of O
treatment O
on O
changes O
in O
craving O
. O

Neuroimaging O
Preprocessing O
. O

MRI O
data O
were O
preprocessed O
using O
standard O
protocols O
via O
SPM12 O
( O
Wellcome O
Department O
of O
Cognitive O
Neurology O
, O
London O
, O
United O
Kingdom O
) O
implemented O
in O
MATLAB O
7.14 O
( O
The O
MathWorks O
, O
Inc O
. O
, O
Natick O
, O
MA O
) O
( O
see O
Supplemental O
Methods O
for O
preprocessing O
details O
) O
. O

Data O
analyses O
were O
conducted O
on O
a O
total O
of O
49 O
participants O
( O
30 O
men O
; O
mean O
age O
= O
34 O
± O
11 O
years O
; O
age O
range O
= O
21 O
– O
54 O
years O
) O
( O
see O
Table O
1 O
for O
detailed O
demographics O
) O
. O

Generalized O
Psychophysiological O
Interaction O
. O

Generalized O
psychophysiological O
interaction O
( O
gPPI O
) O
was O
used O
to O
investigate O
task-modulated O
patterns O
of O
FC O
between O
the O
VMPFC O
and O
eight O
regions O
of O
interest O
( O
ROIs O
) O
during O
the O
drug O
/ O
alcohol O
cue O
reactivity O
task O
. O
gPPI O
was O
conducted O
as O
described O
by O
McLaren O
et O
al O
. O

( O
see O
Supplemental O
Methods O
for O
gPPI O
analysis O
details O
) O
. O

We O
computed O
drug O
/ O
alcohol O
cue O
minus O
neutral O
cue O
“ O
contrast O
betas O
” O
indicating O
the O
relative O
FC O
during O
drug O
versus O
neutral O
conditions O
. O

Four O
contrast O
betas O
were O
computed O
: O
prereal O
cTBS O
, O
postreal O
cTBS O
, O
presham O
, O
and O
postsham O
. O

We O
aimed O
to O
show O
that O
FC O
between O
the O
VMPFC O
and O
several O
striatal O
and O
salience O
regions O
would O
decrease O
during O
drug O
/ O
alcohol O
cue O
versus O
neutral O
cue O
exposure O
following O
real O
but O
not O
sham O
VMPFC O
cTBS O
. O

To O
do O
this O
, O
we O
conducted O
a O
three-way O
repeated-measures O
ANOVA O
involving O
treatment O
type O
( O
real O
vs O
. O
sham O
) O
, O
time O
( O
pre O
vs O
. O
post O
) O
, O
and O
ROI O
as O
independent O
variables O
and O
drug O
/ O
alcohol O
versus O
neutral O
contrast O
betas O
as O
the O
dependent O
variable O
. O

Subsequent O
t O
tests O
were O
then O
used O
to O
determine O
the O
effect O
of O
treatment O
on O
changes O
in O
drug O
/ O
alcohol O
cue–evoked O
FC O
across O
regions O
. O

The O
focus O
on O
FC O
analysis O
in O
the O
present O
study O
, O
rather O
than O
traditional O
general O
linear O
model O
analysis O
, O
was O
due O
to O
the O
nature O
of O
TMS O
effects O
on O
the O
brain O
. O

To O
influence O
subcortical O
brain O
regions O
( O
such O
as O
the O
striatum O
) O
, O
we O
applied O
TMS O
to O
cortical O
targets O
( O
such O
as O
the O
VMPFC O
) O
and O
took O
advantage O
of O
the O
monosynaptic O
functional O
connections O
between O
cortical O
and O
subcortical O
regions O
. O

As O
such O
, O
we O
felt O
that O
measuring O
the O
efficacy O
of O
the O
cTBS-induced O
changes O
in O
frontostriatolimbic O
circuits O
should O
be O
conducted O
at O
the O
level O
of O
these O
functional O
connections O
. O

Relationship O
Between O
Clinical O
/ O
Demographic O
Variables O
and O
FC O
Changes O
. O

To O
determine O
whether O
clinical O
and O
demographic O
variables O
influenced O
or O
predicted O
cTBS O
treatment O
outcomes O
, O
hierarchical O
multiple O
linear O
regressions O
were O
conducted O
with O
clinical O
and O
demographic O
variables O
of O
interest O
as O
the O
predictors O
and O
covariate O
predictors O
and O
changes O
in O
VMPFC O
FC O
after O
real O
versus O
sham O
cTBS O
as O
the O
outcome O
variable O
. O

Scalp-to-Cortex O
Distance O
Measurement O
. O

Given O
that O
the O
effects O
of O
TMS O
on O
cortical O
depolarization O
are O
proportional O
to O
the O
distance O
between O
the O
skull O
and O
cortex O
, O
we O
calculated O
the O
distance O
from O
the O
scalp O
to O
cortex O
on O
the O
transverse O
plane O
of O
magnetization O
prepared O
rapid O
acquisition O
gradient-echo O
images O
for O
each O
participant O
using O
BrainRuler O
software O
, O
a O
dedicated O
tool O
for O
scalp-to-cortex O
distance O
measurements O
. O

The O
average O
distance O
from O
participant-specific O
placement O
of O
Fp1 O
to O
the O
cortex O
was O
17.4 O
± O
3.7 O
mm O
for O
cocaine O
users O
and O
16.4 O
± O
3.2 O
mm O
for O
alcohol O
users O
. O

These O
distances O
were O
incorporated O
into O
the O
analyses O
as O
covariates O
. O

Understanding O
marijuana O
’ O
s O
effects O
on O
functional O
connectivity O
of O
the O
default O
mode O
network O
in O
patients O
with O
schizophrenia O
and O
co-occurring O
cannabis O
use O
disorder O
: O
A O
Pilot O
Investigation O
Nearly O
half O
of O
patients O
with O
schizophrenia B-Schizophrenia
( I-Schizophrenia
SCZ I-Schizophrenia
) I-Schizophrenia
have O
co-occurring O
cannabis B-CannabisAbuse
use I-CannabisAbuse
disorder I-CannabisAbuse
( I-CannabisAbuse
CUD I-CannabisAbuse
) I-CannabisAbuse
, O
which O
has O
been O
associated O
with O
decreased O
treatment O
efficacy O
, O
increased O
risk O
of O
psychotic O
relapse O
, O
and O
poor O
global O
functioning O
. O

While O
reports O
on O
the O
effects O
of O
cannabis O
on O
cognitive O
performance O
in O
patients O
with O
SCZ O
have O
been O
mixed O
, O
study O
of O
brain O
networks O
related O
to O
executive O
function O
may O
clarify O
the O
relationship O
between O
cannabis O
use O
and O
cognition O
in O
these O
dual-diagnosis O
patients O
. O

In O
the O
present O
pilot O
study O
, O
patients B-Schizophrenia
with I-Schizophrenia
SCZ I-Schizophrenia
and O
CUD O
( O
n O
= O
12 O
) O
and O
healthy B-NoKnownDisorder
controls I-NoKnownDisorder
( O
n O
= O
12 O
) O
completed O
two O
functional B-FunctionalMagneticResonanceImaging
magnetic I-FunctionalMagneticResonanceImaging
resonance I-FunctionalMagneticResonanceImaging
imaging I-FunctionalMagneticResonanceImaging
( I-FunctionalMagneticResonanceImaging
fMRI I-FunctionalMagneticResonanceImaging
) I-FunctionalMagneticResonanceImaging
resting B-RestingStateImaging
scans I-RestingStateImaging
. B-FunctionalMagneticResonanceImaging

Prior O
to O
the O
second O
scan O
, O
patients O
smoked O
a O
3.6% O
tetrahydrocannabinol O
( O
THC O
) O
cannabis O
cigarette O
or O
ingested O
a O
15mg O
delta O
- O
9 O
- O
tetrahydrocannabinol O
( O
THC O
) O
pill O
. O

We O
used O
resting-state B-RestingStateImaging
functional I-RestingStateImaging
connectivity O
to O
examine O
the O
default O
mode O
network O
( O
DMN O
) O
during O
both O
scans O
, O
as O
connectivity O
/ O
activity O
within O
this O
network O
is O
negatively O
correlated O
with O
connectivity O
of O
the O
network O
involved O
in O
executive O
control O
and O
shows O
reduced O
activity O
during O
task O
performance O
in O
normal O
individuals O
. O

At O
baseline O
, O
relative O
to O
controls O
, O
patients O
exhibited O
DMN O
hyperconnectivity O
that O
correlated O
with O
positive O
symptom O
severity O
, O
and O
reduced O
anticorrelation O
between O
the O
DMN O
and O
the O
executive O
control O
network O
( O
ECN O
) O
. O

Cannabinoid O
administration O
reduced O
DMN O
hyperconnectivity O
and O
increased O
DMN-ECN O
anticorrelation O
. O

Moreover O
, O
the O
magnitude O
of O
anticorrelation O
in O
the O
controls O
, O
and O
in O
the O
patients O
after O
cannabinoid O
administration O
, O
positively O
correlated O
with O
WM O
performance O
. O

The O
finding O
that O
DMN O
brain O
connectivity O
is O
plastic O
may O
have O
implications O
for O
future O
pharmacotherapeutic O
development O
, O
as O
treatment O
efficacy O
could O
be O
assessed O
through O
the O
ability O
of O
therapies O
to O
normalize O
underlying O
circuit-level O
dysfunction O
. O

Experimental B-StudyMethod
Materials I-StudyMethod
and I-StudyMethod
Methods I-StudyMethod
Subjects O
Twelve O
patients B-Schizophrenia
with I-Schizophrenia
SCZ I-Schizophrenia
and O
CUD B-CannabisAbuse
and O
twelve O
healthy B-NoKnownDisorder
control I-NoKnownDisorder
subjects I-NoKnownDisorder
participated O
in O
this O
study O
. O

As O
previously O
described O
in O
all O
patients O
were O
recruited O
from O
community O
mental O
health O
centers O
and O
met O
criteria O
for O
SCZ B-Schizophrenia
and O
CUD B-CannabisAbuse
, I-CannabisAbuse
defined I-CannabisAbuse
as I-CannabisAbuse
either I-CannabisAbuse
current I-CannabisAbuse
cannabis I-CannabisAbuse
abuse I-CannabisAbuse
or I-CannabisAbuse
dependence I-CannabisAbuse
with I-CannabisAbuse
use I-CannabisAbuse
within I-CannabisAbuse
the I-CannabisAbuse
past I-CannabisAbuse
month I-CannabisAbuse
prior I-CannabisAbuse
to I-CannabisAbuse
study I-CannabisAbuse
enrollment I-CannabisAbuse
, O
as O
determined O
by O
the O
Structured B-StructuredClinicalInterviewforDSMDisorders
Clinical I-StructuredClinicalInterviewforDSMDisorders
Interview I-StructuredClinicalInterviewforDSMDisorders
for I-StructuredClinicalInterviewforDSMDisorders
DSM-IV-TR I-StructuredClinicalInterviewforDSMDisorders
( I-StructuredClinicalInterviewforDSMDisorders
SCID I-StructuredClinicalInterviewforDSMDisorders
) I-StructuredClinicalInterviewforDSMDisorders
. O

While O
a O
history O
of O
alcohol O
or O
substance O
use O
( O
other O
than O
cannabis O
) O
was O
permitted O
in O
the O
patient O
group O
, O
they O
were O
required O
to O
be O
alcohol O
and O
substance O
free O
for O
a O
minimum O
of O
seven O
days O
prior O
to O
testing O
and O
scanning O
. O

Tobacco O
users O
were O
included O
in O
the O
study O
, O
since O
up O
to O
90% O
of O
patients O
with O
SCZ O
smoke O
cigarettes O
. O

All O
patients O
were O
on O
a O
stable O
dose O
of O
antipsychotic O
medication O
for O
a O
minimum O
of O
one O
month O
prior O
to O
study O
participation O
. O

Patients O
taking O
clozapine O
were O
excluded O
given O
its O
proposed O
ability O
to O
decrease O
alcohol O
and O
cannabis O
use O
in O
patients O
with O
SCZ O
. O

Pharmacotherapies O
for O
addiction O
, O
mental O
retardation O
, O
a O
history O
of O
head O
injury O
, O
or O
factors O
that O
contraindicate O
the O
use O
of O
fMRI O
served O
as O
exclusion O
criteria O
. O

The B-NoKnownDisorder
healthy I-NoKnownDisorder
control I-NoKnownDisorder
group I-NoKnownDisorder
was O
matched O
to O
the O
patient O
sample O
on O
age O
, O
gender O
and O
handedness O
. O

In O
addition O
to O
the O
exclusion O
criteria O
noted O
above O
, O
controls O
were O
excluded O
if O
they O
had O
any O
current O
or O
history O
of O
Axis O
I O
or O
II O
disorders O
, O
including O
any O
substance O
use O
disorder O
. O

A O
signed O
informed O
consent O
was O
obtained O
from O
participants O
prior O
to O
initiation O
of O
the O
study O
. O

The O
protocol O
was O
approved O
by O
the O
Committee O
for O
the O
Protection O
of O
Human O
Subjects O
( O
IRB O
) O
at O
Dartmouth O
College O
. O

Further O
details O
of O
the O
study O
design O
were O
reviewed O
in O
. O

Study B-StudyMethod
Design I-StudyMethod
and I-StudyMethod
Procedure I-StudyMethod
Participants O
refrained O
from O
substance O
use O
( O
except O
for O
tobacco O
or O
caffeine O
) O
for O
the O
duration O
of O
the O
study O
. O

Subjects O
completed O
a O
‘ O
baseline O
’ O
session O
( O
T1 O
) O
, O
and O
then O
returned O
one O
week O
later O
for O
a O
second O
scan O
session O
( O
T2 O
) O
during O
which O
patients O
were O
randomized O
to O
one O
of O
two O
double-blinded O
cannabinoid O
intervention O
groups O
: O
an O
oral O
THC O
group O
( O
N O
= O
6 O
) O
or O
an O
active O
cannabis O
cigarette O
( O
3.6% O
THC O
) O
group O
( O
N O
= O
6 O
) O
. O

Those O
in O
the O
THC O
group O
were O
given O
a O
15mg O
THC O
pill O
( O
three O
hours O
prior O
to O
scanning O
) O
and O
then O
smoked O
a O
placebo O
cannabis O
cigarette O
immediately O
prior O
to O
scanning O
. O

Those O
in O
the O
cannabis O
group O
were O
given O
a O
placebo O
pill O
( O
3 O
hours O
prior O
to O
scanning O
) O
and O
then O
smoked O
an O
active O
3.6% O
THC O
cannabis O
cigarette O
immediately O
before O
scanning O
. O

Smoking O
took O
place O
in O
a O
smoking O
chamber O
within O
the O
scanner O
bay O
, O
immediately O
prior O
to O
scanning O
( O
Figure O
1a O
) O
. O

Patients O
who O
were O
tobacco O
smokers O
were O
asked O
to O
smoke O
a O
cigarette O
90 O
minutes O
prior O
to O
scanning O
, O
based O
upon O
pharmacokinetics O
of O
smoked O
tobacco O
. O

Further O
details O
can O
be O
found O
in O
. O

Healthy B-NoKnownDisorder
control I-NoKnownDisorder
participants I-NoKnownDisorder
followed O
the O
same O
study O
protocol O
, O
but O
did O
not O
receive O
any O
pharmacologic O
intervention O
during O
T2 O
. O

In O
order O
to O
assist O
patients O
in O
remaining O
abstinent O
from O
substance O
use O
for O
the O
duration O
of O
the O
study O
, O
they O
were O
assessed O
three O
times O
in O
the O
week O
prior O
to O
each O
scan O
session O
. O

Each O
time O
, O
they O
were O
screened O
for O
substance O
use O
with O
an O
alcohol O
breathalyzer O
, O
a O
Timeline B-SubstanceUseScale
Follow-Back I-SubstanceUseScale
interview I-SubstanceUseScale
, O
and O
a O
urine O
toxicology O
screen O
( O
ToxCup O
Drug O
Screen O
cup O
; O
CLIAwaived O
, O
Sand O
Diego O
, O
CA O
) O
. O

Patients O
were O
discontinued O
from O
the O
study O
if O
screening O
suggested O
substance O
use O
during O
study O
participation O
. O

THC O
and O
symptom O
measures O
Venous O
blood O
samples O
were O
collected O
from O
patients O
at O
T1 O
, O
in O
the O
morning O
of O
the O
T2 O
session O
, O
immediately O
prior O
to O
fMRI B-FunctionalMagneticResonanceImaging
scanning I-FunctionalMagneticResonanceImaging
, O
and O
before O
cognitive O
testing O
( O
Figure O
1b O
) O
. O

The O
Marijuana B-SubstanceCravingScale
Craving I-SubstanceCravingScale
Questionnaire I-SubstanceCravingScale
( I-SubstanceCravingScale
MCQ I-SubstanceCravingScale
) I-SubstanceCravingScale
, O
Cannabis B-SubstanceCravingScale
Withdrawal I-SubstanceCravingScale
Scale I-SubstanceCravingScale
( I-SubstanceCravingScale
CWS I-SubstanceCravingScale
) I-SubstanceCravingScale
, O
and O
Positive B-PositiveandNegativeSyndromeScale
and I-PositiveandNegativeSyndromeScale
Negative I-PositiveandNegativeSyndromeScale
Syndrome I-PositiveandNegativeSyndromeScale
Scale I-PositiveandNegativeSyndromeScale
( I-PositiveandNegativeSyndromeScale
PANSS I-PositiveandNegativeSyndromeScale
) I-PositiveandNegativeSyndromeScale
were O
administered O
to O
assess O
for O
change O
in O
marijuana O
craving O
, O
withdrawal O
, O
and O
positive O
and O
negative O
symptoms O
. O

Change O
in O
these O
measures O
was O
analyzed O
using O
repeated O
measures O
analysis O
of O
variance O
( O
ANOVA O
) O
with O
group O
as O
the O
between O
group O
factor O
and O
time O
as O
the O
within-subjects O
factor O
, O
followed O
by O
post-hoc O
analysis O
using O
Tukey O
’ O
s O
LSD O
test O
for O
pairwise O
comparisons O
. O

Working O
memory O
performance O
To O
assess O
for O
change O
in O
working O
memory O
performance O
induced O
by O
cannabis O
and O
THC O
, O
the B-NeurocognitiveTest
Wechsler I-NeurocognitiveTest
Adult I-NeurocognitiveTest
Intelligence I-NeurocognitiveTest
Scale I-NeurocognitiveTest
( I-NeurocognitiveTest
WAIS I-NeurocognitiveTest
) I-NeurocognitiveTest
III I-NeurocognitiveTest
Letter I-NeurocognitiveTest
Number I-NeurocognitiveTest
Sequencing I-NeurocognitiveTest
Test I-NeurocognitiveTest
was O
administered O
approximately O
30 O
minutes O
after O
the O
end O
of O
the O
scanning O
sessions O
at O
T1 O
and O
T2 O
. O

This O
test O
was O
selected O
because O
of O
availability O
of O
alternate O
forms O
and O
thus O
its O
applicability O
to O
the O
repeated-measures O
study O
design O
. O

The O
change O
in O
WM O
performance O
in O
patients O
was O
evaluated O
with O
a O
repeated-measures O
ANOVA O
. O

A O
correlation O
analysis O
between O
WM O
performance O
and O
the O
magnitude O
of O
DMN-ECN O
anticorrelation O
was O
performed O
between O
the O
MPFC O
component O
of O
the O
DMN O
and O
the O
DLPFC O
component O
of O
the O
ECN O
. O
fMRI B-FunctionalMagneticResonanceImaging
data I-FunctionalMagneticResonanceImaging
acquisition I-FunctionalMagneticResonanceImaging
fMRI I-FunctionalMagneticResonanceImaging
data I-FunctionalMagneticResonanceImaging
were O
obtained O
using O
a O
3T O
Phillips O
Achieva O
fMRI O
scanner O
with O
an O
8 O
channel O
head O
coil O
. O

Each O
subject O
underwent O
two O
8 O
- O
minute O
resting B-RestingStateImaging
scans I-RestingStateImaging
during O
the O
study O
with O
eyes O
open O
, O
one O
at O
baseline O
( O
T1 O
) O
, O
and O
the O
second O
during O
the O
‘ O
intervention O
’ O
session O
( O
T2 O
) O
. O

Further O
details O
can O
be O
found O
in O
. O

The O
resting B-RestingStateImaging
state I-RestingStateImaging
data I-RestingStateImaging
were O
acquired O
transverse O
to O
the O
AC-PC O
plane O
, O
with O
a B-T2WeightedImaging
T2 I-T2WeightedImaging
* I-T2WeightedImaging
- I-T2WeightedImaging
weighted I-T2WeightedImaging
single O
shot O
echo O
planar O
imaging O
( O
EPI O
) O
pulse O
sequence O
designed O
to O
measure O
whole O
brain O
BOLD O
contrast O
with O
optimal O
temporal O
and O
spatial O
resolution O
[ O
repetition O
time O
( O
TR O
) O
= O
2000ms O
; O
echo O
time O
( O
TE O
) O
= O
30ms O
; O
Flip O
angle O
( O
FA O
) O
= O
90 O
degrees O
; O
field O
of O
view O
( O
FOV O
) O
= O
240 O
mm O
; O
Slice O
thickness O
= O
2.5 O
mm O
; O
Slice O
skip O
0.5 O
; O
Slice O
location O
= O
Pat O
. O

Spec O
; O
Fat O
saturation O
= O
SPIR O
; O
Reps O
= O
240 O
; O
NEX O
= O
1 O
; O
yielding O
36 O
contiguous O
transverse O
functional O
images O
in O
an O
80 O
× O
80 O
matrix O
with O
an O
isotropic O
resolution O
of O
3.0 O
mm3 O
] O
. O

T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
anatomic O
reference O
images O
were O
acquired O
in O
the O
same O
planes O
and O
thickness O
immediately O
following O
the O
resting O
scans O
. O
fMRI B-FunctionalMagneticResonanceImaging
data I-FunctionalMagneticResonanceImaging
analysis I-FunctionalMagneticResonanceImaging
Resting B-RestingStateImaging
state I-RestingStateImaging
data I-RestingStateImaging
were O
analyzed O
using O
a O
seed O
driven O
approach O
( O
http O
: O
/ O
/ O
www.nitrc.org O
/ O
projects O
/ O
conn O
) O
. O

We O
used O
methods O
that O
minimize O
the O
influence O
of O
motion O
and O
artifact O
and O
that O
allow O
for O
valid O
identification O
of O
correlated O
and O
anticorrelated O
networks O
. O

Data O
were O
slice O
time O
corrected O
, O
realigned O
, O
coregistered O
, O
normalized O
, O
and O
spatially O
smoothed O
with O
a O
6 O
- O
mm O
kernel O
. O

To O
address O
the O
spurious O
correlations O
in O
resting-state O
networks O
caused O
by O
head O
motion O
we O
used O
quality O
assurance O
software O
Artifact O
Detection O
Tools O
( O
http O
: O
/ O
/ O
www.nitrc.org O
/ O
projects O
/ O
artifact_detect O
; O
http O
: O
/ O
/ O
www.nitrc.org O
/ O
projects O
/ O
conn O
) O
to O
identify O
problematic O
time O
points O
during O
the O
scan O
. O

Specifically O
, O
an O
image O
was O
defined O
as O
an O
outlier O
if O
the O
head O
displacement O
in O
x O
, O
y O
, O
or O
z O
direction O
was O
greater O
than O
.5mm O
from O
the O
previous O
frame O
, O
or O
if O
the O
global O
mean O
intensity O
in O
the O
image O
was O
greater O
than O
3 O
standard O
deviations O
from O
the O
mean O
image O
intensity O
for O
the O
entire O
resting O
scan O
. O

A O
single O
regressor O
for O
each O
outlier O
image O
was O
included O
in O
the O
first O
level O
general O
linear O
model O
along O
with O
motion O
parameters O
and O
first O
order O
derivatives O
. O

Physiological O
and O
other O
spurious O
sources O
of O
noise O
were O
estimated O
and O
regressed O
using O
the O
anatomical O
CompCor O
method O
( O
aCompCor O
) O
as O
opposed O
to O
global O
signal O
regression O
, O
a O
widely O
used O
preprocessing O
method O
known O
to O
artificially O
introduce O
negative O
correlations O
. O

The O
anatomical B-StructuralImaging
image I-StructuralImaging
for O
each O
participant O
was O
segmented O
into O
white O
matter O
, O
grey O
matter O
, O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
masks O
using O
SPM8 O
. O

To O
minimize O
partial O
voluming O
with O
grey O
matter O
, O
the O
white O
matter O
and O
CSF O
masks O
were O
eroded O
by O
one O
voxel O
, O
which O
resulted O
in O
substantially O
smaller O
masks O
than O
the O
original O
segmentations O
. O

The O
eroded O
white O
matter O
and O
CSF O
masks O
were O
then O
used O
as O
noise O
regions O
of O
interest O
( O
ROI O
) O
. O

Signals O
from O
the O
white O
matter O
and O
CSF O
noise O
ROIs O
were O
extracted O
from O
the O
unsmoothed O
functional O
volumes O
to O
avoid O
additional O
risk O
of O
contaminating O
white O
matter O
and O
CSF O
signals O
with O
grey O
matter O
signals O
. O

Previous O
results O
showed O
that O
aCompCor O
signals O
were O
considerably O
different O
from O
the O
global O
signal O
, O
as O
regressing O
higher O
order O
principal O
components O
of O
the O
global O
signal O
diminished O
both O
positive O
and O
negative O
correlations O
whereas O
regressing O
aCompCor O
signals O
resulted O
in O
stronger O
anticorrelations O
and O
eliminated O
spurious O
correlations O
. O

Based O
on O
previous O
results O
, O
five O
principal O
components O
of O
the O
signals O
from O
white O
matter O
and O
CSF O
noise O
ROIs O
were O
removed O
with O
regression O
. O

A O
temporal O
band-pass O
filter O
of O
0.009 O
Hz O
to O
0.08 O
Hz O
was O
applied O
to O
the O
time O
series O
. O

The O
residual O
BOLD O
time-series O
was O
band-pass O
filtered O
over O
a O
low-frequency O
window O
of O
interest O
( O
0.009Hz O
< O
f O
< O
0.08Hz O
) O
. O

Correlation O
maps O
were O
produced O
by O
extracting O
the O
residual O
BOLD O
time O
course O
from O
seed O
regions O
based O
on O
the O
literature O
. O

The O
DMN O
seed O
was O
defined O
using O
a O
10 O
mm O
sphere O
around O
peak O
MPFC O
coordinates O
, O
as O
specified O
in O
. O

Pearson O
’ O
s O
correlation O
coefficients O
were O
then O
calculated O
between O
the O
DMN O
time O
course O
and O
the O
time O
course O
of O
all O
other O
voxels O
in O
the O
brain O
. O

Correlation O
coefficients O
were O
converted O
to O
normally O
distributed O
scores O
using O
Fisher O
’ O
s O
transformation O
to O
allow O
for O
second-level O
General O
Linear O
Model O
analyses O
. O

Second-level O
within-group O
( O
one O
sample O
t-tests O
) O
and O
between O
group O
( O
ANOVA O
) O
analyses O
were O
performed O
on O
the O
Z-maps O
from O
the O
MPFC O
. O

Correction O
for O
multiple O
comparisons O
on O
analyses O
were O
implemented O
with O
an O
FDR O
correction O
of O
p O
< O
0.001 O
. O

Reduced O
Parietal O
Alpha O
Power O
and O
Psychotic O
Symptoms O
: O
Test-Retest O
Reliability O
of O
Resting-State O
Magnetoencephalography O
in O
Schizophrenia O
and O
Healthy O
Controls O
Background O
: O
Despite O
increased O
reporting O
of O
resting-state O
magnetoencephalography O
( O
MEG O
) O
, O
reliability O
of O
those O
measures O
remains O
scarce O
and O
predominately O
reported O
in O
healthy B-NoKnownDisorder
controls I-NoKnownDisorder
( O
HC O
) O
. O

As O
such O
, O
there O
is O
limited O
knowledge O
on O
MEG O
resting-state O
reliability O
in O
schizophrenia B-Schizophrenia
( O
SZ O
) O
. O

Methods O
: O
To O
address O
test-retest O
reliability O
in O
psychosis O
, O
a O
reproducibility O
study O
of O
26 O
participants O
( O
13 O
- O
SZ O
, O
13 O
- O
HC O
) O
was O
performed O
. O

We O
collected O
eyes O
open O
and O
eyes O
closed O
resting-state B-RestingStateImaging
data I-RestingStateImaging
during O
4 O
separate O
instances O
( O
2 O
Visits O
, O
2 O
runs O
per O
visit O
) O
to O
estimate O
spectral O
power O
reliability O
( O
power O
, O
normalized O
power O
, O
alpha O
reactivity O
) O
across O
one O
hour O
and O
one O
week O
. O

Intraclass O
correlation O
coefficients O
( O
ICCs O
) O
were O
calculated O
. O

For O
source O
modeling O
, O
we O
applied O
an O
anatomically O
constrained O
linear O
estimation O
inverse O
model O
known O
as O
dynamic O
statistical O
parametric O
mapping O
( O
MNE O
dSPM O
) O
and O
source-based O
connectivity O
using O
the O
weighted O
phase O
lag O
index O
. O

Results O
: O
Across O
one O
week O
there O
was O
excellent O
test-retest O
reliability O
in O
global O
spectral O
measures O
in O
theta-gamma O
bands O
( O
HC O
ICCAvg O
= O
0.87 O
, O
SZ O
ICCAvg O
= O
0.87 O
) O
, O
regional O
spectral O
measures O
in O
all O
bands O
( O
HC O
ICCAvg O
= O
0.86 O
, O
SZ O
ICCAvg O
= O
0.80 O
) O
, O
and O
parietal O
alpha O
measures O
( O
HC O
ICCAvg O
= O
0.90 O
, O
SZ O
ICCAvg O
= O
0.84 O
) O
. O

Conversely O
, O
functional O
connectivity O
had O
poor O
reliability O
, O
as O
did O
source O
spectral O
power O
across O
one O
hour O
for O
SZ B-Schizophrenia
. O

Relative O
to O
HC B-NoKnownDisorder
, O
SZ B-Schizophrenia
also O
had O
reduced O
parietal O
alpha O
normalized O
power O
during O
eyes O
closed O
only O
, O
reduced O
alpha O
reactivity O
, O
and O
an O
association O
between O
higher O
PANSS O
positive O
scores O
and O
lower O
parietal O
alpha O
power O
. O

Conclusions O
: O
There O
was O
excellent O
to O
good O
test-retest O
reliability O
in O
most O
MEG B-Magnetoencephalography
spectral O
measures O
with O
a O
few O
exceptions O
in O
the O
schizophrenia B-Schizophrenia
patient O
group O
. O

Overall O
, O
these O
findings O
encourage O
the O
use O
of O
resting-state O
MEG O
while O
emphasizing O
the O
importance O
of O
determining O
reliability O
in O
clinical O
populations O
. O

Materials B-StudyMethod
and I-StudyMethod
Methods I-StudyMethod
Participants O
The O
current O
study O
included O
13 O
individuals O
diagnosed O
with O
schizophrenia B-Schizophrenia
( I-Schizophrenia
SZ I-Schizophrenia
) I-Schizophrenia
and O
13 O
healthy B-NoKnownDisorder
controls I-NoKnownDisorder
( I-NoKnownDisorder
HC I-NoKnownDisorder
) I-NoKnownDisorder
, O
age O
and O
gender O
matched O
, O
Table O
1 O
. O

Informed O
consent O
was O
obtained O
from O
all O
participants O
according O
to O
institutional O
guidelines O
. O

The O
study O
was O
approved O
by O
the O
University O
of O
New O
Mexico O
Health O
Sciences O
Center O
Human O
Research O
Review O
Committee O
. O

All O
participants O
were O
within O
21 O
– O
49 O
years O
of O
age O
with O
no O
history O
of O
neurological O
disorder O
( O
e.g O
. O
epilepsy O
) O
, O
no O
history O
of O
major O
head O
trauma O
( O
loss O
of O
consciousness O
> O
5 O
min O
) O
, O
no O
current O
substance O
abuse O
diagnosis O
( O
excluding O
nicotine O
) O
, O
no O
current O
dependence O
/ O
abuse O
of O
PCP O
/ O
amphetamine O
/ O
cocaine O
within O
the O
past O
12 O
months O
, O
and O
were O
not O
currently O
on O
mood O
stabilizers O
such O
as O
lithium O
or O
valproic O
acid O
. O

HC B-NoKnownDisorder
had O
IQ O
scores O
within O
the O
normal O
range O
and O
no O
history O
of O
developmental O
delays O
or O
neurological O
or O
psychiatric O
disorders O
based O
on O
the O
Structured B-MentalHealthDiagnosisScale
Clinical I-MentalHealthDiagnosisScale
Interview I-MentalHealthDiagnosisScale
for I-MentalHealthDiagnosisScale
DSM-IV-Non-patient I-MentalHealthDiagnosisScale
( I-MentalHealthDiagnosisScale
SCIDNP I-MentalHealthDiagnosisScale
) I-MentalHealthDiagnosisScale
. O

HCs O
also O
did O
not O
have O
a O
family O
history O
of O
a O
psychotic O
disorder O
in O
first-degree O
relatives O
or O
a O
history O
of O
more O
than O
1 O
lifetime O
depressive O
episode O
. O

Participants B-Schizophrenia
with I-Schizophrenia
schizophrenia I-Schizophrenia
were O
confirmed O
to O
have O
a O
DSM-IV-TR O
diagnosis O
of O
schizophrenia B-Schizophrenia
with O
the O
Structured B-MentalHealthDiagnosisScale
Clinical I-MentalHealthDiagnosisScale
Interview I-MentalHealthDiagnosisScale
for I-MentalHealthDiagnosisScale
DSM-IV-Patient I-MentalHealthDiagnosisScale
( I-MentalHealthDiagnosisScale
SCID-IP I-MentalHealthDiagnosisScale
) I-MentalHealthDiagnosisScale
and O
retrospective O
clinical O
stability O
. O

Participants O
were O
not O
excluded O
for O
nicotine O
use O
, O
however O
, O
they O
were O
not O
allowed O
to O
smoke O
within O
1 O
hour O
of O
the O
MEG O
session O
or O
be O
more O
than O
5 O
hours O
from O
their O
previous O
cigarette O
to O
avoid O
confounds O
of O
acute O
nicotine O
exposure O
or O
withdrawal O
. O

The O
following O
assessments O
were O
collected O
in O
SZ B-Schizophrenia
participants O
and O
reported O
in O
Table O
1 O
: O
Wechsler B-NeurocognitiveTest
Test I-NeurocognitiveTest
of I-NeurocognitiveTest
Adult I-NeurocognitiveTest
Reading I-NeurocognitiveTest
( I-NeurocognitiveTest
WTAR I-NeurocognitiveTest
) I-NeurocognitiveTest
, I-NeurocognitiveTest
Standard I-NeurocognitiveTest
and I-NeurocognitiveTest
Predicted I-NeurocognitiveTest
( I-NeurocognitiveTest
premorbid I-NeurocognitiveTest
) I-NeurocognitiveTest
IQ I-NeurocognitiveTest
, O
Positive B-PositiveandNegativeSyndromeScale
and I-PositiveandNegativeSyndromeScale
Negative I-PositiveandNegativeSyndromeScale
Syndrome I-PositiveandNegativeSyndromeScale
Scale I-PositiveandNegativeSyndromeScale
( I-PositiveandNegativeSyndromeScale
PANSS I-PositiveandNegativeSyndromeScale
) I-PositiveandNegativeSyndromeScale
, O
antipsychotic O
medication O
dose O
information O
, O
and O
duration O
of O
illness O
. O

PANSS B-PositiveandNegativeSyndromeScale
scores O
were O
determined O
for O
each O
visit O
. O

Antipsychotic O
medication O
was O
converted O
to O
olanzapine O
equivalents O
for O
comparison O
between O
medication O
. O

Duration O
of O
illness O
was O
calculated O
by O
subtracting O
age O
at O
onset O
of O
psychotic O
symptoms O
from O
current O
age O
. O

MEG O
Behavioral O
Tasks O
All O
participants O
had O
two O
visits O
across O
7 O
days O
[ O
HC O
= O
7.54 O
days O
± O
60 O
minutes O
, O
SZ O
= O
7.84 O
days O
± O
51 O
minutes O
] O
. O

Time O
of O
day O
between O
visits O
was O
matched O
to O
take O
into O
account O
circadian O
rhythm O
. O

Each O
visit O
began O
with O
a O
10 O
- O
minute O
rest B-RestingStateImaging
task I-RestingStateImaging
( O
referred O
to O
as O
Rest10 O
) O
and O
ended O
with O
a O
4 O
- O
minute O
rest B-RestingStateImaging
task I-RestingStateImaging
( O
referred O
to O
as O
Rest4 O
) O
, O
see O
Figure O
1 O
. O

No O
responses O
were O
required O
from O
the O
participant O
; O
however O
, O
participants O
were O
instructed O
to O
attend O
the O
instructions O
for O
prompts O
to O
close O
their O
eyes O
or O
fixate O
on O
a O
white O
cross O
. O

Each O
task O
alternated O
between O
EC O
and O
EO O
. O

In O
total O
, O
resting-state B-RestingStateImaging
activity I-RestingStateImaging
was O
recorded O
4 O
separate O
times O
with O
14 O
minutes O
of O
EO O
and O
14 O
minutes O
of O
EC O
. O

MEG O
Data O
Acquisition O
MEG B-Magnetoencephalography
data O
were O
collected O
in O
a O
magnetically O
shielded O
room O
( O
Vacuumschmelze O
– O
Ak3B O
) O
at O
the O
Mind O
Research O
Network O
in O
Albuquerque O
, O
New O
Mexico O
using O
a O
306 O
- O
channel O
whole-head O
MEG B-Magnetoencephalography
system O
( O
Elekta O
Neuromag O
) O
with O
a O
sampling O
rate O
of O
1000 O
Hz O
and O
an O
antialiasing O
filter O
with O
a O
passband O
of O
0.1 O
– O
330 O
Hz O
. O

Prior O
to O
data O
acquisition O
, O
four O
electromagnetic O
coils O
were O
placed O
on O
the O
participant O
’ O
s O
mastoid O
bone O
and O
upper O
forehead O
, O
along O
with O
electro-oculogram O
and O
electrocardiogram O
channels O
. O

The O
location O
of O
the O
coils O
were O
registered O
to O
the O
nasion O
and O
preauricular O
points O
using O
three-dimensional O
digitization O
equipment O
( O
Polhemus O
FastTrack O
) O
. O

Participants O
sat O
upright O
in O
the O
MEG B-Magnetoencephalography
during O
the O
task O
. O

Continuous O
Head O
Position O
Indicator O
( O
cHPI O
) O
monitoring O
allowed O
for O
motion O
correction O
. O

Head O
position O
was O
checked O
between O
visits O
. O

For O
the O
Rest10 B-RestingStateImaging
task I-RestingStateImaging
, O
average O
Euclidean O
distance O
between O
visits O
was O
4.62 O
mm O
for O
HC B-NoKnownDisorder
and O
6.06 O
mm O
for O
SZ B-Schizophrenia
. O

For O
the O
Rest4 B-RestingStateImaging
task I-RestingStateImaging
, O
the O
distance O
was O
4.90 O
mm O
for O
HC B-NoKnownDisorder
and O
6.12 O
mm O
for O
SZ B-Schizophrenia
. O

Head O
position O
consistency O
was O
similar O
between O
HC B-NoKnownDisorder
and O
SZ B-Schizophrenia
( O
all O
p O
’ O
s O
> O
0.31 O
) O
. O

Structural O
MRI O
Data O
Acquisition O
Structural B-StructuralImaging
MRIs I-StructuralImaging
were O
obtained O
for O
mapping O
source O
locations O
. O

Sagittal O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
anatomical B-StructuralImaging
MR I-StructuralImaging
images I-StructuralImaging
were O
obtained O
using O
a O
Siemens O
TIM O
Trio O
3 O
Tesla O
MRI O
system O
with O
a O
32 O
- O
channel O
head O
coil O
. O

Parameters O
of O
the O
multiecho O
3D O
MPRAGE B-T1WeightedImaging
sequence I-T1WeightedImaging
were O
: O
TR O
/ O
TE O
/ O
TI O
= O
2530 O
/ O
1.64 O
, O
3.5 O
, O
5.36 O
, O
7.22 O
, O
9.08 O
/ O
1200 O
ms O
, O
flip O
angle O
= O
7 O
° O
, O
field O
of O
view O
( O
FOV O
) O
= O
256 O
mm O
x O
256 O
mm O
, O
matrix O
= O
256 O
× O
256 O
, O
1 O
mm O
thick O
slice O
, O
192 O
slices O
, O
GRAPPA O
acceleration O
= O
2 O
. O

MEG O
Data O
Preprocessing O
Raw O
MEG B-Magnetoencephalography
data O
were O
filtered O
for O
noise O
and O
corrected O
for O
head O
motion O
with O
the O
Neuromag O
Max-Filter O
2.2 O
software O
using O
the O
temporal O
extension O
of O
signal O
space O
separation O
( O
t-SSS O
) O
method O
with O
movement O
compensation O
. O

MEG B-Magnetoencephalography
data O
from O
each O
subject O
’ O
s O
Visit O
2 O
was O
transformed O
to O
Visit O
1 O
head O
position O
using O
Maxfilter O
2.2 O
MaxMove O
option O
to O
ensure O
equivalent O
sensor O
locations O
between O
visits O
. O

No O
downsampling O
of O
the O
data O
was O
implemented O
at O
the O
preprocessing O
stage O
. O

Heartbeat O
and O
eye-blink O
artifacts O
were O
automatically O
detected O
and O
removed O
using O
signal O
space O
projection O
( O
SSP O
) O
in O
MNE O
software O
. O

The O
continuous O
data O
were O
segmented O
into O
artifact-free O
2 O
second O
epochs O
. O

Epochs O
in O
which O
the O
magnetic O
field O
exceeded O
5 O
pT O
were O
rejected O
. O

HC B-NoKnownDisorder
had O
2.4% O
and O
SZ B-Schizophrenia
had O
4.6% O
of O
all O
epochs O
rejected O
. O

The O
total O
number O
of O
epochs O
used O
for O
further O
analysis O
included O
401 O
EC O
, O
402 O
EO O
epochs O
in O
HC B-NoKnownDisorder
, O
and O
393 O
EC O
, O
403 O
EO O
epochs O
in O
SZ B-Schizophrenia
. O

The O
number O
of O
closed O
/ O
open O
epochs O
did O
not O
differ O
between O
groups O
( O
all O
p O
’ O
s O
> O
0.25 O
) O
. O

MEG O
Spectral O
Analyses O
For O
sensor O
analysis O
, O
we O
applied O
the O
summary O
spectral O
measures O
described O
in O
to O
simplify O
multi-channel O
MEG B-Magnetoencephalography
spectral O
data O
. O

Using O
only O
planar O
gradiometers O
, O
the O
sensor O
array O
was O
divided O
into O
left O
and O
right O
equivalent O
regions O
, O
see O
Figure O
2 O
. O

Spectral O
power O
was O
estimated O
using O
Matlab O
’ O
s O
FFT O
function O
with O
a O
window O
size O
of O
2048 O
for O
the O
following O
frequency O
bands O
: O
Delta O
( O
1 O
– O
4 O
Hz O
) O
, O
Theta O
( O
5 O
– O
8 O
Hz O
) O
, O
Alpha O
( O
9 O
– O
13 O
Hz O
) O
, O
Beta O
( O
14 O
– O
29 O
Hz O
) O
, O
and O
Gamma O
( O
31 O
– O
58 O
Hz O
) O
. O

Spectral O
measures O
included O
: O
power O
, O
normalized O
power O
, O
half-power O
, O
Shannon O
Spectral O
Entropy O
( O
SSE O
) O
, O
and O
alpha O
reactivity O
. O

Normalized O
power O
was O
obtained O
by O
dividing O
the O
power O
within O
the O
frequency O
band O
by O
total O
1 O
– O
50 O
Hz O
power O
. O

Half O
power O
was O
defined O
as O
the O
midpoint O
frequency O
where O
half O
of O
the O
power O
is O
below O
/ O
above O
for O
the O
1 O
– O
50 O
Hz O
range O
and O
indicates O
overall O
spectral O
power O
shifts O
from O
low O
to O
high O
frequencies O
. O

Alpha O
reactivity O
was O
calculated O
using O
normalized O
spectral O
power O
values O
with O
the O
following O
: O
( O
EC-EO O
) O
/ O
EO O
. O

Global O
measures O
were O
the O
average O
of O
all O
regions O
and O
gradiometers O
. O

For O
source O
analysis O
, O
the O
cortical O
surface O
of O
each O
participant O
was O
reconstructed O
from O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
MRI O
files O
using O
FreeSurfer O
with O
a O
repeatedly O
subdivided O
octahedron O
as O
the O
spatial O
subsampling O
method O
, O
creating O
4,098 O
locations O
per O
hemisphere O
with O
a O
source O
space O
of O
4.9 O
mm O
. O

Source O
analysis O
was O
performed O
with O
MNE O
software O
using O
an O
anatomically O
constrained O
linear O
estimation O
inverse O
model O
known O
as O
dynamic O
statistical O
parametric O
mapping O
( O
dSPM O
) O
. O

The O
regularization O
parameter O
corresponded O
with O
a O
signal-to-noise O
ratio O
of O
3 O
. O

Source O
orientation O
had O
a O
loose O
constraint O
of O
0.2 O
. O

The O
forward O
solution O
was O
calculated O
with O
a O
single O
layer O
( O
inner O
skull O
) O
boundary O
element O
method O
. O

The O
dSPM O
inverse O
model O
identified O
where O
the O
estimated O
current O
at O
each O
cortical O
surface O
vertex O
differed O
significantly O
from O
baseline O
noise O
( O
empty O
room O
data O
) O
. O

Power O
spectral O
density O
( O
PSD O
) O
measures O
were O
computed O
from O
epochs O
using O
a O
multi-taper O
method O
with O
Discrete O
Prolate O
Spheroidal O
Sequence O
( O
DPSS O
) O
windows O
for O
each O
frequency O
band O
and O
region O
, O
using O
7 O
tapers O
at O
4 O
Hz O
and O
regions O
of O
interest O
based O
on O
the O
FreeSurfer O
DKT O
atlas O
. O

PSD O
represents O
the O
average O
spectral O
power O
derived O
from O
each O
voxel O
time O
series O
for O
each O
regional O
label O
. O

Global O
measures O
were O
data O
from O
all O
regional O
labels O
averaged O
. O

Normalized O
power O
was O
obtained O
by O
dividing O
the O
power O
within O
frequency O
band O
by O
the O
total O
1 O
– O
58 O
Hz O
power O
. O

Functional O
network O
connectivity O
was O
estimated O
using O
a O
debiased O
estimator O
of O
the O
squared O
weighted O
phase O
lag O
index O
( O
wPLI-debiased O
) O
. O

The O
FNC O
measure O
, O
wPLI-debiased O
, O
detects O
true O
changes O
in O
phase-synchronization O
, O
while O
reducing O
the O
influence O
of O
common O
noise O
sources O
, O
changes O
in O
phase O
of O
coherency O
, O
and O
avoids O
spuriously O
increases O
by O
volume-conduction O
. O

It O
estimates O
the O
extent O
of O
observed O
phase O
leads O
and O
lags O
by O
the O
magnitude O
of O
the O
imaginary O
component O
of O
the O
cross-spectrum O
. O

All O
data O
were O
exported O
to O
MATLAB O
( O
2018a O
, O
MathWorks O
) O
and O
run O
through O
custom O
scripts O
. O

Intraclass O
Correlation O
( O
ICC O
) O
ICC O
estimates O
and O
their O
95% O
confidence O
intervals O
were O
calculated O
in O
SPSS O
to O
assess O
the O
between O
and O
within-subject O
variability O
using O
a O
two-way O
mixed O
effects O
model O
with O
absolute O
agreement O
, O
single O
measurement O
criteria O
, O
also O
known O
as O
ICC O
( O
3,1 O
) O
model O
. O

ICCs O
were O
calculated O
for O
multiple O
rest O
iterations O
: O
for O
each O
visit O
( O
across O
one O
hour O
) O
, O
for O
each O
task O
( O
across O
one O
week O
) O
and O
for O
all O
runs O
. O

ICCs O
ranged O
from O
0 O
to O
1 O
( O
negative O
values O
scored O
as O
zero O
) O
with O
higher O
values O
indicating O
better O
reliability O
. O

Following O
the O
guidelines O
of O
we O
defined O
ICCs O
as O
: O
excellent O
reliability O
> O
0.75 O
, O
good O
reliability O
0.75 O
– O
0.60 O
, O
fair O
reliability O
0.59 O
– O
0.40 O
, O
and O
poor O
reliability O
< O
0.40 O
. O

Statistical O
Analysis O
All O
statistics O
were O
performed O
using O
SPSS O
( O
version O
25 O
for O
Macintosh O
) O
. O

Mixed O
Effect O
Repeated O
Measures-Analysis O
of O
Variance O
( O
RM-ANOVAs O
) O
had O
statistical O
thresholds O
set O
at O
p O
< O
0.05 O
. O

Greenhouse-Geisser O
corrections O
were O
made O
for O
sphericity O
violations O
. O

The O
between-subject O
factor O
was O
Group O
( O
HC O
, O
SZ O
) O
, O
within-subject O
factors O
included O
Hemisphere O
( O
Left O
, O
Right O
) O
, O
Resting-State O
( O
EO O
, O
EC O
) O
, O
and O
/ O
or O
Region O
[ O
Superior O
Parietal O
( O
SupPar O
) O
, O
Inferior O
Parietal O
( O
InfPar O
) O
, O
Precuneus O
] O
depending O
on O
measure O
explored O
. O

Significant O
interactions O
were O
followed-up O
with O
separate O
one-way O
ANOVAs O
, O
or O
t-tests O
on O
the O
factors O
of O
interest O
with O
familywise O
multiple O
comparisons O
correction O
using O
false O
discovery O
rate O
( O
FDR O
) O
correction O
with O
q O
= O
0.05 O
. O

Alcohol O
effects O
on O
globus O
pallidus O
connectivity O
: O
Role O
of O
impulsivity O
and O
binge O
drinking O
Despite O
the O
harm O
caused O
by O
binge O
drinking O
, O
the O
neural O
mechanisms O
leading O
to O
risky O
and O
disinhibited O
intoxication-related O
behaviors O
are O
not O
well O
understood O
. O

Evidence O
suggests O
that O
the O
globus O
pallidus O
externus O
( O
GPe O
) O
, O
a O
substructure O
within O
the O
basal O
ganglia O
, O
participates O
in O
inhibitory O
control O
processes O
, O
as O
examined O
in O
stop-signaling O
tasks O
. O

In O
fact O
, O
studies O
in O
rodents O
have O
revealed O
that O
alcohol O
can O
change O
GPe O
activity O
by O
decreasing O
neuronal O
firing O
rates O
, O
suggesting O
that O
the O
GPe O
may O
have O
a O
central O
role O
in O
explaining O
impulsive O
behaviors O
and O
failures O
of O
inhibition O
that O
occur O
during O
binge O
drinking O
. O

In O
this O
study O
, O
twenty-five O
healthy B-NoKnownDisorder
volunteers I-NoKnownDisorder
underwent O
intravenous O
alcohol O
infusion O
to O
achieve O
a O
blood O
alcohol O
level O
of O
0.08 O
g O
/ O
dl O
, O
which O
is O
equivalent O
to O
a O
binge O
drinking O
episode O
. O

A O
resting B-RestingStateImaging
state I-RestingStateImaging
functional I-RestingStateImaging
magnetic I-RestingStateImaging
resonance I-RestingStateImaging
imaging O
scan O
was O
collected O
prior O
to O
the O
infusion O
and O
at O
binge-level O
exposure O
. O

Functional O
connectivity O
analysis O
was O
used O
to O
investigate O
the O
association O
between O
alcohol-induced O
changes O
in O
GPe O
connectivity O
, O
drinking O
behaviors O
, O
and O
impulsivity O
traits O
. O

We O
found O
that O
individuals B-NondependentAlcoholAbuse
with I-NondependentAlcoholAbuse
greater I-NondependentAlcoholAbuse
number I-NondependentAlcoholAbuse
of I-NondependentAlcoholAbuse
drinks I-NondependentAlcoholAbuse
or I-NondependentAlcoholAbuse
heavy I-NondependentAlcoholAbuse
drinking I-NondependentAlcoholAbuse
days I-NondependentAlcoholAbuse
in O
the O
recent O
past O
had O
greater O
alcohol-induced O
deficits O
in O
GPe O
connectivity O
, O
particularly O
to O
the O
striatum O
. O

Our O
data O
also O
indicated O
an O
association O
between O
impulsivity O
and O
alcohol-induced O
deficits O
in O
GPe—frontal O
/ O
precentral O
connectivity O
. O

Moreover O
, O
alcohol O
induced O
changes O
in O
GPe-amygdala O
circuitry O
suggested O
greater O
vulnerabilities O
to O
stress-related O
drinking O
in O
some O
individuals O
. O

Taken O
together O
, O
these O
findings O
suggest O
that O
alcohol O
may O
interact O
with O
impulsive O
personality O
traits O
and O
drinking O
patterns O
to O
drive O
alterations O
in O
GPe O
circuitry O
associated O
with O
behavioral O
inhibition O
, O
possibly O
indicating O
a O
neural O
mechanism O
by O
which O
binge O
drinking O
could O
lead O
to O
impulsive O
behaviors O
. O

Methods B-StudyMethod
This O
study O
was O
approved O
by O
the O
NIH O
Addictions O
Institutional O
Review O
Board O
under O
12 O
- O
AA O
- O
0032 O
. O

All O
subjects O
provided O
written O
informed O
consent O
prior O
to O
their O
participation O
in O
the O
study O
. O

Participants O
Twenty-five O
healthy B-NoKnownDisorder
( I-NoKnownDisorder
13 I-NoKnownDisorder
males I-NoKnownDisorder
, I-NoKnownDisorder
12 I-NoKnownDisorder
females I-NoKnownDisorder
; I-NoKnownDisorder
mean I-NoKnownDisorder
age I-NoKnownDisorder
: I-NoKnownDisorder
28.85 I-NoKnownDisorder
years I-NoKnownDisorder
) I-NoKnownDisorder
, I-NoKnownDisorder
light I-NoKnownDisorder
social I-NoKnownDisorder
drinkers I-NoKnownDisorder
were O
recruited O
by O
local O
advertisement O
, O
according O
to O
approved O
National O
Institutes O
of O
Health O
Institutional O
Review O
Board O
procedures O
. O

The O
demographic O
data O
of O
participants O
is O
summarized O
in O
Table O
1 O
. O

After O
obtaining O
written O
informed O
consent O
, O
all O
participants O
underwent O
a O
comprehensive O
medical O
screen O
, O
including O
blood O
work O
, O
urinalysis O
, O
medical O
history O
, O
physical O
exam O
, O
and O
a O
Structured B-StructuredClinicalInterviewforDSMDisorders
Clinical I-StructuredClinicalInterviewforDSMDisorders
Interview I-StructuredClinicalInterviewforDSMDisorders
for I-StructuredClinicalInterviewforDSMDisorders
the I-StructuredClinicalInterviewforDSMDisorders
DSM I-StructuredClinicalInterviewforDSMDisorders
Axis-I I-StructuredClinicalInterviewforDSMDisorders
Disorders I-StructuredClinicalInterviewforDSMDisorders
( I-StructuredClinicalInterviewforDSMDisorders
SCID-IV I-StructuredClinicalInterviewforDSMDisorders
) I-StructuredClinicalInterviewforDSMDisorders
. I-StructuredClinicalInterviewforDSMDisorders

Criteria O
for O
inclusion O
in O
this O
study O
were O
: O
healthy O
, O
21 O
– O
45 O
years O
old O
, O
consumption B-DrinkingEpisode
of I-DrinkingEpisode
1 I-DrinkingEpisode
to I-DrinkingEpisode
10 I-DrinkingEpisode
drinks I-DrinkingEpisode
per I-DrinkingEpisode
week I-DrinkingEpisode
for I-DrinkingEpisode
females I-DrinkingEpisode
and I-DrinkingEpisode
1 I-DrinkingEpisode
to I-DrinkingEpisode
14 I-DrinkingEpisode
drinks I-DrinkingEpisode
per I-DrinkingEpisode
week I-DrinkingEpisode
for I-DrinkingEpisode
males I-DrinkingEpisode
. O

Subjects B-DrinkingSession
also I-DrinkingSession
had I-DrinkingSession
to I-DrinkingSession
have I-DrinkingSession
consumed I-DrinkingSession
at I-DrinkingSession
least I-DrinkingSession
two I-DrinkingSession
standard I-DrinkingSession
drinks I-DrinkingSession
of I-DrinkingSession
alcohol I-DrinkingSession
within I-DrinkingSession
one I-DrinkingSession
hour I-DrinkingSession
on I-DrinkingSession
at I-DrinkingSession
least I-DrinkingSession
one I-DrinkingSession
occasion I-DrinkingSession
in I-DrinkingSession
their I-DrinkingSession
lifetime I-DrinkingSession
. O

Criteria O
for O
exclusion O
included O
: O
abnormal O
blood O
or O
urine O
lab O
test O
values O
or O
findings O
from O
the O
medical O
screen O
, O
DSM-IV O
criteria O
for O
alcohol O
or O
other O
substance O
dependence O
( O
excluding O
nicotine O
) O
at O
any O
time O
; O
current O
or O
past O
major O
psychiatric O
disorder O
( O
DSM-IV O
Axis O
I O
) O
, O
head O
injury O
requiring O
hospitalization O
, O
Body O
Mass O
Index O
( O
BMI O
) O
value O
over O
30 O
, O
inability O
to O
stop O
taking O
any O
medication O
or O
drugs O
3 O
days O
prior O
to O
study O
days O
, O
and O
MRI O
contraindications O
. O

Also O
, O
non-drinkers O
were O
excluded O
from O
the O
study O
due O
to O
ethical O
concerns O
related O
to O
alcohol O
administration O
. O

Demographic O
, O
drinking O
, O
and O
impulsivity O
characteristics O
. O

Variable O
Count O
Total O
n O
25 O
Gender O
( O
Male O
/ O
Female O
) O
13 O
/ O
12 O
Smokers O
1 O
Mean O
SD O
Age O
28.85 O
7.40 O
Years O
Of O
Education O
15.88 O
1.88 O
BIS O
: O
Total O
54.76 O
9.62 O
Attentional O
Impulsiveness O
12.96 O
2.99 O
Motor O
Impulsiveness O
20.92 O
3.32 O
Nonplanning O
Impulsiveness O
19.72 O
4.21 O
UPPS-P O
: O
Positive O
Urgency O
1.36 O
0.31 O
Negative O
Urgency O
1.66 O
0.44 O
Premeditation O
1.78 O
0.42 O
Perseverence O
1.53 O
0.39 O
Sensation O
Seeking O
2.85 O
0.70 O
Delay O
Discounting O
Rate O
( O
K O
) O
0.02 O
0.06 O
TLFB—Drinks O
Per O
Thirty O
Days O
20.19 O
13.69 O
TLFB—Heavy O
Drinking O
Days O
19.08 O
10.96 O
Abbreviations O
as O
follow O
: O
BIS B-ImpulsivityScale
- I-ImpulsivityScale
Barratt I-ImpulsivityScale
Impulsiveness I-ImpulsivityScale
Scale I-ImpulsivityScale
; O
TLFB B-MentalHealthDiagnosisScale
- I-MentalHealthDiagnosisScale
Alcohol I-MentalHealthDiagnosisScale
Timeline I-MentalHealthDiagnosisScale
Followback I-MentalHealthDiagnosisScale
. O

Measures O
Alcohol O
drinking O
measures O
The O
amount O
of O
daily O
alcohol O
consumption O
over O
the O
last O
90 O
days O
was O
measured O
using O
the O
Alcohol B-AlcoholUseQuestionnaire
Timeline-Followback I-AlcoholUseQuestionnaire
( I-AlcoholUseQuestionnaire
TLFB I-AlcoholUseQuestionnaire
) I-AlcoholUseQuestionnaire
calendar—a O
drinking O
assessment O
method O
with O
good O
psychometric O
characteristics O
for O
estimating O
retrospective O
daily O
drinking O
patterns O
. O

The O
number O
of O
heavy O
drinking O
days O
in O
the O
last O
90 O
days O
was O
calculated O
from O
the O
TLFB B-AlcoholUseQuestionnaire
; O
a O
heavy O
drinking O
day O
is O
defined O
as O
4 O
or O
more O
drinks O
per O
day O
for O
women O
and O
5 O
or O
more O
drinks O
per O
day O
for O
men O
. O

We O
used O
this O
as O
a O
measure O
for O
binge B-DrinkingBinge
drinking I-DrinkingBinge
. O

Total O
drinks O
in O
the O
past O
30 O
days O
was O
also O
calculated O
from O
the O
TLFB B-AlcoholUseQuestionnaire
. O

Past B-DrinkingDay
30 I-DrinkingDay
- I-DrinkingDay
day I-DrinkingDay
drinking I-DrinkingDay
was I-DrinkingDay
used I-DrinkingDay
rather I-DrinkingDay
than I-DrinkingDay
90 I-DrinkingDay
- I-DrinkingDay
day I-DrinkingDay
drinking I-DrinkingDay
given I-DrinkingDay
that I-DrinkingDay
we I-DrinkingDay
were I-DrinkingDay
interested I-DrinkingDay
in I-DrinkingDay
recent I-DrinkingDay
drinking I-DrinkingDay
, I-DrinkingDay
and I-DrinkingDay
that I-DrinkingDay
recent I-DrinkingDay
reports I-DrinkingDay
of I-DrinkingDay
drinking I-DrinkingDay
may I-DrinkingDay
be I-DrinkingDay
more I-DrinkingDay
reliable I-DrinkingDay
. I-DrinkingDay

Impulsivity O
measures O
Impulsive O
behavioral O
traits O
were O
measured O
using O
the O
Barratt B-ImpulsivityScale
Impulsiveness I-ImpulsivityScale
Scale I-ImpulsivityScale
( I-ImpulsivityScale
BIS I-ImpulsivityScale
- I-ImpulsivityScale
11 I-ImpulsivityScale
) I-ImpulsivityScale
and O
the O
UPPS-P B-ImpulsivityScale
Impulsive I-ImpulsivityScale
Behavior I-ImpulsivityScale
Scale I-ImpulsivityScale
, O
two O
of O
the O
most O
widely-used O
self-report O
tools O
in O
the O
evaluation O
of O
trait O
impulsivity O
. O

The O
BIS B-ImpulsivityScale
- I-ImpulsivityScale
11 I-ImpulsivityScale
scale O
evaluates O
impulsive O
behavior O
in O
general O
, O
and O
the O
motor O
, O
attentional O
and O
non-planning O
sub-scales O
evaluate O
acting O
without O
thinking O
, O
inability O
to O
focus O
attention O
and O
lack O
of O
forethought O
, O
respectively O
. O

The O
UPPS-P B-ImpulsivityScale
measures O
personality O
traits O
conducive O
to O
impulsive O
behavior O
including O
Urgency O
( O
negative O
) O
— O
tendency O
to O
impulsively O
act O
under O
strong O
negative O
emotions O
, O
Premeditation O
( O
lack O
of O
) O
— O
tendency O
to O
act O
without O
thinking O
, O
Perseverance O
( O
lack O
of O
) O
to O
remain O
focused O
on O
a O
task O
, O
Sensation-seeking—tendency O
to O
seek O
out O
novel O
/ O
thrilling O
experiences O
, O
and O
Positive-urgency—tendency O
to O
impulsively O
act O
under O
strong O
positive O
emotions O
. O

We O
also O
evaluated O
choice O
impulsivity O
with O
the O
Delay B-ImpulsivityScale
Discounting I-ImpulsivityScale
Task I-ImpulsivityScale
( I-ImpulsivityScale
DDT I-ImpulsivityScale
) I-ImpulsivityScale
. O

The O
DDT B-ImpulsivityScale
measures O
impulsivity O
by O
presenting O
the O
subject O
with O
a O
series O
of O
hypothetical O
choices O
between O
receiving O
a O
smaller O
immediate O
monetary O
reward O
or O
a O
larger O
delayed O
reward O
. O

Subjects O
were O
presented O
as O
their O
immediate O
reward O
values O
between O
$100 O
and O
$0 O
dollars O
in O
increments O
of O
$10 O
, O
while O
the O
delayed O
reward O
was O
$100 O
. O

Delays O
were O
0 O
, O
7 O
, O
14 O
, O
20 O
, O
25 O
, O
or O
30 O
days O
. O

Subjects O
completed O
trials O
with O
all O
iterations O
of O
these O
parameters O
. O

The O
rate O
of O
discounting O
of O
the O
delayed O
outcome O
( O
k O
) O
was O
calculated O
and O
then O
a O
natural O
log-transformation O
was O
applied O
to O
correct O
for O
the O
non-normal O
distribution O
of O
k O
values O
. O

The O
resulting O
ln O
( O
k O
) O
is O
used O
to O
represent O
delay O
discounting O
, O
where O
higher O
ln O
( O
k O
) O
values O
mean O
greater O
preference O
for O
immediate O
rewards O
( O
see O
Table O
1 O
for O
descriptive O
statistics O
of O
drinking O
and O
impulsivity O
scores O
for O
the O
sample O
) O
. O

Experimental O
design O
and O
statistical O
analysis O
Overall O
timeline O
In O
this O
two-session O
study O
, O
healthy O
light O
drinkers O
received O
an O
IV O
alcohol O
infusion O
on O
two O
separate O
days O
. O

The O
first O
session O
was O
conducted O
outside O
the O
scanner O
to O
establish O
the O
alcohol O
infusion O
rate O
profile O
to O
achieve O
and O
maintain O
the O
target O
BrAC O
exposure O
, O
and O
to O
ensure O
tolerability O
. O

The O
alcohol O
infusion O
for O
the O
second O
session O
was O
conducted O
inside O
the O
scanner O
at O
least O
three O
days O
after O
the O
first O
session O
( O
Fig O
1 O
) O
. O

Participants O
were O
asked O
to O
fast O
the O
night O
before O
each O
session O
. O

At O
the O
start O
of O
each O
visit O
, O
breath O
alcohol O
levels O
, O
urine O
pregnancy O
tests O
( O
if O
applicable O
) O
and O
urine O
drug O
screens O
were O
collected O
. O

In O
addition O
, O
we O
conducted O
a O
brief O
history O
interview O
about O
recent O
alcohol O
, O
medication O
, O
and O
nicotine O
use O
, O
changes O
in O
physical O
health O
, O
and O
menstruation O
( O
if O
applicable O
) O
. O

Timeline O
of O
intravenous O
alcohol O
infusion O
study O
. O

The O
timeline O
depiction O
of O
the O
two-session O
intravenous O
alcohol O
infusion O
study O
; O
sessions O
were O
separated O
at O
least O
three O
days O
from O
each O
other O
. O

The O
session O
2 O
timeline O
indicates O
timepoints O
of O
resting O
state O
and O
BAC O
measurement O
alongside O
IV O
infusion O
; O
the O
first O
resting O
state O
scan O
occurred O
before O
the O
IV O
infusion O
at O
blood O
alcohol O
level O
of O
0.0 O
g O
/ O
dl O
and O
the O
second O
one O
was O
collected O
when O
the O
blood O
alcohol O
level O
reached O
the O
binge O
levels O
( O
0.08 O
g O
/ O
dl O
) O
. O

Alcohol O
infusion O
to O
binge O
level O
exposure O
We O
performed O
the O
alcohol O
infusion O
procedure O
following O
previously O
published O
methods O
( O
fMRI B-FunctionalMagneticResonanceImaging
and O
PET B-PositronEmissionTomography
) O
. O

In O
both O
sessions O
, O
participants O
received O
an O
intravenous O
( O
IV O
) O
infusion O
of O
6% O
v O
/ O
v O
ethanol O
solution O
in O
saline O
to O
achieve O
a O
target O
breath O
alcohol O
concentration O
( O
BrAC O
) O
of O
0.08 O
± O
0.005 O
g O
/ O
dl O
at O
15 O
min O
after O
the O
start O
of O
the O
infusion O
, O
and O
to O
maintain O
( O
or O
clamp O
) O
the O
target O
BrAC O
level O
for O
30 O
min O
( O
Fig O
1 O
) O
. O

The O
infusion-rate O
profile O
was O
computed O
for O
each O
subject O
using O
a O
physiologically-based O
pharmacokinetic O
( O
PBPK O
) O
model-based O
algorithm O
, O
with O
individualized O
estimates O
of O
the O
model O
parameters O
estimated O
from O
the O
subject O
’ O
s O
height O
, O
weight O
, O
age O
and O
sex O
. O

During O
the O
first O
session O
conducted O
outside O
the O
scanner O
, O
serial O
BrACs O
were O
measured O
at O
frequent O
intervals O
( O
5 O
– O
15 O
minutes O
) O
using O
the O
Alcotest O
7410 O
+ O
handheld O
breathalyzer O
( O
Drager O
Safety O
Inc O
. O
, O
CO O
) O
, O
to O
ensure O
that O
each O
BrAC O
was O
within O
0.005 O
g O
/ O
dl O
of O
the O
target O
, O
and O
to O
enable O
minor O
adjustments O
to O
the O
infusion O
rates O
to O
overcome O
errors O
in O
parameter O
estimation O
and O
experimental O
variability O
. O

The O
adjusted O
infusion O
rate O
profile O
from O
the O
first O
session O
was O
used O
in O
the O
imaging O
session O
to O
replicate O
the O
target O
BrAC O
profile O
for O
each O
subject O
. O

This O
approach O
has O
been O
used O
to O
successfully O
achieve O
and O
maintain O
target O
BrACs O
, O
as O
verified O
by O
blood O
alcohol O
concentrations O
measured O
in O
samples O
drawn O
during O
the O
scan O
in O
other O
neuroimaging O
studies O
. O

After O
the O
end O
of O
the O
infusion O
, O
subjects O
were O
provided O
a O
meal O
, O
and O
BrAC O
was O
tracked O
until O
it O
dropped O
to O
0.02 O
g O
/ O
dL O
or O
below O
, O
at O
which O
time O
subjects O
were O
taken O
home O
by O
a O
designated O
driver O
or O
taxi O
. O

Neuroimaging O
acquisition O
and O
preprocessing O
During O
session O
2 O
, O
after O
the O
IV O
catheters O
were O
placed O
for O
alcohol O
infusion O
, O
participants O
were O
placed O
in O
a O
3T O
SIEMENS O
Skyra O
MR O
scanner O
at O
the O
NMR O
Research O
Center O
at O
the O
NIH O
. O

Before O
starting O
the O
IV O
infusion O
of O
alcohol O
, O
a O
5 O
- O
min O
closed B-RestingStateImaging
eyes I-RestingStateImaging
resting-state I-RestingStateImaging
fMRI I-RestingStateImaging
scan O
was O
acquired O
with O
an O
echo-planar O
imaging O
sequence O
( O
36 O
axial O
slices O
, O
3.8 O
mm O
thickness O
, O
64 O
× O
64 O
matrix O
and O
repetition O
time O
of O
2000 O
ms O
, O
echo O
time O
30 O
, O
flip O
angle O
90 O
) O
. O

After O
collecting O
this O
baseline O
resting-state B-RestingStateImaging
fMRI I-RestingStateImaging
scan O
, O
the O
alcohol O
infusion O
started O
and O
once O
the O
target O
BAC O
was O
achieved O
, O
a O
10 O
- O
minute O
waiting O
period O
was O
allowed O
to O
ensure O
the O
BAC O
was O
stable O
at O
the O
0.08 O
g O
/ O
dl O
level O
. O

During O
the O
waiting O
period O
, O
whole-brain B-StructuralImaging
structural I-StructuralImaging
and O
diffusion-weighted B-DiffusionWeightedImaging
images I-DiffusionWeightedImaging
of O
the O
brain O
were O
collected O
. O

Then O
, O
a O
second O
eyes-closed B-RestingStateImaging
resting-state I-RestingStateImaging
fMRI I-RestingStateImaging
scan O
was O
collected O
while O
the O
target O
BAC O
( O
0.08 O
g O
/ O
dl O
) O
was O
maintained O
. O

Following O
the O
MRI B-RestingStateImaging
session O
, O
the O
Drug B-Questionnaire
Effects I-Questionnaire
Questionnaire I-Questionnaire
was O
used O
to O
evaluate O
and O
quantify O
subjective O
effects O
of O
alcohol O
( O
DEQ O
) O
. O

CONN O
ver O
.17f O
( O
http O
: O
/ O
/ O
www.conn-toolbox.org O
) O
, O
a O
MATLAB O
/ O
SPM-based O
( O
www.fil.ion.ucl.ac.uk O
/ O
spm O
/ O
) O
software O
, O
was O
used O
to O
conduct O
spatial O
/ O
temporal O
preprocessing O
and O
analyses O
. O

Spatial O
preprocessing O
included O
slice-timing O
correction O
, O
realignment O
, O
co-registration O
, O
normalization O
, O
and O
spatial O
smoothing O
( O
8 O
mm O
) O
. O

Using O
the O
default O
settings O
in O
CONN O
, O
images O
were O
resliced O
into O
isotropic O
2mm O
voxels O
. O

Anatomical O
volumes O
were O
segmented O
into O
grey O
matter O
, O
white O
matter O
, O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
areas O
and O
the O
resulting O
masks O
were O
eroded O
to O
minimize O
partial O
volume O
effects O
. O

At O
the O
individual O
level O
, O
the O
temporal O
timeseries O
of O
the O
participant-specific O
six O
rotation-translation O
motion O
parameters O
and O
the O
timeseries O
from O
within O
the O
white O
matter O
/ O
CSF O
masks O
were O
used O
as O
temporal O
covariates O
, O
and O
removed O
from O
the O
blood O
oxygen O
level-dependent O
( O
BOLD O
) O
functional O
data O
using O
linear O
regression O
. O

The O
resulting O
residual O
BOLD O
timeseries O
were O
band-pass O
filtered O
( O
0.008Hz O
< O
f O
< O
0.15Hz O
) O
. O

Neuroimaging O
analysis O
To O
our O
knowledge O
there O
is O
no O
reported O
sub-division O
of O
human O
GPe O
with O
concrete O
landmark O
definition O
and O
/ O
or O
Talairach O
coordinate O
demarcation O
. O

Therefore O
, O
for O
these O
analyses O
, O
we O
used O
right O
and O
left O
GPe O
masks O
obtained O
from O
the O
Lead-DBS O
toolbox O
( O
http O
: O
/ O
/ O
www.lead-dbs.org O
/ O
) O
. O

These O
anatomical O
masks O
were O
generated O
using O
manual O
tracing O
of O
several O
structural O
MRIs O
and O
subsequent O
co-registration O
with O
histological O
studies O
, O
and O
have O
a O
combined O
volume O
of O
approximately O
929 O
mm3 O
. O

Seed-based O
correlations O
were O
calculated O
as O
Fisher-transformed O
bivariate O
correlation O
coefficients O
between O
the O
BOLD O
activity O
timeseries O
in O
the O
seed O
ROI O
and O
each O
other O
individual O
voxel O
BOLD O
. O

CSF O
, O
grey O
matter O
, O
white O
matter O
signals O
and O
motion O
were O
included O
as O
covariates O
for O
this O
model O
at O
the O
single O
subject O
level O
. O

These O
correlations O
were O
calculated O
separately O
for O
the O
pre-infusion O
and O
post-infusion O
scans O
and O
for O
right O
and O
left O
GPe O
seeds O
. O

For O
each O
of O
the O
pre O
- O
and O
post-infusion O
analyses O
, O
150 O
time O
points O
( O
across O
300 O
seconds O
) O
were O
used O
. O

To O
examine O
group O
level O
effects O
, O
the O
resulting O
single-subject O
connectivity O
maps O
were O
used O
as O
input O
for O
second O
level O
analyses O
in O
a O
general O
linear O
model O
. O

We O
modeled O
the O
within-subject O
effect O
of O
timepoint O
( O
i.e O
. O
, O
post O
- O
versus O
pre-alcohol O
infusion O
; O
see O
S1 O
File O
, O
S1 O
Fig O
and O
S1 O
Table O
for O
report O
of O
the O
main O
effects O
of O
alcohol O
administration O
) O
and O
between-subject O
effects O
of O
impulsivity O
( O
BIS O
- O
11 O
, O
UPPS-P O
, O
and O
DDT O
) O
and O
recent O
drinking O
behaviors O
( O
number O
of O
drinks O
in O
the O
last O
30 O
days O
, O
number O
of O
heavy O
drinking O
days O
) O
. O

S1 O
Table O
indicates O
clusters O
identified O
as O
showing O
significant O
changes O
from O
pre O
to O
post O
alcohol O
infusion O
, O
as O
well O
as O
associated O
statistics O
. O

For O
the O
seed-to-voxel O
analysis O
, O
reported O
clusters O
survived O
a O
height O
threshold O
of O
uncorrected O
p O
< O
0.001 O
with O
a O
cluster O
level O
extent O
threshold O
of O
FDR-corrected O
p O
< O
0.05 O
. O

In O
Figs O
3 O
– O
5 O
, O
these O
clusters O
are O
shown O
overlaid O
on O
structural O
brain O
cutaways O
. O

Corresponding O
line O
plots O
are O
only O
for O
visual O
interpretation O
of O
these O
effects O
. O

We O
also O
examined O
sex O
effects O
on O
alcohol-related O
changes O
in O
GPe O
connectivity O
at O
the O
whole O
brain O
level O
; O
there O
were O
no O
significant O
differences O
between O
males O
and O
females O
. O

In O
order O
to O
test O
our O
hypothesis O
that O
the O
interaction O
between O
recent O
drinking O
behaviors O
and O
impulsivity O
would O
contribute O
to O
alcohol-induced O
changes O
in O
GPe O
functional O
connectivity O
, O
we O
extracted O
ROI-to-voxel O
correlation O
values O
between O
the O
seeds O
and O
significant O
clusters O
and O
used O
those O
values O
to O
conduct O
multiple O
regression O
analysis O
in O
R O
/ O
RStudio O
( O
version O
3.4.2 O
/ O
1.1.383 O
) O
. O

We O
modeled O
drinking O
history O
, O
impulsivity O
, O
and O
the O
interaction O
between O
the O
two O
as O
independent O
variables O
on O
the O
dependent O
variable O
of O
change O
in O
GPe O
connectivity O
. O

We O
conducted O
these O
analyses O
only O
for O
significant O
clusters O
identified O
in O
the O
seed-to-voxel O
analysis O
, O
and O
only O
for O
the O
significant O
drinking O
and O
impulsivity O
measures O
. O

For O
the O
drinking O
measures O
identified O
in O
that O
seed-to-voxel O
analysis O
, O
models O
( O
for O
the O
specific O
significant O
cluster O
only O
) O
included O
the O
significant O
drinking O
variable O
as O
well O
as O
one O
of O
the O
two O
significant O
impulsivity O
variables O
; O
thus O
, O
2 O
regressions O
per O
cluster O
were O
run O
. O

Similarly O
, O
for O
significant O
impulsivity O
measures O
, O
2 O
regressions O
per O
cluster O
were O
run O
( O
as O
there O
are O
two O
drinking O
variables O
) O
. O

This O
resulted O
in O
a O
total O
of O
20 O
tests O
. O

We O
then O
adjusted O
the O
omnibus O
test O
statistics O
to O
correct O
for O
multiple O
comparisons O
using O
FDR O
of O
< O
0.05 O
. O

Of O
those O
regressions O
, O
only O
those O
with O
significant O
interaction O
effects O
are O
reported O
. O

Disturbances O
across O
whole O
brain O
networks O
during O
reward O
anticipation O
in O
an O
abstinent O
addiction O
population O
Graphical O
abstract O
Network O
based O
statistics O
( O
NBS O
) O
analyses O
detected O
a O
graph O
sub-network O
comprising O
153 O
edges O
between O
59 O
nodes O
of O
the O
connectome O
where O
the O
ADD B-SubstanceDisorder
group O
demonstrated O
significantly O
less O
connectivity O
compared O
with O
the O
CON B-SubstanceDisorder
group O
. O

These O
differences O
in O
connectivity O
were O
mostly O
intra-hemispheric O
( O
55% O
) O
, O
the O
majority O
( O
38% O
) O
being O
in O
the O
right O
hemisphere O
. O

The O
anatomical O
distribution O
of O
these O
connectivity O
differences O
between O
the O
two O
groups O
involved O
frontal O
( O
insula O
, O
inferior O
frontal O
gyrus O
, O
orbitofrontal O
cortex O
) O
, O
limbic-associated O
( O
anterior O
cingulate O
gyrus O
, O
thalamus O
) O
, O
and O
striatal O
( O
accumbens O
, O
caudate O
, O
pallidum O
) O
regions O
. O

The O
connectivity O
differences O
reported O
in O
this O
ADD B-SubstanceDisorder
sample O
indicate O
alterations O
between O
cognitive O
, O
striatal O
and O
limbic-associated O
regions O
during O
reward O
anticipation O
that O
persist O
into O
extended O
abstinence O
. O

Highlights O
Analytical O
methods O
can O
capture O
key O
features O
of O
whole O
brain O
networks O
in O
addiction O
. O

We O
compared O
reward O
network O
connectivity O
in O
addiction B-SubstanceDisorder
( O
ADD O
) O
and O
control B-NoKnownDisorder
( O
CON O
) O
groups O
. O

The O
ADD B-SubstanceDisorder
group O
showed O
disruptions O
in O
global O
network O
connectivity O
. O

Global O
network O
measures O
may O
be O
more O
sensitive O
than O
traditional O
voxel-wise O
analyses O
. O

The O
prevalent O
spatial O
distribution O
of O
abnormalities O
reported O
in O
cognitive O
fMRI O
studies O
in O
addiction O
suggests O
there O
are O
extensive O
disruptions O
across O
whole O
brain O
networks O
. O

Studies O
using O
resting O
state O
have O
reported O
disruptions O
in O
network O
connectivity O
in O
addiction O
, O
but O
these O
studies O
have O
not O
revealed O
characteristics O
of O
network O
functioning O
during O
critical O
psychological O
processes O
that O
are O
disrupted O
in O
addiction O
populations O
. O

Analytic O
methods O
that O
can O
capture O
key O
features O
of O
whole O
brain O
networks O
during O
psychological O
processes O
may O
be O
more O
sensitive O
in O
revealing O
additional O
and O
widespread O
neural O
disturbances O
in O
addiction O
, O
that O
are O
the O
provisions O
for O
relapse O
risk O
, O
and O
targets O
for O
medication O
development O
. O

The O
current O
study O
compared O
a O
substance O
addiction B-SubstanceDisorder
( O
ADD O
; O
n O
  O
= O
  O
83 O
) O
group O
in O
extended O
abstinence O
with O
a O
control B-NoKnownDisorder
( O
CON O
; O
n O
  O
= O
  O
68 O
) O
group O
on O
functional B-FunctionalMagneticResonanceImaging
MRI I-FunctionalMagneticResonanceImaging
( O
voxel-wise O
activation O
) O
and O
global O
network O
( O
connectivity O
) O
measures O
related O
to O
reward O
anticipation O
on O
a O
monetary O
incentive O
delay O
task O
. O

In O
the O
absence O
of O
group O
differences O
on O
MID O
performance O
, O
the O
ADD B-SubstanceDisorder
group O
showed O
reduced O
activation O
predominantly O
across O
temporal O
and O
visual O
regions O
, O
but O
not O
across O
the O
striatum O
. O

The O
ADD B-SubstanceDisorder
group O
also O
showed O
disruptions O
in O
global O
network O
connectivity O
( O
lower O
clustering O
coefficient O
and O
higher O
characteristic O
path O
length O
) O
, O
and O
significantly O
less O
connectivity O
across O
a O
sub-network O
comprising O
frontal O
, O
temporal O
, O
limbic O
and O
striatal O
nodes O
. O

These O
results O
show O
that O
an O
addiction B-SubstanceDisorder
group O
in O
extended O
abstinence O
exhibit O
localised O
disruptions O
in O
brain O
activation O
, O
but O
more O
extensive O
disturbances O
in O
functional O
connectivity O
across O
whole O
brain O
networks O
. O

We O
propose O
that O
measures O
of O
global O
network O
functioning O
may O
be O
more O
sensitive O
in O
highlighting O
latent O
and O
more O
widespread O
neural O
disruptions O
during O
critical O
psychological O
processes O
in O
addiction O
and O
other O
psychiatric O
disorders O
. O

Material O
and O
methods B-StudyMethod
Participants O
Sixty-eight O
control B-NoKnownDisorder
( O
CON O
: O
mean O
age O
39.79 O
  O
± O
  O
1.22 O
; O
18 O
females O
, O
50 O
males O
) O
and O
83 O
addiction B-SubstanceDisorder
( O
ADD O
: O
mean O
age O
40.05 O
  O
± O
  O
0.92 O
; O
16 O
females O
, O
67 O
males O
) O
participants O
completed O
the O
current O
study O
. O

The O
current O
dataset O
was O
collected O
as O
part O
of O
a O
multi-centre O
study O
involving O
three O
study O
sites O
in O
the O
United O
Kingdom O
( O
Imperial O
College O
London O
, O
University O
of O
Cambridge O
and O
University O
of O
Manchester O
– O
ICCAM O
) O
. O

For O
a O
more O
detailed O
description O
of O
the O
ICCAM O
Platform O
, O
see O
) O
and O
. O

Inclusion O
criteria O
were O
individuals O
who O
met O
DSM-IV O
measures O
for O
current O
or O
prior O
substance O
dependence O
( O
e.g O
. O
, O
alcohol O
, O
cocaine O
, O
opiates O
) O
. O

The O
ADD B-SubstanceDisorder
group O
consisted O
of O
29 O
( O
35% O
) O
pure O
alcohol-dependent O
, O
42 O
( O
50% O
) O
poly O
substance-dependent O
( O
e.g O
. O
, O
alcohol O
and O
cocaine O
, O
cocaine O
and O
opiate O
) O
and O
12 O
( O
15% O
) O
mono O
substance-dependent O
( O
e.g O
. O
, O
cocaine O
, O
opiates O
) O
volunteers O
. O

While O
addiction O
studies O
typically O
recruit O
volunteers O
in O
early O
abstinence O
, O
there O
was O
no O
upper O
limit O
in O
the O
current O
study O
. O

The O
mean O
abstinence O
length O
from O
alcohol O
in O
the O
current O
sample O
was O
15.00 O
  O
± O
  O
3.50 O
  O
months O
, O
while O
for O
cocaine O
and O
opiates O
it O
was O
27.99 O
  O
± O
  O
3.72 O
and O
39.04 O
  O
± O
  O
7.75 O
  O
months O
, O
respectively O
. O

Therefore O
, O
the O
current O
ADD O
group O
was O
made O
of O
a O
heterogenous O
sample O
with O
former O
substance-dependencies O
, O
and O
with O
variable O
levels O
of O
substance O
abstinence O
at O
the O
time O
of O
testing O
. O

This O
meant O
that O
there O
was O
no O
substance O
dependence O
measure O
that O
was O
shared O
by O
all O
members O
of O
the O
ADD B-SubstanceDisorder
group O
. O

The O
CON B-NoKnownDisorder
group O
had O
no O
previous O
history O
of O
substance O
abuse O
, O
as O
assessed O
using O
the O
Alcohol B-MentalHealthDiagnosisScale
, I-MentalHealthDiagnosisScale
Smoking I-MentalHealthDiagnosisScale
and I-MentalHealthDiagnosisScale
Substance I-MentalHealthDiagnosisScale
Involvement I-MentalHealthDiagnosisScale
Screening I-MentalHealthDiagnosisScale
Test I-MentalHealthDiagnosisScale
( I-MentalHealthDiagnosisScale
ASSIST I-MentalHealthDiagnosisScale
) I-MentalHealthDiagnosisScale
and O
timeline O
follow-back O
. O

All O
participants O
were O
required O
to O
provide O
a O
negative O
breath O
alcohol O
test O
and O
a O
negative O
urine O
sample O
for O
various O
drugs O
of O
abuse O
on O
the O
day O
of O
testing O
( O
screening O
for O
the O
presence O
of O
amphetamines O
, O
benzodiazepines O
, O
cannabinoids O
, O
cocaine O
and O
opiates O
) O
. O

The O
Mini-International B-MentalHealthDiagnosisScale
Neuropsychiatric I-MentalHealthDiagnosisScale
Interview I-MentalHealthDiagnosisScale
( I-MentalHealthDiagnosisScale
MINI I-MentalHealthDiagnosisScale
) I-MentalHealthDiagnosisScale
was O
administered O
to O
all O
participants O
by O
a O
trained O
psychiatrist O
to O
screen O
for O
the O
presence O
of O
Axis O
I O
psychiatric O
disorders O
that O
were O
part O
of O
the O
study O
exclusion O
criteria O
. O

Exclusion O
criteria O
included O
1 O
) O
current O
use O
of O
regular O
prescription O
or O
non-prescription O
medication O
that O
could O
not O
be O
stopped O
; O
2 O
) O
current O
primary O
axis O
I O
diagnosis O
, O
past O
history O
of O
psychosis O
( O
unless O
drug-induced O
) O
; O
3 O
) O
current O
or O
past O
history O
of O
enduring O
severe O
mental O
illness O
( O
e.g O
. O
, O
schizophrenia O
, O
bipolar O
affective O
disorder O
) O
; O
4 O
) O
other O
current O
or O
past O
psychiatric O
history O
that O
, O
in O
the O
opinion O
of O
a O
psychiatrist O
, O
contraindicated O
participation O
; O
5 O
) O
history O
or O
presence O
of O
a O
significant O
neurological O
diagnosis O
that O
may O
have O
influenced O
the O
outcome O
or O
analysis O
of O
the O
results O
; O
6 O
) O
claustrophobia O
or O
unable O
to O
lie O
still O
in O
the O
MRI O
scanner O
for O
up O
to O
90 O
  O
min O
and O
7 O
) O
presence O
of O
a O
cardiac O
pacemaker O
, O
other O
electronic O
device O
or O
other O
MRI O
contraindication O
, O
including O
pregnancy O
, O
as O
assessed O
by O
a O
standard O
pre-MRI O
questionnaire O
. O

Secondary O
or O
lifetime O
history O
of O
depression O
or O
anxiety O
was O
permitted O
in O
both O
the O
ADD B-Abstinent
and O
CON B-NoKnownDisorder
groups O
since O
these O
are O
very O
common O
psychiatric O
disorders O
. O

All O
participants O
provided O
written O
informed O
consent O
. O

The O
study O
was O
conducted O
in O
accordance O
with O
the O
Declaration O
of O
Helsinki O
. O

Ethical O
approval O
was O
obtained O
from O
West O
London O
and O
Gene O
Therapy O
Advisory O
Committee O
National O
Research O
Ethics O
Service O
Committee O
( O
11 O
/ O
H0707 O
/ O
9 O
) O
and O
relevant O
research O
governance O
and O
Participant O
Identification O
Centre O
( O
PIC O
) O
approvals O
obtained O
. O

Monetary O
incentive O
delay O
task O
( O
MID O
) O
We O
used O
a O
“ O
monetary O
incentive O
delay O
task O
” O
( O
MID O
) O
, O
which O
was O
based O
on O
that O
originally O
employed O
by O
Knutson O
, O
and O
which O
we O
have O
used O
to O
already O
publish O
data O
from O
the O
ICCAM O
platform O
. O

At O
the O
beginning O
of O
each O
trial O
, O
participants O
viewed O
one O
of O
three O
symbols O
( O
a O
cue O
) O
that O
indicated O
the O
potential O
to O
gain O
fifty O
pence O
( O
square O
containing O
an O
ascending O
arrow O
) O
, O
lose O
fifty O
pence O
( O
square O
containing O
a O
descending O
arrow O
) O
or O
experience O
no O
financial O
outcome O
( O
square O
containing O
a O
horizontal O
line O
- O
here O
referred O
to O
as O
a O
neutral O
trial O
) O
. O

Each O
cue O
was O
presented O
for O
one O
second O
, O
with O
a O
variable O
duration O
( O
2 O
– O
4 O
  O
s O
) O
for O
the O
subsequent O
anticipation O
period O
. O

Following O
the O
anticipation O
period O
, O
participants O
made O
a O
button O
press O
response O
upon O
the O
presentation O
of O
a O
visual O
target O
( O
star O
located O
within O
a O
circle O
) O
. O

Following O
their O
response O
to O
the O
visual O
target O
, O
participants O
received O
feedback O
( O
1.5 O
  O
s O
) O
as O
to O
whether O
they O
were O
successful O
( O
“ O
Hit O
” O
) O
or O
unsuccessful O
( O
“ O
Miss O
” O
) O
on O
that O
trial O
and O
saw O
a O
running O
total O
of O
their O
winnings O
up O
to O
that O
point O
in O
the O
task O
. O

Following O
feedback O
, O
there O
was O
an O
end O
fixation O
period O
( O
3 O
– O
5 O
  O
s O
) O
before O
the O
commencement O
of O
the O
next O
trial O
. O

Because O
the O
primary O
objective O
of O
ICCAM O
was O
to O
examine O
the O
neural O
correlates O
of O
reward O
anticipation O
, O
we O
chose O
to O
use O
a O
smaller O
number O
of O
loss O
trials O
in O
order O
to O
amplify O
the O
incentive O
salience O
of O
the O
gain O
trials O
during O
the O
task O
. O

Consequently O
, O
there O
was O
a O
total O
of O
18 O
gain O
, O
6 O
lose O
and O
18 O
neutral O
trials O
on O
each O
run O
of O
the O
task O
. O

The O
MID O
task O
was O
tailored O
to O
adapt O
to O
the O
visual O
target O
reaction O
time O
of O
each O
participant O
by O
using O
a O
staircase O
algorithm O
, O
such O
that O
the O
presentation O
of O
the O
visual O
target O
became O
shorter O
as O
performance O
improved O
during O
the O
experiment O
. O

This O
enabled O
us O
to O
set O
a O
limit O
on O
the O
success O
rate O
of O
each O
participant O
( O
∼ O
66% O
) O
, O
which O
additionally O
served O
to O
incentivize O
participants O
to O
engage O
in O
the O
task O
. O

Participants O
were O
instructed O
to O
maximize O
their O
winnings O
and O
were O
told O
they O
would O
receive O
them O
at O
the O
end O
of O
the O
study O
. O

Dependent O
measures O
were O
accuracy O
( O
percentage O
) O
and O
mean O
reaction O
time O
( O
milliseconds O
) O
to O
the O
visual O
target O
on O
each O
of O
the O
gain O
, O
lose O
and O
neutral O
trials O
, O
and O
the O
amount O
won O
( O
£ O
) O
on O
the O
task O
. O

Participants O
completed O
two O
runs O
of O
the O
task O
( O
432 O
  O
s O
each O
) O
during O
scanning O
. O

The O
task O
was O
programmed O
using O
E-Prime O
version O
2.0 O
( O
Psychology O
Software O
Tools O
, O
Pittsburgh O
, O
USA O
) O
. O

Statistics O
Group O
demographics O
were O
compared O
using O
simple O
independent O
samples O
t-test O
analyses O
. O

For O
analyses O
conducted O
on O
MID O
performance O
, O
two O
( O
Group O
: O
CON O
vs O
. O

ADD O
) O
by O
two O
( O
Condition O
: O
Gain O
vs O
. O

Neutral O
) O
analyses O
of O
variance O
were O
conducted O
. O

The O
CON B-NoKnownDisorder
and O
ADD B-SubstanceDisorder
groups O
were O
also O
compared O
on O
the O
lose O
accuracy O
and O
lose O
reaction O
time O
performance O
measures O
, O
as O
well O
as O
the O
amount O
of O
money O
won O
( O
£ O
) O
, O
using O
analyses O
of O
variance O
. O

These O
analyses O
were O
conducted O
controlling O
for O
study O
site O
. O

For O
the O
graph O
measures O
( O
see O
below O
) O
we O
conducted O
two O
( O
Group O
: O
CON O
vs O
. O

ADD O
) O
by O
five O
( O
1 O
  O
⩽ O
  O
K O
  O
⩽ O
  O
5 O
) O
analyses O
of O
variance O
, O
while O
also O
controlling O
for O
study O
site O
. O

All O
these O
analyses O
were O
conducted O
using O
permutation O
testing O
( O
5000 O
iterations O
) O
in O
the O
R O
statistical O
software O
package O
( O
www.R-project.org O
) O
. O

Functional B-FunctionalMagneticResonanceImaging
MRI I-FunctionalMagneticResonanceImaging
( I-FunctionalMagneticResonanceImaging
fMRI I-FunctionalMagneticResonanceImaging
) I-FunctionalMagneticResonanceImaging
Data O
acquisition O
The O
ICCAM O
platform O
was O
designed O
to O
allow O
the O
rapid O
testing O
across O
sites O
of O
multiple O
compounds O
relevant O
to O
addiction O
treatment O
. O

Imaging O
at O
multiple O
sites O
in O
parallel O
on O
the O
ICCAM O
platform O
accelerated O
study O
completion O
, O
through O
the O
sharing O
of O
expertise O
, O
infrastructure O
and O
capacity O
. O
  O

For O
a O
more O
comprehensive O
description O
of O
data O
acquisition O
across O
the O
three O
sites O
on O
ICCAM O
, O
please O
see O
McGonigle O
et O
al O
. O

Briefly O
, O
all O
centres O
operated O
MRI O
machines O
with O
a O
main O
magnetic O
field O
of O
3 O
  O
T O
( O
T O
) O
. O

Centres O
in O
London O
and O
Cambridge O
operated O
nominally O
identical O
3 O
  O
T O
Siemens O
Tim O
Trio O
systems O
running O
the O
syngo O
MR O
B17 O
software O
with O
a O
Siemens O
32 O
channel O
receive-only O
phased-array O
head O
coil O
. O

The O
Manchester O
centre O
operated O
a O
3 O
  O
T O
Philips O
Achieva O
running O
version O
2.6.3.5 O
software O
and O
an O
8 O
element O
SENSE O
head O
coil O
. O

For O
anatomical O
images O
, O
160 O
high-resolution O
T1 B-T1WeightedImaging
- I-T1WeightedImaging
weighted I-T1WeightedImaging
anatomic O
MPRAGE O
axial O
images O
( O
FOV O
256 O
  O
mm O
, O
thickness O
1.0 O
  O
mm O
, O
voxel O
size O
1.0 O
  O
× O
  O
1.0 O
  O
× O
  O
1.0 O
) O
were O
acquired O
( O
total O
duration O
303 O
  O
s O
) O
. O

Functional B-FunctionalMagneticResonanceImaging
data I-FunctionalMagneticResonanceImaging
were O
acquired O
using O
a O
T2 B-T2WeightedImaging
* I-T2WeightedImaging
weighted I-T2WeightedImaging
echo-planar O
imaging O
sequence O
collecting O
36 O
non-contiguous O
( O
0% O
gap O
) O
3.0 O
  O
mm O
axial O
slices O
covering O
the O
entire O
brain O
( O
TE O
  O
= O
  O
31 O
  O
ms O
, O
TR O
  O
= O
  O
2000 O
  O
ms O
, O
FOV O
225 O
  O
mm O
, O
64 O
  O
× O
  O
64 O
  O
mm O
matrix O
size O
in O
Fourier O
space O
) O
. O

Each B-TaskParadigmImaging
run I-TaskParadigmImaging
of I-TaskParadigmImaging
the I-TaskParadigmImaging
MID I-TaskParadigmImaging
task I-TaskParadigmImaging
produced I-TaskParadigmImaging
a I-TaskParadigmImaging
total I-TaskParadigmImaging
of I-TaskParadigmImaging
216 I-TaskParadigmImaging
volumes I-TaskParadigmImaging
of I-TaskParadigmImaging
functional B-FunctionalMagneticResonanceImaging
MRI I-FunctionalMagneticResonanceImaging
data I-FunctionalMagneticResonanceImaging
. O
fMRI O
Data O
analyses O
Data O
pre-processing O
and O
statistical O
analysis O
were O
conducted O
using O
FEAT O
( O
fMRI O
Expert O
Analysis O
Tool O
) O
from O
the O
FMRIB O
Software O
Library O
( O
www.fmrib.ox.ac.uk O
/ O
fsl O
) O
. O

Pre-statistical O
processing O
was O
as O
follows O
: O
motion O
correction O
utilizing O
FMRIB O
’ O
s O
Linear O
Image O
Registration O
Tool O
( O
MCFLIRT O
; O
non-brain O
matter O
removal O
using O
Brain O
Extraction O
Tool O
( O
BET O
) O
; O
spatial O
smoothing O
with O
a O
5 O
- O
mm O
full-width O
half O
maximum O
Gaussian O
kernel O
; O
mean-based O
intensity O
normalization O
; O
nonlinear O
high-pass O
temporal O
filtering O
( O
Gaussian-weighted O
least O
squares O
straight O
line O
fit O
, O
with O
sigma O
  O
= O
  O
25.0 O
  O
s O
) O
. O

The O
six O
rigid O
body O
movement O
parameters O
were O
also O
included O
as O
regressors O
in O
the O
model O
in O
FSL O
FEAT O
. O

For O
each O
participant O
, O
first O
level O
whole-brain O
mixed-effects O
analyses O
were O
performed O
by O
modelling O
the O
MID O
anticipation O
periods O
( O
i.e O
. O
gain O
, O
neutral O
) O
as O
explanatory O
variables O
within O
the O
context O
of O
the O
general O
linear O
model O
on O
a O
voxel-by-voxel O
basis O
( O
variable O
boxcar O
functions O
for O
the O
cue O
  O
+ O
  O
variable O
anticipation O
period O
regressors O
were O
convolved O
with O
the O
haemodynamic O
response O
function O
) O
. O

The O
gain O
and O
neutral O
outcome O
periods O
( O
“ O
Hit O
” O
and O
“ O
Miss O
” O
) O
were O
regressed O
out O
of O
the O
functional O
time O
series O
as O
conditions O
of O
no O
interest O
for O
the O
analyses O
reported O
here O
. O

During O
these O
first O
level O
analyses O
, O
the O
gain O
anticipation O
  O
> O
  O
neutral O
anticipation O
contrast O
was O
formulated O
. O

Owing O
to O
the O
small O
number O
of O
loss O
trials O
in O
the O
current O
task O
, O
the O
lose O
cue O
  O
+ O
  O
anticipation O
and O
outcome O
periods O
( O
“ O
Hit O
” O
and O
“ O
Miss O
” O
) O
were O
additionally O
regressed O
out O
of O
the O
functional O
time O
series O
as O
conditions O
of O
no O
interest O
. O

Therefore O
, O
the O
fewer O
number O
of O
lose O
trials O
on O
the O
MID O
task O
meant O
we O
were O
unable O
to O
examine O
voxel-wise O
group O
differences O
in O
loss O
anticipation O
. O

The O
end O
fixation O
period O
of O
the O
task O
served O
as O
the O
implicit O
baseline O
. O

Registration O
was O
conducted O
through O
a O
two-step O
procedure O
, O
whereby O
EPI O
images O
were O
first O
registered O
to O
the O
high-resolution O
T1 O
structural O
image O
, O
then O
into O
standard O
( O
Montreal O
Neurological O
Institute O
, O
MNI O
avg152 O
template O
) O
space O
, O
with O
12 O
- O
parameter O
affine O
transformations O
. O

Higher-level O
( O
within O
group O
one-sample O
t-tests O
and O
between-group O
independent O
samples O
t-tests O
) O
were O
conducted O
on O
the O
gain O
anticipation O
  O
> O
  O
neutral O
anticipation O
contrast O
using O
the O
randomise O
programme O
in O
FSL O
. O

Randomise O
employs O
a O
permutation O
approach O
through O
resampling O
. O

Significance O
( O
PFWE O
  O
< O
  O
0.05 O
) O
for O
the O
gain O
anticipation O
  O
> O
  O
neutral O
anticipation O
contrast O
on O
both O
the O
one-sample O
and O
independent O
samples O
t-tests O
was O
conducted O
taking O
a O
threshold-free O
cluster O
enhancement O
( O
TFCE O
) O
approach O
and O
using O
5000 O
permutations O
. O

TFCE O
aims O
to O
maintain O
the O
sensitivity O
of O
cluster-based O
thresholding O
, O
while O
avoiding O
the O
arbitrary O
nature O
of O
threshold O
choice O
. O

Given O
the O
differences O
in O
scanners O
across O
the O
three O
sites O
, O
these O
analyses O
were O
conducted O
while O
also O
controlling O
for O
study O
site O
. O

Trial-Wise O
beta O
value O
image O
analyses O
Data O
pre-processing O
was O
also O
initially O
conducted O
using O
FEAT O
( O
fMRI O
Expert O
Analysis O
Tool O
) O
from O
the O
FMRIB O
Software O
Library O
( O
www.fmrib.ox.ac.uk O
/ O
fsl O
) O
as O
described O
above O
. O

For O
each O
participant O
, O
each O
individual O
gain O
and O
neutral O
anticipation O
epoch O
( O
cue O
  O
+ O
  O
variable O
anticipation O
period O
) O
was O
separately O
modelled O
within O
the O
context O
of O
the O
general O
linear O
model O
. O

This O
approach O
yielded O
a O
total O
of O
18 O
unique O
beta O
value O
images O
for O
each O
of O
the O
gain O
and O
neutral O
anticipation O
conditions O
on O
each O
run O
of O
the O
MID O
task O
. O

This O
meant O
that O
each O
voxel-wise O
beta O
value O
image O
reflected O
the O
magnitude O
of O
the O
hemodynamic O
response O
evoked O
by O
each O
of O
the O
gain O
and O
neutral O
anticipation O
epochs O
. O

Each O
beta O
value O
image O
for O
each O
MID O
run O
was O
then O
subsequently O
registered O
into O
standard O
( O
MNI O
avg152 O
template O
) O
space O
before O
being O
concatenated O
to O
generate O
a O
beta O
value O
“ O
trial-wise O
” O
( O
e.g O
. O
, O
gain O
anticipation O
) O
time O
series O
. O

Each O
beta O
value O
trial-wise O
time O
series O
for O
each O
MID O
run O
was O
further O
concatenated O
across O
runs O
to O
generate O
a O
single O
beta O
value O
trial-wise O
time O
series O
for O
the O
gain O
and O
neutral O
MID O
anticipation O
conditions O
. O

This O
procedure O
yielded O
a O
thirty-six O
beta O
value O
trial-wise O
time O
series O
image O
for O
each O
participant O
for O
the O
gain O
and O
neutral O
anticipation O
conditions O
. O

The O
neutral O
trial-wise O
time O
series O
was O
then O
simply O
subtracted O
from O
the O
gain O
trial-wise O
time O
series O
to O
yield O
a O
gain O
anticipation O
  O
> O
  O
neutral O
anticipation O
contrast O
time O
series O
( O
see O
Supplementary O
Fig O
. O
1 O
) O
. O

This O
beta O
value O
trial-wise O
time O
series O
method O
has O
been O
previously O
used O
to O
examine O
connectivity O
during O
cognitive O
tasks O
, O
including O
the O
MID O
task O
. O

The O
small O
, O
variable O
( O
performance-dependent O
) O
number O
of O
events O
for O
the O
outcome O
periods O
( O
“ O
hits O
” O
and O
“ O
misses O
” O
) O
, O
and O
the O
small O
number O
of O
loss O
trials O
in O
the O
task O
, O
meant O
that O
we O
could O
not O
generate O
trial-wise O
beta O
value O
images O
for O
these O
events O
. O

Therefore O
, O
gain O
and O
neutral O
outcome O
( O
well O
as O
lose O
anticipation O
and O
outcome O
) O
events O
were O
regressed O
out O
of O
the O
functional O
time O
series O
as O
conditions O
of O
no O
interest O
during O
the O
first O
level O
analyses O
. O

This O
meant O
that O
the O
same O
end O
fixation O
period O
of O
the O
task O
also O
served O
as O
the O
implicit O
baseline O
for O
these O
analyses O
. O

Time O
series O
Extraction O
and O
correlation O
matrices O
Using O
the O
Harvard-Oxford O
atlas O
( O
96 O
cortical O
and O
14 O
subcortical O
nodes O
/ O
regions O
) O
as O
our O
connectome O
of O
interest O
, O
we O
used O
the O
fslmeants O
programme O
to O
extract O
the O
mean O
beta O
value O
time O
series O
from O
each O
of O
110 O
anatomical O
regions O
of O
interest O
( O
ROI O
) O
for O
the O
gain O
anticipation O
  O
> O
  O
neutral O
contrast O
beta O
image O
for O
each O
participant O
. O

Using O
these O
mean O
ROI O
time O
series O
outputs O
, O
we O
then O
conducted O
Pearson O
correlation O
coefficient O
analyses O
to O
construct O
whole O
brain O
ROI‐to‐ROI O
pairwise O
matrices O
( O
see O
Supplementary O
Fig O
. O
1 O
) O
. O

Each O
matrix O
was O
made O
up O
of O
5995 O
( O
= O
N O
* O
( O
N O
  O
− O
  O
1 O
) O
/ O
2 O
, O
with O
N O
  O
= O
  O
110 O
nodes O
) O
pairwise O
connections O
( O
edges O
) O
. O

These O
matrices O
were O
generated O
in O
MATLAB O
( O
The O
MathWorks O
, O
Inc O
. O
, O
Natick O
, O
Massachusetts O
, O
United O
States O
) O
and O
used O
to O
compare O
network O
connectivity O
between O
the O
CON O
and O
ADD O
groups O
( O
see O
below O
) O
. O

Graph O
measures O
Global O
( O
characteristic O
path O
length O
and O
clustering O
coefficient O
) O
graph O
measures O
were O
estimated O
from O
each O
correlation O
matrix O
using O
the O
GraphVar O
( O
www.rfmri.org O
/ O
GraphVar O
) O
toolbox O
for O
functional O
brain O
connectivity O
in O
MATLAB O
( O
The O
MathWorks O
, O
Inc O
. O
, O
Natick O
, O
Massachusetts O
, O
United O
States O
) O
. O

More O
detailed O
descriptions O
of O
brain O
network O
graph O
measures O
can O
be O
found O
elsewhere O
, O
but O
we O
will O
briefly O
describe O
these O
metrics O
here O
. O

Characteristic O
path O
length O
is O
the O
minimum O
number O
of O
edges O
that O
must O
be O
traversed O
to O
go O
from O
one O
node O
( O
brain O
region O
) O
to O
another O
in O
a O
network O
. O

For O
a O
pair O
of O
nodes O
that O
are O
nearest O
neighbours O
, O
the O
path O
length O
is O
1 O
. O

The O
clustering O
coefficient O
, O
by O
contrast O
, O
quantifies O
the O
density O
of O
connections O
between O
the O
nearest O
neighbour O
of O
a O
node O
, O
and O
describes O
how O
segregated O
the O
network O
is O
. O

The O
path O
and O
clustering O
measures O
are O
first O
estimated O
at O
each O
node O
of O
the O
connectome O
before O
an O
average O
( O
global O
value O
) O
is O
computed O
for O
the O
entire O
connectome O
for O
each O
participant O
’ O
s O
correlation O
matrix O
. O

Graph O
measures O
for O
each O
participant O
were O
then O
estimated O
by O
thresholding O
each O
matrix O
at O
a O
selection O
of O
proportional O
cost O
( O
K O
) O
thresholds O
– O
i.e O
. O
thresholds O
that O
retain O
only O
a O
percentage O
of O
the O
strongest O
connections O
( O
edges O
) O
in O
the O
network O
. O

Biological O
networks O
are O
represented O
by O
sparse O
connections O
, O
however O
, O
and O
thresholding O
is O
a O
necessary O
step O
to O
extract O
the O
appropriate O
topological O
properties O
of O
networks O
. O

Because O
graph O
measures O
can O
also O
be O
sensitive O
to O
threshold O
value O
, O
we O
have O
reported O
our O
measures O
across O
a O
range O
of O
K O
thresholds O
( O
1 O
  O
⩽ O
  O
K O
  O
⩽ O
  O
5 O
, O
increments O
of O
1 O
) O
. O

Here O
K O
represents O
the O
percentage O
( O
e.g O
. O
, O
1 O
  O
= O
  O
10% O
) O
number O
of O
edges O
in O
each O
matrix O
that O
are O
maintained O
following O
thresholding O
. O

We O
employed O
a O
range O
of O
thresholds O
to O
represent O
the O
lower O
and O
upper O
bound O
of O
a O
small-world O
system O
, O
and O
that O
preserve O
only O
the O
strongest O
functional O
connections O
for O
efficient O
parallel O
information O
processing O
at O
a O
relatively O
low O
wiring O
cost O
. O

All O
graph O
measures O
were O
computed O
from O
matrices O
in O
their O
weighted O
form O
following O
this O
thresholding O
procedure O
. O

Functional O
connectivity O
Group O
comparisons O
in O
ROI‐to‐ROI O
connectivity O
across O
matrices O
were O
assessed O
using O
the O
Networks O
Based O
Statistics O
( O
NBS O
) O
Toolbox O
for O
MATLAB O
( O
The O
MathWorks O
, O
Inc O
. O
, O
Natick O
, O
Massachusetts O
, O
United O
States O
) O
. O

Comparisons O
between O
the O
CON O
and O
ADD O
groups O
were O
conducted O
to O
identify O
those O
nodes O
across O
the O
connectome O
that O
showed O
differences O
in O
connectivity O
. O

Independent O
groups O
t-tests O
were O
first O
performed O
to O
test O
for O
a O
between-group O
difference O
in O
the O
correlation O
coefficients O
at O
each O
of O
the O
110 O
  O
× O
  O
( O
110 O
– O
1 O
) O
/ O
2 O
  O
= O
  O
5995 O
regional O
pairings O
. O

Graph O
sub-components O
were O
identified O
among O
the O
connections O
using O
a O
t-statistic O
threshold O
t O
  O
> O
  O
3.1 O
. O

From O
here O
, O
a O
family-wise O
error O
( O
FWE O
) O
corrected O
p-value O
( O
p O
  O
< O
  O
0.05 O
) O
was O
calculated O
for O
the O
size O
of O
each O
resulting O
component O
using O
permutation O
testing O
( O
5000 O
permutations O
) O
. O

Two O
( O
CON O
  O
> O
  O
ADD O
and O
ADD O
  O
> O
  O
CON O
) O
analyses O
were O
conducted O
independently O
on O
the O
gain O
anticipation O
  O
> O
  O
neutral O
anticipation O
contrast O
matrices O
. O

Given O
the O
differences O
in O
scanners O
across O
the O
three O
sites O
, O
these O
NBS O
analyses O
were O
conducted O
while O
controlling O
for O
study O
site O
. O

NBS O
has O
previously O
been O
used O
to O
identify O
specific O
networks O
of O
nodes O
across O
a O
connectome O
that O
differ O
between O
clinical O
populations O
during O
different O
psychological O
processes O
. O

Network O
visualisation O
Networks O
that O
emerged O
from O
group O
comparisons O
in O
NBS O
were O
visualised O
and O
presented O
using O
brain O
connectivity O
maps O
and O
circular O
connectograms O
using O
the O
NeuroMArVL O
software O
( O
www.immersive.erc.monash.edu.au O
/ O
neuromarvl O
) O
. O

